Methods and treatment of viral infection caused by SARS-cov-2 with fused bicyclic heterocyclic compounds and uses thereof

Fused bicyclic heterocyclic compounds, particularly PIKfyve inhibitors, are administered to block SARS-CoV-2 entry into host cells by inhibiting endosomal acidification, addressing the need for effective COVID-19 treatments by targeting the viral entry process.

WO2024229253A1PCT designated stage expired Publication Date: 2024-11-07VERGE ANALYTICS INC

Patent Information

Application Number
PCT/US2024/027462
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-04
Filing Date
2024-05-02
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current treatments for COVID-19 caused by SARS-CoV-2 lack effective methods to block viral entry into host cells, necessitating the development of antiviral drugs that target specific steps in the viral entry process.

Method used

Administration of fused bicyclic heterocyclic compounds, specifically phosphoinositide kinase inhibitors like PIKfyve inhibitors, to block SARS-CoV-2 entry into host cells by inhibiting endosomal acidification, thereby preventing infection.

Benefits of technology

The use of these compounds effectively inhibits SARS-CoV-2 entry and infection by disrupting the viral entry process, offering a potential treatment for COVID-19 and future viral outbreaks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000023_0001
    Figure IMGF000023_0001
  • Figure IMGF000024_0001
    Figure IMGF000024_0001
Patent Text Reader

Abstract

The present disclosure provides compounds that are useful for blocking SARS-CoV-2 from entering a host cell and preventing diseases and disorders caused by SARS-CoV-2, including COVID-19.
Need to check novelty before this filing date? Find Prior Art

Description

METHODS AND TREATMENT OF VIRAL INFECTION CAUSED BY SARS-CoV-2WITH FUSED BICYCLIC HETEROCYCLIC COMPOUNDS AND USES THEREOFCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 500,074, filed on May 4, 2023, the disclosure of which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION

[0002] The present disclosure relates to methods of blocking SARS-CoV-2 entry into a host cell; and ii) preventing and treating an infection caused by SARS-CoV-2. including COVID-19, with compounds that are phosphoinositide kinase inhibitors, in particular FYVE-type fingercontaining phosphoinositide kinase (“PIKfyve”) inhibitors.BACKGROUND OF THE INVENTION

[0003] According to the World Health Organization, there have been over 517 million confirmed cases and about 6.3 million deaths worldwide due to COVID-19 as of May 2022. The SARS-CoV-2, which is responsible for the COVID-19 (2019 novel coronavirus (2019-nCoV) disease, is an enveloped, positive-sense, RNA virus that belongs to the Betacoronavirus genus. Bouhaddou et al. Cell 182: 1-28 (2020). Improved understanding of key steps in viral entry and ways to disrupt them can lead to the development of effective antiviral drugs, not only for COVID-19, but for future viral outbreaks as well. Treatments for COVID-19 are greatly needed.

[0004] Coronavirus entry into susceptible cells is a complex process that requires the concerted action of receptor-binding and proteolytic processing of the coronavirus S protein to promote virus-cell fusion. Heald-Sargent and Gallagher, Viruses 4:557-580 (2012); Millet and Whittaker, Virus Res. 202: 120-134 (2015). For example, viral entry into cells may be mediated by a viral glycoprotein (GP), which attaches viral particles to the cell surface, delivers them to endosomes, and catalyzes fusion between viral and endosomal membranes. Murray, et al, J. Virology 79: 11742-11751 (2005). In the case of SARS-CoV-2, its spike (S) protein binds to an ACE2 receptor on the target cell and is subsequently primed by a serine protease, TMPRSS2, that cleaves the S protein and allows fusion of viral and lysosomal membranes. Hoffmann, et al.. Cell 181 :271-280. e8 (2020).

[0005] Like most viruses, coronavirus membrane fusion with host cell membrane takes place within acidified endosomes. Kang, et al. PNAS 117(34):20803-20813 (2020). Coronaviruses are known to interact with phosphatidylinositol (PI) kinases, which are distributed across various subcellular compartments. Beziau et al, Viruses 12, 1124; doi: 10.3390 / vl2101124 (2020). The PI kinase phosphatidylinositol 3-phosphate 5 kinase (PIKfy ve) involved in endosomalacidification is required for SARS-CoV-2 to enter the cell. Ou, et al, Nat. Commun. 11(1620): 1- 12 (2020). PIKfy ve inhibition with small molecule inhibitors has been shown to inhibit SARS- CoV-2 infection. Kang et al, PNAS 117(34):20803-20813 (2020); Nelson, et al, PLoS Negl. Trop. Dis. l l(4):e0005540 (2017). Ablation of PIKfyve arrests endosomal maturation (Ikonomov et al, J. Biol. Chem. 276(28):26141-26147 (2001); Ikonomov et al, J. Biol. Chem. 277(11):9206-9211 (2002); Jefferies et al, EMBO Rep. 9(2): 164-170 (2008); Rutherford, et al, J. Cell Sci. 119(19):3944-3957 (2006); Sbrissa, et al, J. Biol. Chem. 277(8):6073-6079 (2002)), which makes PIKfy ve a candidate target for new drugs against viruses that exploit the endosomal pathway.SUMMARY OF THE INVENTION

[0006] Embodiment 1 is a method of blocking SARS-CoV-2 entry into a host cell and preventing an infection caused by SARS-CoV-2, comprising administering to a subject in need thereof a compound of Formula (I): wherein:Y1is N or C-R1;Y2is N or C-R2;X is N, or CH; provided that when Y1is N, Y2is C-R2and when Y2is N, Y1is C-R1;R1is H, or Cs-saryl, Cs-sheteroaryl. Cs-scycloalkyl, or Cs-sheterocyclyl, each optionally substituted with from 1 to 3 Rs;R2is H, or Cs-saryl, Cs-sheteroaryl, C3-8cycloalkyl, or Cs-sheterocyclyl, each optionally substituted with from 1 to 3 Rs;R3is H, halo, OH, Ci-4alkyl, NRpRq. Ci-4alkyl-NRpRq, Ci-4alkyl-OH, Ci-4alkyl-OCi-4alkyl. OCi-4alkyl, C(O)-Ci-4alkyl. C(O)-Ci-4alkyl-NRpRq, C(O)OH, C(O)-OCi-4alkyl, or C(O)-OCi-4alkyl-NRpRq;R4is Cs-saryl, Cs-sheteroaryl, Cs-scycloalkyl, Cs-sheterocyclyl, Ci-4alkyl, Ci-4alkylP(O))(ORx)2, (Ci-4alky l)C3-8 aryl, (Ci-4alky l)C3-8 heteroaryl, (Ci-4alkyl)C3-8cycloalkyl, or (Ci-4alkyl)C3-8heterocyclyl, each optionally substituted with from 1 to 3 Rs, or R4is C(O)Ry, -C(O)NRxRy, NRxC(O)Ry, Ci-4 alkylNRxC(O)Ry, or C(O)Ci-4 alkylNRxC(O)Ry;Rsis halo, amino, oxo, OH, C3-8 heterocyclyl, OCi-ealkyl, Ci-ealkyl, Ci-ealkenyl, Ci- ealkyl-OH, Ci-6 alkyl-O-Ci-4 alkyl, Ci-e alkyl-O-Ci-4 alkyl-O-Ci-4 alkyl, (Ci-4 alkyl)C3-8 aryl, (C1-4 alkyl)C3-8 heteroaryl, (C 1-4 alkyl)C3-8 cycloalkyl, (Ci-4 alkyl)C3-8 heterocyclyl or C1-6 alkyl-NRpRq;Rxis H or Ci-4alkyl, optionally substituted with R°;Ryis H, Ci-4alkyl-Rr. Ci-4alkyl, -O-Ci-4alkyl, -SO2-Ci-4alkyl, Ci-4alkyl-SO2- Rr. cycloalkyl, (-Ci-4alkyl)cycloalkyl, heterocyclyl, (-Ci-4alkyl)heterocyclyl, O-heterocyclyl, C 3-8 ary l, (-Ci-4alkyl)Cs-8 aryl, C3-8 heteroaryl, (-C i-4alkyl)Cs-8 heteroaryl, each optionally substituted with 1 to 3 R° substituents; or Rxand Rytaken together with the nitrogen to which they are attached form a heterocyclyl. optionally substituted with Cwalkyl; each Rris Cwalkyl or -NRpRq; each R° substituent is independently Ci-ralkyl, oxo, -OH, -OCi-ralkyl, halo, cyano, heterocyclyl, or -NRpRq;Rpand Rqare each independently H or Cwalkyl; or Rpand Rqtaken together with the nitrogen to which they are attached form a heterocyclyl;R5is H, Ci-ealkyl, halo, -OH, or -OCi-ealkyl; or a pharmaceutically acceptable salt thereof.

[0007] Embodiment 2 is the method of embodiment 1, wherein the infection is caused by SARS-CoV-2, and wherein the infection is COVID-19.

[0008] Embodiment 3 is the method of embodiments 1 or 2, wherein Y1is N, Y2is C-R2.

[0009] Embodiment 4 is the method of embodiments 1 or 2, wherein Y2is N, Y1is C-R1.

[0010] Embodiment 5 is the method of embodiments 1 or 2, wherein Y1is C-R1and Y2is C-R2.

[0011] Embodiment 6 is the method of any one of embodiments 1, 2, or 5, wherein Y1is C-R1and Y2is C-R2, and wherein one of R1and R2is not H.

[0012] Embodiment 7 is the method of any one of embodiments 1-6, wherein X is N.

[0013] Embodiment 8 is the method of any one of embodiments 1 , 2, or 6, wherein X is N, and one of Y1and Y2is N.

[0014] Embodiment 9 is the method of any one of embodiments 1, 2, or 6, wherein X is N, Y1is C-R1, and Y2is C-R2

[0015] Embodiment 10 is the method of any one of embodiments 1, 2, or 6, wherein X is N, Y1is C-R1, and Y2is C-R2, and wherein one of R1and R2is not H.

[0016] Embodiment 11 is the method of embodiments 1 or 2, wherein X is CH.

[0017] Embodiment 12 is the method of any one of embodiments 1, 2, or 11. wherein X is CH, and one of Y1and Y2is N.

[0018] Embodiment 13 is the method of any one of embodiments 1 , 2, or 11 , wherein X is CH, and Y1and Y2are N.

[0019] Embodiment 14 is the method of any one of embodiments 1, 2, or 4-12. wherein Y1is C-R1and R1is H, or phenyl or Cs-sheteroaryl each optionally substituted with from 1 to 3 Rs.

[0020] Embodiment 15 is the method of any one of embodiments 1 - 14, wherein R1is phenyl, pyridinyl, pyrimidinyl, pyrazolyl, or cyclopentenyl, each optionally substituted with 1 or 2 Rs.

[0021] Embodiment 16 is the method of any one of embodiments 1 - 14, wherein R1is phenyl, pyridinyl, or pyrazolyl each optionally substituted with 1 Rs.

[0022] Embodiment 17 is the method of any one of embodiments 1-3, 5-12, or 14-16, wherein Y2is C-R2and R2is H, or phenyl or CYxheteroaryl each optionally substituted with from 1 to 3 Rs.

[0023] Embodiment 18 is the method of any one of embodiments 1 - 17, wherein R2is phenyl, pyridinyl, pyrimidinyl. pyrazolyl or cyclopentenyl, each optionally substituted with 1 or 2 Rs.

[0024] Embodiment 19 is the method of any one of embodiments 1 - 17, wherein R2is phenyl, pyridinyl, or pyrazolyl each optionally substituted with 1 Rs.

[0025] Embodiment 20 is the method of any one of embodiments 1 - 19, wherein R3is H, Ci-4 alkyl-NRpRq. Cwalkyl-OH, Ci-4alkyl-OCi-4 alkyl, C(O)OH, or C(O)-OCi-4alkyl.

[0026] Embodiment 21 is the method of any one of embodiments 1 - 19, wherein R3is (CH2)NH2, (CH2)N(CH3)2, (CH2)OH, (CH2)OCH3, C(O)OH, or C(O)OCH2CH3.

[0027] Embodiment 22 is the method of any one of embodiments 1 - 21, wherein R4is phenyl, pyridinyl, pyrimidinyl. or pyrazolyl, each optionally substituted with from 1 to 2 Rs.

[0028] Embodiment 23 is the method of any one of embodiments 1 - 21, wherein R4is pyrazolylmethyl, imidazolylmethyl, morpholinomethyl, piperidinylmethyl, dioxanylmethy, dioxanylethyl, dioxanylethylenyl, dioxanylpropyl, dioxanylpropylenyl, cyclohexenyl, cyclopentenyl, dihydropyridinyl, each optionally substituted with from 1 to 2 Rs.

[0029] Embodiment 24 is the method of any one of embodiments 1 - 23, wherein Rsis H, F, Cl, Br, NH2, OH, OXO, OCi-ealkyl, or Ci-ealkyl.

[0030] Embodiment 25 is the method of any one of embodiments 1 - 23, wherein Rsis H, F, Cl, OH, oxo, methyl, ethyl, or propyl.

[0031] Embodiment 26 is the method of any one of embodiments 1 - 23, wherein Rsis H or methyl.

[0032] Embodiment 27 is the method of any one of embodiments 1 - 26, wherein R4is C(O)Ry, -C(O)NRxRy, NRxC(O)Ry, Ci-4 alkylNRxC(O)Ry, or C(O)Ci-4 alkylNRxC(O)Ry.

[0033] Embodiment 28 is the method of any one of embodiments 1 - 27, wherein Rxis H, or methyl or ethyl, optionally substituted with one R°.

[0034] Embodiment 29 is the method of any one of embodiments 1 - 27, wherein Rxis H or methyl.

[0035] Embodiment 30 is the method of any one of embodiments 1 - 27, wherein Ryis C1-alkyl-Rr, C1-4alkyl, -O-C1-4alkyl, -SO2-C1-4alkyl, C1-4alkyl-SO2- Rr, cycloalkyl, , (C1-4alkyl)cycloalkyl, heterocyclyl, (C1-4alkyl)heterocyclyl, O-heterocyclyl, C'3-8aryl. (C1-4alky l)C3-8aryl, C3-8heteroaryl, (C1-4alky l)C3-8heteroaryl,, each optionally substituted with 1 to 3 R° substituents.

[0036] Embodiment 31 is the method of any one of embodiments 1 - 27, wherein Ryis Ci- lalkyl. optionally substituted with one, two, or three R° substituents.

[0037] Embodiment 32 is the method of any one of embodiments 1 - 27, wherein Ryis methyl, ethyl, propyl, or isopropyl, each optionally substituted with one, two, or three R° substituents.

[0038] Embodiment 33 is the method of any one of embodiments 1 - 27, wherein Ryis methyl, ethyl, isopropyl, methoxyethyl, dimethoxypropanyl, (dimethylamino)ethyl, or (dimethylamino)butyl.

[0039] Embodiment 34 is the method of any one of embodiments 1 - 27, wherein Ryis methoxy.

[0040] Embodiment 35 is the method of any one of embodiments 1 - 27, wherein Ryis -SO2- methyl.

[0041] Embodiment 36 is the method of any one of embodiments 1 - 27, wherein Ryis cycloalkyl or -Ci-2alkyl(cycloalkyl), each optionally substituted with one, two, or three R° substituents.

[0042] Embodiment 37 is the method of any one of embodiments 1 - 27, wherein Ryis monocyclic cycloalkyl, or (C1-4alkyl)monocyclic cycloalkyl, optionally substituted with one, two, or three R° substituents.

[0043] Embodiment 38 is the method of any one of embodiments 1 - 27, wherein Ryis cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, or cyclopentenyl, each optionally substituted with one, two, or three R° substituents.

[0044] Embodiment 39 is the method of any one of embodiments 1 - 27, wherein Ryis cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylmethyl, 1 -cyclopropylethyl, 2- cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexenylmethyl, cyclopentenylmethyl, cyclohexenylethyl, cyclopentenylethyl, cyclohexenylpropyl, or cyclopentenylpropyl.

[0045] Embodiment 40 is the method of any one of embodiments 1 - 27, wherein Ryis heterocyclyl or -O- heterocyclyl, optionally substituted with one, tw o, or three R° substituents.

[0046] Embodiment 41 is the method of any one of embodiments 1 - 27, wherein Ryis tetrahydrofuranyl, tetrahydropyranyl, oxetanyl, azetidinyl, pyrrolidinyl. piperidinyl, morpholinyl, piperazinyl, dioxanyl, pyrazolyl, dihydropyridinyl, or oxetanyloxy, each optionally substituted with one, tw o. or three R° substituents.

[0047] Embodiment 42 is the method of any one of embodiments 1 - 27, wherein Ryis tetrahydrofuranylmethyl, tetrahydropyranylmethyl, oxetanylmethyl, azetidinylmethyl, pyrrolidinylmethyl, piperidinylmethyl, morpholinylmethyl, piperazinylmethyl, dioxanylmethyl, pyrazolylmethyl, dihydropyridinylmethyl, or oxetanyloxymethyl, tetrahydrofuranylpropyl, tetrahydropyranylpropyl, oxetanylpropyl, azetidinylpropyl, pyrrolidinylpropyl, piperidinylpropyl, morpholinylpropyl, piperazinylpropyl, dioxanylpropyl, pyrazolylpropyl, dihydropyridinylpropyl, or oxetanyloxypropyl, each optionally substituted with one, two, or three R° substituents.

[0048] Embodiment 43 is the method of any one of embodiments 1 - 27, wherein Rxand Rytaken together with the nitrogen to which they are attached form a heterocyclyl, optionally substituted with Cwalkyl.

[0049] Embodiment 44 is the method of any one of embodiments 1 - 27, wherein Rxand Rytaken together with the nitrogen to which they are attached form a heterocycloalkyl, optionally substituted with C1-4alkyl.

[0050] Embodiment 45 is the method of any one of embodiments 1 - 27, wherein Rxand Rytaken together with the nitrogen to which they are attached form a monocyclic heterocyclyl, optionally substituted with methyl.

[0051] Embodiment 46 is the method of any one of embodiments 1 - 27, wherein Rxand Ryare taken together with the nitrogen to which they are attached to form azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 6-oxa-l-azaspiro[3.3]heptanyl. or 2-oxa- 6-azaspiro[3.3]heptanyl, each optionally substituted with methyl.

[0052] Embodiment 47 is the method of any one of embodiments 1 - 46, wherein each R° substituent is independently C1-4alkyl, -OEI, oxo, -OC1-4alkyl, or -NRpRq.

[0053] Embodiment 48 is the compo method of any one und of any one of embodiments 1 - 46, wherein at least one R° substituent is C1-4alkyl.

[0054] Embodiment 49 is the method of any one of embodiments 1 - 46, wherein at least one R° substituent is -OH.

[0055] Embodiment 50 is the method of any one of embodiments 1 - 46, wherein at least one R° substituent is -NRpRq.

[0056] Embodiment 51 is the method of any one of embodiments 1 - 46, wherein at least one R° substituent is oxo.

[0057] Embodiment 52 is the method of any one of embodiments 1 - 51, wherein Rpand Rqare each independently H or methyl.

[0058] Embodiment 53 is the method of any one of embodiments 1 - 51, wherein Rpand Rqtaken together with the nitrogen to which they are attached form a heterocyclyl.

[0059] Embodiment 54 is the method of any one of embodiments 1 - 51, wherein Rpand Rqtaken together with the nitrogen to which they are attached form azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl 6-oxa-l-azaspiro[3.3]heptanyl, or 2-oxa- 6-azaspiro[3.3]heptanyl.

[0060] Embodiment 55 is the method of any one of embodiments 1 - 54, wherein R5is H, methyl, ethyl, propyl, Cl, Br, or -OH.

[0061] Embodiment 56 is the method of any one of embodiments 1 - 54, wherein R5is H or methyl.

[0062] Embodiment 57 is the method of any one of embodiments 1 - 54, wherein R5is H.

[0063] Embodiment 58 is a method of any one of the preceding embodiments, wherein the compound is selected from Table 1, and / or pharmaceutically acceptable salts thereof.

[0064] Embodiment 59 is the method of any one of embodiments 1 - 58, wherein one or more hydrogen atoms attached to carbon atoms of the compound are replaced by deuterium atoms.

[0065] Embodiment 60 is the method of any one of the preceding embodiments, wherein the compound and / or the pharmaceutically acceptable salt is in a pharmaceutical composition.

[0066] Embodiment 61 is the method of embodiment 60, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.DETAILED DESCRIPTION OF THE INVENTION

[0067] The present disclosure provides methods and compositions for blocking SARS-CoV-2 entry into a host cell; and ii) preventing an infection caused by SARS-CoV-2.

[0068] Reference will now be made in detail to certain embodiments of the invention. While the invention will be described in conjunction with the described embodiments, it will be understood that such descriptions are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the invention as defined by the appended claims.

[0069] Before describing the present teachings in detail, it is to be understood that the disclosure is not limited to specific compositions or process steps, as such may vary. It should be noted that, as used in this specification and the appended claims, the singular form “a,” "an.'’ and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, reference to “a surfactant” includes a plurality of surfactants and the like.

[0070] Numeric ranges are inclusive of the numbers defining the range. Measured and measurable values are understood to be approximate, taking into account significant digits and the error associated with the measurement. Also, the use of “comprise,” “comprises,” “comprising,” “contain,” “contains,” “containing,” “include,” “includes,” “included,” and “including” are not intended to be limiting. It is to be understood that both the foregoing general description and detailed description are exemplary and explanatory' only and are not restrictive of the teachings.

[0071] Unless specifically noted in the above specification, embodiments in the specification that recite “comprising” various components are also contemplated as “consisting of’ or “consisting essentially of’ the recited components; embodiments in the specification that recite “consisting of various components are also contemplated as “comprising” or “consisting essentially of’ the recited components; and embodiments in the specification that recite “consisting essentially of’ various components are also contemplated as “consisting of’ or “comprising” the recited components (this interchangeability does not apply to the use of these terms in the claims).

[0072] The section headings used herein are for organizational purposes only and are not to be construed as limiting the desired subject matter in any way. In the event that any literature incorporated by reference contradicts any term defined in this specification, this specification controls. While the present teachings are described in conjunction with various embodiments, it is not intended that the present teachings be limited to such embodiments. On the contrary, the present teachings encompass various alternatives, modifications, and equivalents, as will be appreciated by those of skill in the art.I. Definitions

[0073] Unless otherwise defined herein, scientific and technical terms used herein have the meanings that are commonly understood by those of ordinary skill in the art. In the event of any latent ambiguity, definitions provided herein take precedence over any dictionary’ or extrinsic definition. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[0074] Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this disclosure and have the following meanings.

[0075] As used herein, the term “about” refers to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. For example, “about” or “approximately” can mean within one or more than one standard deviation per the practice in the art. Alternatively, “about” or “approximately” can mean a range of up to 10% (i.e., ±10%) or more depending on the limitations of the measurement system. For example, about 5 mg can include any number between 4.5 mg and 5.5 mg. Furthermore, particularly with respect to biological systems or processes, the terms can mean up to an order of magnitude or up to 5-fold of a value. When particular values or compositions are provided in the instant disclosure, unless otherwise stated, the meaning of “about” or “approximately” should be assumed to be within an acceptable error range for that particular value or composition. “Or” is used in the inclusive sense, i.e., equivalent to “and / or.” unless the context requires otherwise.

[0076] The term “and / or” used herein is to be taken mean specific disclosure of each of the specified features or components with or without the other. For example, the term “and / or” as used in a phrase such as “A and / or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Likewise, the term “and / or” as used in a phrase such as “A, B, and / or C” is intended to encompass each of the following aspects: A, B, and C; A. B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone). The terms “or a combination thereof’ and “or combinations thereof’ as used herein refers to any and all permutations and combinations of the listed terms preceding the term. For example, “A, B, C, or combinations thereof’ is intended to include at least one of: A, B. C, AB. AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, ACB, CBA, BCA. BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, AAB, BBC, AAABCCCC, CBBAAA, CAB ABB, andso forth. The skilled artisan will understand that ty pi cal ly there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.

[0077] The term “subject” and “patient” as used herein refers to human and non-human animals, including vertebrates, mammals, and non-mammals. In one embodiment, the subject can be human, non-human primates, simian, ape, murine (e.g., mice and rats), bovine, porcine, equine, canine, feline, caprine, lupine, ranine or piscine.

[0078] The term “administering”, “administered” and grammatical variants refers to the physical introduction of an agent to a subject, using any of the various methods and delivery systems known to those skilled in the art. Exemplary routes of administration for the formulations disclosed herein include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal, or other parenteral routes of administration, for example by injection or infusion. The phrase “parenteral administration” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrastemal injection and infusion, as well as in vivo electroporation. In one embodiment, the formulation is administered via a non-parenteral route, e.g., orally. Other non-parenteral routes include a topical, epidermal or mucosal route of administration, for example, intranasally, vaginally, rectally, sublingually or topically. Administering can also be performed, for example, once, a plurality7of times, and / or over one or more extended periods.

[0079] The terms “treatment” and “treating” refer to ameliorating or slowing the progression of a disease or disorder, such as a coronavirus infection, in a human or animal subject. By virtue of the administration of at least one embodiment of the compositions described herein, the severity of at least one symptom in the subject will decrease, and the disease or disorder may completely disappear from the subject. The terms “treatment” and “treating” also refers to attenuating symptoms associated with a viral infection (e.g., respiratory- syndrome, kidney failure, fever, and other symptoms relating to virus infections).

[0080] The terms “prevent” and “preventing” as used herein, means inhibiting or arresting development of a disease / disorder in a subject deemed to be disease / disorder free.

[0081] The terms “block” and “blocking” as used herein with reference to viral entry into a host cell refers to stopping the entry of some or all of a virus, such as a coronavirus, into a host cell or host cells. The blocking may be complete or partial. Partial blocking includes preventingat least some virus from entering host cells, for example, enough virus to prevent the subject from displaying at least one symptom associated with such viral infection.

[0082] The terms “effective amount”, “therapeutically effective amount” or “effective dose” or related terms may be used interchangeably and refer to an amount of a described PIKty ve inhibitor that when administered to a subject, is sufficient to affect a measurable improvement or prevention of a disease or disorder associated with a virus infection.

[0083] A “pharmaceutically acceptable vehicle” for therapeutic purposes is a physical embodiment that can be administered to a subj ect. Pharmaceutically acceptable vehicles include pills, capsules, caplets, tablets, oral fluids, injection fluids, sprays, aerosols, troches, dietary supplements, creams, lotions, oils, solutions, pastes, powders, steam, or a liquid, but is not limited to these. An example of a pharmaceutically acceptable vehicle is a buffered isotonic solution such as phosphate buffered saline (PBS).

[0084] A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -C(O)NH2is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary- meaning. A wavy line or a dashed line drawn through a line in a Formula indicates a specified point of attachment of a group. Unless chemically or structurally required, no directionality or stereochemistry is indicated or implied by the order in which a chemical group is written or named.

[0085] The prefix “Cu-v” indicates that the following group has from u to v carbon atoms. For example, “C1-6alkyl” indicates that the alkyl group has from 1 to 6 carbon atoms.

[0086] “Alkenyl” means a linear unsaturated or partially unsaturated monovalent hydrocarbon radical of two to six carbon atoms or a branched unsaturated or partially unsaturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., ethylenyl, propylenyl. 2-propylenyl, butenyl (including all isomeric forms), pentenyl (including all isomeric forms), and the like. C2-Xalkenyl refers to an alkenyl group with from 2 to x carbon atoms.

[0087] “Alkyl” means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl (including all isomeric forms), pentyl (including all isomeric forms), and the like. C1-Xalkyl refers to an alkyl group with from 1 to x carbon atoms.

[0088] “Alkylene” and in some instances “-alkyl-” or “-C1-Xalkyl-” means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalenthydrocarbon radical of three to six carbon atoms unless otherwise stated e.g., methylene, ethylene, propylene, 1 -methylpropylene, 2-methylpropylene, butylene, pentylene, and the like.

[0089] “Aryl” refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic) including fused systems. As used herein, aryl has 6 to 20 ring carbon atoms (i.e., C6-20aryl), 6 to 18 carbon ring atoms (i.e., C6- 18 aryl), 6 to 12 carbon ring atoms (i.e., C6-12aryl) or 6 to 10 carbon ring atoms (i.e., C6- 10aryl). Examples of aryl groups include phenyl, naphthyl, fluorenyl and anthry l. Ary l, however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl, the resulting ring system is heteroaryl. If one or more aryl groups are fused with a heterocyclyl, the resulting ring system is heterocyclyl.

[0090] ‘ ‘Amino” means a -NH2.

[0091] “Alkoxy” means a -OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or c / ter bxy , and the like.

[0092] “Cycloalkyl” means a cyclic saturated or partially unsaturated monovalent or divalent hydrocarbon radical of three to ten carbon atoms. In some embodiments, one or two carbon atoms of the cycloalkyl ring may be replaced by an oxo group. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and the like. Cx-ycycloalkyl refers to a cycloalkyd group with from x to y carbon atoms in the ring, where x and y are integers.

[0093] “Carboxy” means -COOH.

[0094] A “coronavirus,” “corona respiratory’ virus,” and “CoV” are used interchangeably herein to refer to a virus belonging to the family Coronaviridae. Coronaviruses are enveloped, positive-sense RNA viruses of approximately 31 Kb, making these viruses the largest known RNA viruses. Coronaviruses infect a variety of host species, including humans and several other vertebrates. These viruses predominantly cause respiratory and intestinal tract infections and induce a wide range of clinical manifestations. In general, coronaviruses can be classified into low pathogenic CoVs (including human CoVs (hCoVs)) and highly pathogenic CoVs. such as severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV). Low pathogenic hCoV infect upper airways and cause seasonal mild to moderate cold-like respiratory7illnesses in healthy individuals. In contrast, the highly pathogenic hCoVs (pathogenic hCoV) infect the lower respiratory7tract and cause severe pneumonia, which sometimes leads to fatal acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), resulting in high morbidity and mortality.

[0095] “Halo” means fluoro, chloro, bromo, or iodo.

[0096] “Heterocyclyl” means a saturated or partially unsaturated monovalent or divalent monocyclic or bi-cyclic group (fused bi-cyclic or bridged bi-cyclic) of 4 to 10 ring atoms in which one or two ring atoms are heteroatom selected from N, O, and S(O)n, where n is an integer from 0 to 2, the remaining ring atoms being C. Additionally, one or two ring carbon atoms in the heterocyclyl ring can optionally be replaced by a -CO- group. More specifically the term heterocyclyl includes, but is not limited to, oxetanyl, pyrrolidine, piperidine, homopiperidino, 2-oxopyrrolidinyl, 2-oxopiperidinyl, morpholino, piperazine, tetrahydropyranyl, thiomorpholino, hexahydropyrrolo[l,2-a]pyrazin-6(2H)-one-yl, tetrahydro- lH-oxazolo[3,4-alpyrazin-3(5H)-one-yl, 5,6,7,8-tetrahydro-[l,2,4]triazolo[4.3-a]pyrazine-yl, 3- oxa-8-azabicyclo[3.2.1]octane-yl, and the like. When the heterocyclyl ring is unsaturated it can contain one or two ring double bonds provided that the ring is not aromatic. Cx-yheterocyclyl refers to a heterocyclyl group with from x to y carbon atoms in the ring, where x and y are integers.

[0097] “Heteroaryl” means a monovalent or divalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms where one or more, (in one embodiment one, two, or three), ring atoms are heteroatom selected from N, O, and S, the remaining ring atoms being carbon. Representative examples include, but are not limited to. pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl. isoindolyl, oxazolyl. isoxazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl. pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, pyrazolopyridinyl, indazolyl, furopyrimidinyl, and the like. Cx-yheteroaryl refers to a heteroaryl group with from x to y carbon atoms, where x and y are integers.

[0098] “Mammal” as used herein means domesticated animals (such as dogs, cats, and horses), and humans. In one embodiment, mammal is a human.

[0099] The term “salt” or “pharmaceutically acceptable salt” refers to salts derived from a variety of organic and inorganic counter ions well known in the art. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-tol uenesul fonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese,aluminum, and the like. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, the pharmaceutically acceptable base addition salt is chosen from ammonium, potassium, sodium, calcium, and magnesium salts. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington ’s Pharmaceutical Sciences, 17thed.. Mack Publishing Company, Easton. PA, 1985, which is incorporated herein by reference.

[0100] "Oxo" means an =(O) group and “carbonyl” means a >C(O) group.

[0101] “Optional” or “optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “heterocyclyl group optionally substituted with an alkyl group” means that the alkyl may but need not be present, and the description includes situations where the heterocyclyl group is substituted with an alkyl group and situations where the heterocyclyl group is not substituted with alky l.

[0102] The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.

[0103] The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0104] The phrase “pharmaceutically acceptable excipient” or “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch: (3) cellulose, and its derivatives, such assodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate: (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository' waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen- free water; (17) isotonic saline; (18) Ringer’s solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.

[0105] ■‘PIKfyve inhibitor” refers to a molecule that inhibits phosphatidylinositol 3-phosphate 5-kinase (PIKfyve).II. Methods of Treating, Uses, Administration, and Pharmaceutical Compositions

[0106] Provided herein are methods of treating an infection caused by a virus, inhibiting entry of a virus into a host cell, or inhibiting fusion of viral membrane with a host cell membrane comprising administering to a subject in need thereof a compound of Formula (I) or any of the embodiments thereof (e.g., compounds of Table 1) described herein. In one aspect, the disclosure relates to a method for treating or preventing COVID-19 or a SARS-CoV-2 infection comprising administering to the subject a compound of Formula (I) or any of the embodiments thereof described herein. In one aspect, the disclosure relates to a method for preventing SARS- CoV-2 entry into a host cell comprising administering to the subject a compound of Formula (I) or any of the embodiments thereof described herein.

[0107] In some embodiments, a method of inhibiting SARS-CoV-2 viral membrane fusion with an early endosomal membrane in a host cell is provided comprising administering a compound of Formula (I) or any of the embodiments thereof (e.g., compounds of Table 1) described herein. In some embodiments, a method of inhibiting SARS-CoV-2 viral membrane fusion with a maturing endosomal membrane is provided comprising administering a compound of Formula (1) or any of the embodiments thereof (e.g., compounds of Table 1) described herein. In some embodiments, a method of inhibiting SARS-CoV-2 viral membrane fusion with a late endosomal membrane is provided comprising administering a compound of Formula (I) or any of the embodiments thereof (e.g., compounds of Table 1) described herein. In some embodiments, a method of inhibiting SARS-CoV-2 viral membrane fusion with an endo- lysosomal membrane is provided comprising administering a compound of Formula (I) or any of the embodiments thereof (e.g., compounds of Table 1) described herein. In some embodiments, a method of inhibiting SARS-CoV-2 viral membrane fusion with a lysosomal membrane isprovided comprising administering a compound of Formula (I) or any of the embodiments thereof (e.g., compounds of Table 1) described herein. In some embodiments, a method of inhibiting SARS-CoV-2 viral membrane fusion with an early macropinosomal membrane is provided comprising administering a compound of Formula (I) or any of the embodiments thereof (e.g., compounds of Table 1) described herein. In some embodiments, a method of inhibiting SARS-CoV-2 viral membrane fusion with a macropinosomal membrane is provided comprising administering a compound of Formula (I) or any of the embodiments thereof (e.g., compounds of Table 1) described herein. In some embodiments, a method of inhibiting SARS- CoV-2 viral membrane fusion with a late macropinosomal membrane is provided comprising administering a compound of Formula (I) or any of the embodiments thereof (e.g., compounds of Table 1) described herein. In some embodiments, a method of inhibiting SARS-CoV-2 viral membrane fusion with the endoplasmic reticulum (ER) is provided comprising administering a compound of Formula (I) or any of the embodiments thereof (e.g., compounds of Table 1) described herein. In some embodiments, a method of inhibiting SARS-CoV-2 viral membrane fusing with the plasma membrane directly is provided comprising administering a compound of Formula (I) or any of the embodiments thereof (e.g., compounds of Table 1) described herein.

[0108] In general, the compounds of this disclosure will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Therapeutically effective amounts of compounds of Formula (I) may range from about 0.01 to about 500 mg per kg patient body weight per day, which can be administered in single or multiple doses. In one embodiment, the dosage level will be about 0.1 to about 250 mg / kg per day. In another embodiment the dosage level will be about 0.5 to about 100 mg / kg per day. A suitable dosage level may be about 0.01 to about 250 mg / kg per day, about 0.05 to about 100 mg / kg per day, or about 0. 1 to about 50 mg / kg per day. Within this range the dosage can be about 0.05 to about 0.5, about 0.5 to about 5 or about 5 to about 50 mg / kg per day. For oral administration, the compositions may be provided in the form of tablets containing about 1.0 to about 1000 milligrams of the active ingredient, particularly about 1.0, 5.0, 10, 15, 20, 25, 50, 75. 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient. The actual amount of the compound of this disclosure, i.e., the active ingredient, will depend upon numerous factors such as the virus, severity of the disease to be treated, the age and relative health of the subject, the potency of the compound being utilized, the route and form of administration, and other factors.

[0109] In general, compounds of this disclosure will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal orby suppository), or parenteral (e.g., intramuscular, intravenous, or subcutaneous) administration. In some embodiments, the manner of administration is nasal using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropnate compositions.

[0110] Pharmaceutical compositions can be formulated using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries. The formulation can be modified depending upon the route of administration chosen. The pharmaceutical compositions can also include the compounds described herein in a free base form or a pharmaceutically acceptable salt form.

[0111] Methods for formulation of the pharmaceutical compositions can include formulating any of the compounds described herein with one or more inert, pharmaceutically acceptable excipients or earners to form a solid, semi-solid, or liquid composition. Solid compositions can include, for example, powders, tablets, dispersible granules and capsules, and in some aspects, the solid compositions further contain nontoxic, auxiliary substances, for example wetting or emulsifying agents, pH buffering agents, and other pharmaceutically acceptable additives. Alternatively, the compositions described herein can be lyophilized or in powder form for reconstitution with a suitable vehicle, e.g.. sterile pyrogen-free water, before use. The active ingredients can be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (e.g., hydroxymethylcellulose or gelatin microcapsules and poly-(methylmethacylate) microcapsules, respectively), in colloidal drugdelivery systems (e.g., liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.

[0112] The pharmaceutical compositions and formulations can be sterilized. Sterilization can be accomplished by filtration through sterile filtration.

[0113] The pharmaceutical compositions described herein can be formulated for administration as an injection. Non-limiting examples of formulations for injection can include a sterile suspension, solution, or emulsion in oily or aqueous vehicles. Suitable oily vehicles can include, but are not limited to, lipophilic solvents or vehicles such as fatty oils, synthetic fatty acid esters, or liposomes. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension. The suspension can also contain suitable stabilizers. Injections can be formulated for bolus injection or continuous infusion.

[0114] For parenteral administration, the compounds can be formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceuticallyacceptable parenteral vehicle. Such vehicles can be inherently nontoxic, and non-therapeutic. A vehicle can be water, saline, Ringer’s solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils and ethyl oleate can also be used. Liposomes can be used as carriers. The vehicle can contain minor amounts of additives such as substances that enhance isotonicity and chemical stability (e.g., buffers and preservatives).

[0115] Sustained-release preparations can also be prepared. Examples of sustained-release matrices can include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides, copolymers of L-glutamic acid and y ethyl-L-glutamate, non- degradable ethylene- vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPO™ (i.e., injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.

[0116] Pharmaceutical formulations of the compositions described herein can be prepared for storage by mixing a compound with a pharmaceutically acceptable carrier, excipient, and / or a stabilizer. This formulation can be a lyophilized formulation or an aqueous solution.Acceptable carriers, excipients, and / or stabilizers can be nontoxic to recipients at the dosages and concentrations used. Acceptable carriers, excipients, and / or stabilizers can include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives, polypeptides; proteins, such as serum albumin or gelatin; hydrophilic polymers; amino acids; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes; and / or nonionic surfactants or polyethylene glycol.

[0117] Compounds of the present disclosure may be used in methods of treating in combination with one or more other combination agents (e.g., one, two, or three other drugs) that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which compounds of the present disclosure are useful. In some embodiments, the combination of the drugs together is safer or more effective than either drug alone. In some embodiments the compounds disclosed herein and the one or more combination agents have complementary activities that do not adversely affect each other. Such molecules can be present in combination in amounts that are effective for the purpose intended. Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present disclosure. When a compound of the present disclosure is used contemporaneously with one or more other drugs, in some embodiments, the agents are administered together in a single pharmaceutical compositionin unit dosage form. Accordingly, the pharmaceutical compositions of the present disclosure also include those that contain one or more other active ingredients, in addition to a compound of the present disclosure. The weight ratio of the compound of the present disclosure to the second active agent may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. In some embodiments, combination therapy includes therapies in which the compound of the present disclosure and one or more other drugs are administered separately, and in some cases, the two or more agents are administered on different, overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of the present disclosure and the other active ingredients may be used in lower doses than when each is used singly.

[0118] The compounds, pharmaceutical compositions, and methods of the present disclosure can be useful for treating and preventing infection in a subject such as, but not limited to, a mammal, a human, a non-human mammal, a domesticated animal (e.g., laboratory animals, household pets, or livestock), a non-domesticated animal (e.g., wildlife), a dog, a cat, a rodent, a mouse, a hamster, a cow, a bird, a chicken, a fish, a pig, a horse, a goat, a sheep, or a rabbit. In preferred embodiments, compounds, pharmaceutical compositions, and methods of the present disclosure are used for treating a human.

[0119] The compounds, pharmaceutical compositions, and methods described herein can be useful as a therapeutic or preventative, for example a treatment or preventative that can be administered to a subject in need thereof. A therapeutic or preventative effect can be obtained in a subject by prevention (complete or partial), reduction, suppression, remission, or eradication of a disease state, including, but not limited to. a symptom thereof. A therapeutic effect in a subject having a disease or condition, or pre-disposed to have or is beginning to have the disease or condition, can be obtained by a reduction, a suppression, a prevention, a remission, or an eradication of the condition or disease, or pre-condition or pre-disease state.

[0120] In practicing the methods described herein, therapeutically effective amounts of the compounds or pharmaceutical compositions described herein can be administered to a subject in need thereof, often for treating and / or preventing a condition or progression thereof. A pharmaceutical composition can affect the physiology' of the subject, such as the immune system, inflammatory response, or other physiologic affect. A therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compounds used, and other factors.

[0121] Treat and / or treating can refer to any indicia of success in the treatment or amelioration of the disease or condition. Treating can include, for example, reducing, delaying or alleviatingthe severity of one or more symptoms of the disease or condition, or it can include reducing the frequency with which symptoms of a disease, defect, disorder, or adverse condition, and the like, are experienced by a patient. Treat can be used herein to refer to a method that results in some level of treatment or amelioration of the disease or condition and can contemplate a range of results directed to that end, including but not restricted to prevention of the condition entirely.

[0122] Prevent, preventing, and the like can refer to the prevention of the disease or condition in the patient. For example, if an individual at risk of contracting a disease is treated with the methods of the present disclosure and does not later contract the disease, then the disease has been prevented, at least over a period of time, in that individual. In some embodiments the PIKfyve inhibitors described herein can prevent SARS-CoV-2 entry into a SARS-CoV-2host cell and can treat or prevent a SARS-CoV-2 virus infection (e.g., COVID-19). SARS-CoV-2

[0123] A therapeutically effective amount can be the amount of a compound or pharmaceutical composition or an active component thereof sufficient to provide a beneficial effect or to otherwise reduce a detrimental non-beneficial event to the individual to whom the composition is administered. A therapeutically effective dose can be a dose that produces one or more desired or desirable (e.g., beneficial) effects for which it is administered, such administration occurring one or more times over a given period of time. An exact dose can depend on the purpose of the treatment and can be ascertainable by one skilled in the art using known techniques.

[0124] The compounds or pharmaceutical compositions described herein that can be used in the methods and uses described herein can be formulated and dosages established in a fashion consistent with good medical practice taking into account the disorder to be treated, the condition of the individual patient, the site of delivery of the compound or pharmaceutical composition, the method of administration and other factors known to practitioners. The compounds or pharmaceutical compositions can be prepared according to the description of preparation described herein.

[0125] One of ordinary skill in the art would understand that the amount, duration, and frequency of administration of a pharmaceutical composition or compound described herein to a subject in need thereof depends on several factors including, for example but not limited to, the health of the subject, the specific disease or condition of the patient, the grade or level of a specific disease or condition of the patient, the additional therapeutics the subject is being or has been administered, and the like.

[0126] The methods, uses, compounds, and pharmaceutical compositions described herein can be for administration to a subject in need thereof. Often, administration of the compounds orpharmaceutical compositions can include routes of administration, non-limiting examples of administration routes include intravenous, intraarterial, subcutaneous, subdural, intramuscular, intracranial, intrastemal, intratumoral, or intraperitoneally. Additionally, a pharmaceutical composition or compound can be administered to a subject by additional routes of administration, for example, by inhalation, oral, dermal, intranasal, or intrathecal administration.

[0127] Pharmaceutical compositions or compounds of the present disclosure can be administered to a subject in need thereof in a first administration, and in one or more additional administrations. The one or more additional administrations can be administered to the subject in need thereof minutes, hours, days, weeks, or months following the first administration. Anyone of the additional administrations can be administered to the subject in need thereof less than 21 days, or less than 14 days, less than 10 days, less than 7 days, less than 4 days or less than 1 day after the first administration. The one or more administrations can occur more than once per day, more than once per week, or more than once per month. The compounds or pharmaceutical compositions can be administered to the subject in need thereof in cycles of 21 days, 14 days, 10 days, 7 days, 4 days, or daily over a period of one to seven days.

[0128] The compounds, pharmaceutical compositions, and methods provided herein can be useful for the treatment of a plurality of diseases or conditions or preventing a disease or a condition in a subject, or other therapeutic applications for subjects in need thereof.III.PIKfyve inhibitor compounds

[0129] The compounds described herein may in some cases exist as diastereomers, enantiomers, or other stereoisomeric forms. All chiral, diastereomeric, racemic forms, as individual forms and mixtures thereof, are within the scope of this disclosure, unless the specific stereochemistry or isomeric form is specifically indicated. Compounds of the present disclosure containing an asymmetrically substituted atom may be isolated in optically active, optically enriched, optically pure, or racemic forms, ft is well known in the art how to prepare optically active forms, such as by resolution of materials. Separation of stereoisomers may be performed by chromatography or by forming diastereomers and separating by recrystallization, or chromatography, or any combination thereof. (Jean Jacques, Andre Collet, Samuel H. Wilen, “Enantiomers, Racemates and Resolutions”, John Wiley and Sons, Inc., 1981, herein incorporated by reference for this disclosure). Stereoisomers may also be obtained by stereoselective synthesis.

[0130] Certain compounds of Formula (I) (or any of the embodiments thereof described herein) and / or a pharmaceutically acceptable salt thereof may exist as tautomers and / or geometric isomers. All possible tautomers and cis and trans isomers, as individual forms andmixtures thereof, are within the scope of this disclosure. For example, pyrazole tautomers as shown below are equivalent structures. The depiction of one such structure is intended to encompass both structures.

[0131] Additionally, as used herein the term alkyl includes all the possible isomeric forms of said alkyl group albeit only a few examples are set forth. Furthermore, when the cyclic groups such as heteroaryl and heterocyclyl are substituted, they include all the positional isomers.

[0132] Pharmaceutically acceptable salts of the compounds of Formula (I) (or any of the embodiments thereof described herein) are within the scope of this disclosure. In addition, the compounds described herein include hydrates and solvates of the compounds or pharmaceutically acceptable salts thereof.

[0133] The present disclosure also includes the prodrugs of compounds of Formula (I) (or any of the embodiments thereof described herein) and / or a pharmaceutically acceptable salt thereof. The term prodrug is intended to represent covalently bonded carriers, which are capable of releasing the active ingredient of Formula (I) (or any of the embodiments thereof described herein) when the prodrug is administered to a mammalian subject. Release of the active ingredient occurs in vivo. Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups how ever regenerate original functional groups in vivo or by routine manipulation. Prodrugs of compounds of Formula (I) (or any of the embodiments thereof described herein) include compounds wherein a hydroxy, amino, carboxylic, or a similar group is modified. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., N, A-dimethylaminocarbonyl) of hydroxy or amino functional groups in compounds of Formula (I)), amides (e.g., trifluoroacetylamino, acetylamino, and the like), and the like. Prodrugs of compounds of Formula (I) (or any of the embodiments thereof described herein) and / or a pharmaceutically acceptable salt thereof are also within the scope of this disclosure.

[0134] The present disclosure also includes polymorphic forms (amorphous as well as crystalline) and deuterated forms of compounds of Formula (I) (or any of the embodiments thereof described herein) and / or a pharmaceutically acceptable salt thereof and / or a prodrug thereof.

[0135] The compounds disclosed herein, in some embodiments, are used in different enriched isotopic forms, e.g., enriched in the content of2H,3H,nC,13C and / or14C. In one particularembodiment, the compound is deuterated in at least one position. Such deuterated forms can be made by the procedure described in U.S. Patent Nos. 5,846,514 and 6,334,997. As described in U.S. Patent Nos. 5,846,514 and 6,334,997, deuteration can improve the metabolic stability and or efficacy, thus increasing the duration of action of drugs.

[0136] Unless otherwise stated, structures depicted herein are intended to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by13C- or14C-enriched carbon are within the scope of the present disclosure.

[0137] The compounds of the present disclosure optionally contain unnatural proportions of atomic isotopes at one or more atoms that constitute such compounds. For example, the compounds may be labeled with isotopes, such as for example, deuterium (2H), tritium (3H), iodine-125 (125I) or carbon-14 (14C). Isotopic substitution with2H,nC.13C,14C,15C,12N,13N.15N,16N,16O,17O,14F,15F,16F,17F,18F,33S,34S,35S,36S,33C1,37C1,79Br,81Br, and125I are all contemplated. All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

[0138] In certain embodiments, the compounds disclosed herein have some or all of theatoms replaced with2H atoms. The methods of synthesis for deuteri um-containing compounds are known in the art and include, by w ay of non-limiting example only, the following synthetic methods.

[0139] Deuterium substituted compounds are synthesized using various methods such as described in: Dean, Dennis C.; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [In: Curr., Pharm. Des., 2000; 6(10)] 2000, 110 pp; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.

[0140] Deuterated starting materials are readily available and are subjected to the synthetic methods described herein to provide for the synthesis of deuterium-containing compounds.Large numbers of deuterium-containing reagents and building blocks are available commercially from chemical vendors, such as Aldrich Chemical Co.

[0141] In one aspect is a compound of Formula (I):whereinY1is N or C-R1;Y2is N or C-R2;X is N, or CH; provided that when Y1is N, Y2is C-R2and when Y2is N. Y1is C-R1;R1is H, or C3-8aryl, Cs-sheteroaryL Cs-scycloalkyL or Cs-sheterocyclyl, each optionally substituted with from 1 to 3 Rs;R2is H, or C3-8aryl, C'3-8heteroaryl. Cs-scycloalkyl, or Cs-sheterocyclyl, each optionally substituted with from 1 to 3 Rs;R3is H, halo. OH, C1-4kyl, NRpRq, C1-4 alkyl-NRpRq, Ci-4alkyl-OH, C1-4alkyl-OC1-4 alkyl, OC1-4 alkyl, C(O)-C1-4 alkyl, C(O)-C1-4 alkyl-NRpRq, C(O)OH, C(O)-OC1-4 alkyl, or C(O)-OC1-4 alkyl -NRpRq;R4is C3-8aryl, C3-8heteroaryl. C3-8cycloalkyl, C3-8heterocyclyl, C1-4 alkyl, C1-4 alkylP(O))(ORx)2, (C1-4 alky l)C3-8 aryl. (C1-4 alky l)C3-8 heteroaryl, (C3-4 alkyl)C3-8 cycloalkyl, or (C3-4 alkyl)C3-8heterocyclyl, each optionally substituted with from 1 to 3 Rs, or R4is C(O)Ry, -C(O)NRxRyNRxC(O)Ry, C114 alkylNRxC(O)Ry, or C(O)C1-4 alkylNRxC(O)Ry;Rsis halo, amino, oxo, OH, C3-8 heterocyclyl, O1icealkyl, C1-6alkyl, C1-6alkyl , C1- ealkyl-OH, C1-8 alkyl-O-C 1-4 alkyl, Ci-6 alkyl-O-C1-4 alkyl-O-Ci-4 alkyl, (C1-4 alkyl)C3-8 aryl, (C 1-4 alky l)Cs-8 heteroaryl, (C 1-4 alkyl)C3-s cycloalkyl, (Ci-4 alkyl)C3-8 heterocyclyl or C1-6 alkyl-NRpRq;Rxis H or Ci-4alkyl, optionally substituted with R°;Ryis H, Ci-4alkyl-Rr. Cwalkyl, -O-C1-4alkyl, -SO2-C1-4alkyl, C1-4alkyl-SO2- Rr. cycloalkyl, (-C1-4alkyl)cycloalkyl, heterocyclyl, (-C1-4alkyl)heterocyclyl, O-heterocyclyl, C3-8 aryl, (-C1-4alkyl)C3-saryl, C3-8 heteroaryl, (-C1-4alkyl)C3-8 heteroaryl, each optionally substituted with 1 to 3 R° substituents; or Rxand Rytaken together with the nitrogen to which they are attached form a heterocyclyl. optionally substituted with C1-4alkyl;each Rris Cwalkyl or -NRpRq; each R° substituent is independently Cwalkyl, oxo, -OH, -OCwalkyl, halo, cyano, heterocyclyl, or -NRpRq;Rpand Rqare each independently H or C1-4alkyl; or Rpand Rqtaken together with the nitrogen to which they are attached form a heterocyclyl;R5is H, Ci-ealkyl, halo, -OH, or -OC1-6alkyl.

[0142] In another aspect is a compound of Formula (la):whereinY1is N or C-R1;Y2is N or C-R2;X is N, or CH; provided that when Y1is N, Y2is C-R2and when Y2is N, Y1is C-R1;R1is H, or C3-8aryl, C3-8heteroaryl. C3-8cycloalkyl, or C3-8heterocyclyl, each optionally substituted with from 1 to 3 Rs;R2is H, or C3-8aryl, C3-8heteroaryl, C3-8cycloalkyl, or Cs-sheterocyclyl, each optionally substituted with from 1 to 3 Rs;R4is C3-8aryl, Cs-sheteroaryl. C3-8cycloalkyl, or C3-8heterocyclyl, each optionally substituted with from 1 to 3 Rs, or -C(O)NRxRy;Rsis H, halo, amino, OH, OC1-6alkyl, Ci-ealkyl;Rxis H or Ci-4alkyl, optionally substituted with R°;Ryis H, C1-4alkyl, -O-C1-4alkyl, -SO2-C1-4kyl, C1-4alkyl-SO2- Rr, cycloalkyl, -C1-4alkyl(cycloalkyl), heterocyclyl, -O-heterocyclyl, each optionally substituted with 1 to 3 R° substituents; or Rxand Rytaken together with the nitrogen to which they are attached form a heterocyclyl, optionally substituted with Cwalkyl; each Rris C1-4alkyl or -NRpRq; each R° substituent is independently C1-4alkyl. -OH. -OCwalkyl, halo, cyano, or -NRpRq;Rpand Rqare each independently H or Cwalkyl; or Rpand Rqtaken together with thenitrogen to which they are attached form a heterocyclyl;R5is H, Ci ealkyl, halo, -OH, or -OC- 6alkyl.

[0143] In some embodiments, Y1is N, Y2is C-R2. In some embodiments, Y2is N, Y1is C-R1. In some embodiments, Y1is C-R1and Y2is C-R2. In some embodiments. Y1is C-R1and Y2is C-R2, and one of R1and R2is not H.

[0144] In some embodiments, X is N. In some embodiments, X is N, and one of Y1and Y2is N. In some embodiments, X is N, Y1is C-R1, and Y2is C-R2. In some embodiments, X is N, Y1is C-R1, and Y2is C-R2, and one of R1and R2is not H. In some embodiments, X is CH. In some embodiments, X is CH, and one of Y1and Y2is N. In some embodiments, X is CH, and Y1and Y2are N.

[0145] In some embodiments, Y1is C-R1and R1is H, or phenyl or C3-8heteroaryl each optionally substituted with from 1 to 3 Rs. In some embodiments, R1is phenyl, pyridinyl, pyrimidinyl, pyrazolyl , or cyclopentenyl, each optionally substituted with 1 or 2 Rs. In some embodiments, R1is phenyl, pyridinyl, or pyrazolyl each optionally substituted with 1 Rs.

[0146] In some embodiments, Y2is C-R2and R2is H, or phenyl or C3-8eteroaryl each optionally substituted with from 1 to 3 Rs. In some embodiments, R2is phenyl, pyridinyl, pyrimidinyl, pyrazolyl or cyclopentenyl, each optionally substituted with 1 or 2 Rs. In some embodiments, R2is phenyl, pyridinyl. or pyrazolyl each optionally substituted with 1 Rs.

[0147] In some embodiments, R3is H, C1-4 alkyl-NRpRq, C1-4alkyl-OH, C1-4 alkyl-OC1-4 alkyl, C(O)OH, or C(O)-OC 1-4 alkyl. In other embodiments. R3is (CH2)NH2, (CH2)N(CH3)2, (CH2)OH, (CH2)OCH3, C(O)OH, or C(O)OCH2CH3.

[0148] In some embodiments, R4is phenyl, pyridinyl. pyrimidinyl, or pyrazolyl each optionally substituted with from 1 to 2 Rs. In some embodiments, R4is phenyl, pyridinyl, or pyrazolyl each optionally substituted with 1 Rs.

[0149] In some embodiments, Rsis H, F, C1, Br, NH2, OH, oxo, OC1-6alkyl, or C1-6alkyl. In some embodiments, Rsis H, F, Cl. OH, oxo, methyl, ethyl, or propyl. In some embodiments. Rsis H or methyl.

[0150] In some embodiments, R4is pyrazolylmethyl , imidazolylmethyl, morpholinomethyl, piperidinylmethyl, dioxanylmethy, dioxanylethyl, dioxanylethylenyl, dioxanylpropyl, dioxanylpropylenyl, cyclohexenyl, cyclopentenyl, dihydropyridinyl, each optionally substituted with from 1 to 2 Rs.

[0151] In some embodiments, R4is C(O)Ry, -C(O)NRxRy.NRxC(O)Ry, C1-4 alkylNRxC(O)Ry, or C(O)C1-4 alkylNRxC(O)Ry. In some embodiments, R4is -C(O)NRxRy.

[0152] In some embodiments, Rxis H, or methyl or ethyl, optionally substituted with one R°. In some embodiments, Rxis H or methyl.

[0153] In some embodiments, Ryis C1-4alkyl-Rr, C1-4alkyl, -O-C1-4alkyl, -SO2-C1-4alkyl, C1-4alkyl-SO2- Rr, cycloalkyl, , (C114alkyl)cycloalkyl, heterocyclyl, (C1-4alkyl)heterocyclyl. O- heterocyclyl, C3-8aryL (C1-4alky 1)C3-8aryl, C3-8heteroaryl, (C1-4alkyl)C3-8heteroaryl,, each optionally substituted with 1 to 3 R° substituents. In some embodiments, Ryis Ci-4alkyl, -O-C1-4alkyl, -SO2-C1-4alkyl, Ci-4alkyl-SO2-Rr, cycloalkyd, -C1-4alkyl(cycloalkyl), heterocyclyl, -O- heterocyclyl, each optionally substituted with 1 to 3 R° substituents. In some embodiments, Ryis C1-4alkyl, optionally substituted with one, two, or three R° substituents. In some embodiments. Ryis methyl, ethyl, propyl, or isopropyl, each optionally substituted with one, two, or three R° substituents. In some embodiments, Ryis methyl, ethyl, isopropyl, methoxy ethyl, dimethoxypropanyl, (dimethylamino)ethyl, or (dimethylamino)butyl. In some embodiments, Ryis methoxy. In some embodiments, Ryis -SCh-methyl.

[0154] In some embodiments, Ryis cycloalkyl, or (C1-4alkyl)monocychc cycloalkyl, or -C1-2alkyl(cycloalkyl), each optionally substituted with one, two, or three R° substituents. In some embodiments, Ryis monocyclic cycloalkyl, or (C1-4alkyl)monocyclic cycloalkyl, optionally substituted with one, two, or three R° substituents. In some embodiments, Ryis cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, or cyclopentenyL. each optionally substituted with one, two, or three R° substituents. In some embodiments, Ryis cyclopropyl, cyclobutyl, cy cl opentyl, cyclopropylmethyl, 1 -cyclopropylethyl, 2-cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexenylmethyl, cyclopentenylmethyl, cyclohexenylethyl, cyclopentenylethyl, cyclohexenylpropyl, or cyclopentenylpropyl.

[0155] In some embodiments, Ryis heterocyclyl or -O- heterocyclyl, optionally substituted with one, two, or three R° substituents. In some embodiments, Ryis tetrahydrofuranyl, tetrahydropyranyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, dioxanyl. pyrazolyl, dihydropyridinyl, or oxetanyloxy, each optionally substituted with one, two, or three R° substituents.

[0156] In some embodiments, Ryis tetrahydrofuranylmethyl, tetrahydropyranylmethyl, oxetanylmethyl, azetidinylmethyl, pyrrolidinylmethyl, piperidinylmethyl, morpholinylmethyl, pi11razinylmethyl, dioxanylmethyl, pyrazolylmethyl, dihydropyridinylmethyl, or oxetanyloxymethyl, tetrahydrofuranylpropyl, tetrahydropyranylpropyl, oxetanylpropyl, azetidinylpropyl, pyrrolidinylpropyl, piperidinylpropyl, morpholinylpropyl, piperazinylpropyl, dioxanylpropyl, pyrazolylpropyl, dihydropyridinylpropyl, or oxetanyloxypropyl, each optionally substituted with one, two, or three R° substituents.

[0157] In some embodiments, Rxis H and Ryis methyl, ethyl, isopropyl, cyclopropyl, methoxy, or cyclopentyl. In some embodiments, Rxis H and Ryis isopropyl.

[0158] In some embodiments, Rxand Rytaken together with the nitrogen to which they are attached form a heterocyclyl, optionally substituted with Cwalkyl. In some embodiments, Rxand Rytaken together with the nitrogen to which they are attached form a heterocycloalkyl, optionally substituted with Ci-4alkyl. In some embodiments, Rxand Rytaken together with the nitrogen to which they7are attached form a monocyclic heterocyclyl, optionally substituted with methyl. In some embodiments, Rxand Ryare taken together with the nitrogen to which they are attached to form azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl. morpholinyl. thiomorpholinyl. 6-oxa-l-azaspiro[3.3]heptanyl, or 2-oxa-6-azaspiro[3.3]heptanyl, each optionally substituted with methyl.

[0159] In some embodiments, each Rris Ci-4alkyl or -NRpRq. In some embodiments, Rris methyl, ethyl, propyl, or isopropyl or -NRpRq.

[0160] In some embodiments, each R° substituent is independently Cwalkyl, -OH, oxo, -OC1-4alkyl, or -NRpRq. In some embodiments, at least one R° substituent is C1-4alkyl. In some embodiments, at least one R° substituent is -OH. In some embodiments, at least one R° substituent is -NRpRq. In some embodiments, at least one R° substituent is oxo.

[0161] In some embodiments, Rpand Rqare each independently H or methyl.

[0162] In some embodiments, Rpand Rqtaken together with the nitrogen to which they are attached form a heterocyclyl. In some embodiments, Rpand Rqtaken together wi th the nitrogen to which they are attached form azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl 6-oxa-l-azaspiro[3.3]heptanyl. or 2-oxa-6-azaspiro[3.3]heptanyl.

[0163] In some embodiments, R5is H, methyl, ethyl, propyl, C1, Br, or -OH. In some embodiments, R5is H or methyl.

[0164] In some embodiments, the compound of Formula (I) or the pharmaceutically acceptable salt thereof is a compound of Formula (I):as defined herein, wherein one or more hydrogen atoms attached to carbon atoms of the compound are replaced by deuterium atoms.

[0165] In some embodiments, one or more hydrogen atoms attached to carbon atoms of R1, R2, R3, R4, and / or R5are replaced by deuterium atoms.

[0166] In some embodiments, one or more hydrogen atoms attached to carbon atoms of R°, Rs, Rp, Rq, Rr, Rx, and / or Ryare replaced by deuterium atoms.

[0167] In some embodiments, one or more Ci-4alkyl group has one or more hydrogen atoms attached to carbon atoms replaced by deuterium atoms. In some embodiments, one or more methyl groups have one or more hydrogen atoms attached to the carbon atom replaced by deuterium atoms.

[0168] In some embodiments, the compound of Formula (I) comprises a -D in place of at least one -H, or a -CDs substituent in place of at least one CHs.

[0169] In some embodiments, the compound is a compound selected from those of Table 1 :and pharmaceutically acceptable salts thereof.IV. Kits and Articles of Manufacture

[0170] Any of the aforementioned methods can be implemented via kits for the treatment of a viral infection, such as an infection caused by an enveloped virus. Such viruses include coronavirus, such as SAR.S-CoV-2.

[0171] The kit may contain a compound of Formula I (or any of the embodiments thereof described herein), a pharmaceutically acceptable carrier, a physiologically acceptable carrier, instructions for use, a container, a vessel for administration, or any combination thereof.

[0172] The disclosure further provides any compounds disclosed herein for use in a method of treatment of the human or animal body by therapy . Therapy may be by any mechanism disclosed herein, such as inhibiting, reducing, or reducing progression of the diseases disclosedherein. The disclosure further provides any compound disclosed herein for prevention or treatment of any condition disclosed herein. The disclosure also provides any compound or pharmaceutical composition thereof disclosed herein for obtaining any clinical outcome disclosed herein for any condition disclosed herein. The disclosure also provides use of any compound disclosed herein in the manufacture of a medicament for preventing or treating any disease or condition disclosed herein.EXAMPLES

[0173] The following preparations of compounds of Formula (I) and intermediates are given to enable those skilled in the art to more clearly understand and to practice the present disclosure. They should not be considered as limiting the scope of the disclosure, but merely as being illustrative and representative thereof.

[0174] The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee. Wis.), Bachem (Torrance, Calif), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser’s Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd’s Chemistry of Carbon Compounds, Volumes 1-5 and Suppiementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991). March’s Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock’s Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods by which the compounds of this disclosure can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art having referred to this disclosure. The starting materials and the intermediates, and the final products of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, cry stallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.

[0175] Unless specified to the contrary, the reactions described herein take place at atmospheric pressure over a temperature range from about -78 °C to about 150 °C, or from about 0 °C to about 125 °C or at about room (or ambient) temperature, e.g., about 20 °C.

[0176] Compounds of Formula (I) and subformulae and species described herein, including those where the substituent groups as defined herein, can be prepared as illustrated and described below.

[0177] Unless otherwise noted, all reagents were used without further purification.1H NMR spectra were obtained in CDCh, DMSO-cL. or CD3OD at room temperature on a Bruker 300MHz instrument. When more than one conformer was detected, the chemical shifts for the most abundant one is reported. Chemical shifts of1H NMR spectra were recorded in parts per million (ppm) on the 3 scale from an internal standard of residual solvent. Splitting patterns are designed as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. LC-MS conditions were as described below:

[0178] LCMS Column: Agilent Zorbax XDB C 18 4.6x50 mm, 3.5pm a. Mobile phase: Solvent A: Water (with 0.1% formic acid); Solvent B: MeOH b. Flow rate: l.O mL / min, c. Run time: 2 min gradient (20%-90% B), then 3 min @90% B, d. Temperature: 30 °C

[0179] HPLC Column: Agilent SB-C18 4.6x 150 mm, 3.5pm a. Mobile phase: Solvent A: water (with 0.02% TFA); Solvent B: MeOH b. Flow rate: l.O mL / min, c. Run time: 0.5 min @10% B, 9.5 min gradient (10%-90% B), then 10 min@90% B, d. Temperature: 30 °C

[0180] Preparative LC Column: Phenomenex Luna 5u 100 A, 21.2x250mm, 5pm a. Mobile phase: Solvent A: Water; Solvent B: MeOH b. Flow rate: 10 mL / min, c. Run time: 1 min @20% B, 30 min gradient (20%-80% B), then 10 min @90%B, d. Temperature: Ambient

[0181] The following abbreviations are used in the text:

[0185] A solution of 7-chlorofuro[3,2-b]pyridine (1 g, 6.49 mmol), K.2CO3 (3.6 g, 25.97 mmol), morpholine (30 mL) in water (10 mL) was stirred at 100 °C overnight. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated, and concentrated under reduce pressure. The residue was purified by silica gel column chromatography with a gradient elution of 20% EtOAc / PE to 50% EtOAc / PE to provide 7-morpholinofuro[3,2-b]pyridine (1.1 g, 5.39 mmol) as a colorless oil. LC-MS (ESI+): m / z 205 (MH+).1HNMR (300 MHz, CDCh) ™8.27 (d, J= 5.4 Hz, 1H). 7.72 (d, J= 2.1 Hz, 1H). 6.92 (d, J = 2.4 Hz, 1H), 6.53 (d, J = 5.4 Hz, 1H), 3.94-3.90 (m, 4H), 3.67-3.61 (m, 4H).

[0186] Synthesis of 7-morpholinofuro[3.2-b ]pyridine 4-oxide

[0187] To a solution of 7-morpholinofuro [3, 2-b] pyridine (1.1 g, 5.39 mmol) in DCM (10 mL) was added m-CPBA (3.3 g, 19.6 mmol). The mixture was stirred at rt overnight. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly and purified by silica gel column chromatography with a gradient elution of 5% MeOH / DCM to 10% MeOH / DCM to provide 7-morpholinofuro[3,2-b]pyridine 4-oxide (0.32 g, 1.45 mmol) as a white solid. LC-MS (ESI+): m / z 220 (MH+). 'HNMR (300 MHz, CDCh)7W8.07 (d, J= 5.4 Hz,1H), 7.73 (d, J= 2.4 Hz, 1H), 7.27 (d, J= 3.6 Hz, 1H), 6.49 (d, J= 6.9 Hz, 1H), 3.94-3.90 (m,4H), 3.60-3.54 (m. 4H).

[0188] Synthesis of 5-chloro-7-morpholinofii.ro [3, 2-b Jpyridine

[0189] A solution of 7-morpholinofurot3.2-bJpyridine 4-oxide (0.32 g. 1.45 mmol) in POCh(8 mL) and toluene (8 mL) was heated to 80 °C for 2 h. The reaction mixture was quenched with saturated NaHCCh solution until the pH = 8. The aqueous solution was extracted with EtOAc (3 x 30 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated andconcentrated under reduce pressure to provide crude 5-chloro-7-morpholinofuro[3,2-b]pyridine (170 mg, 0.71 mmol). The crude product was used directly for the next step without further purification. LC-MS (ESI+): m / z 239 (MH+)

[0190] Synthesis of 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3, 2-b ]pyridine

[0191] A suspension of crude 5 -chi oro-7-morpholinofuro[3, 2-b] pyridine (170 mg, 0.71 mmol). 3-phenyl-lH-pyrazole (123 mg, 0.86 mmol), CS2CO3 (466 mg, 1.43 mmol) and CU2O (31 mg, 0.21 mmol) in DMF (10 mL) was heated to 1 10 °C overnight. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phase was dried over anhydrousNa2SO4, filtrated and concentrated under reduce pressure. The residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 3% MeOH / DCM to provide 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine (120 mg, 0.35 mmol) as a yellow solid. LC-MS (ESI+): m / z 347 (MH )

[0192] Synthesis of7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine-2- carboxylic acid

[0193] To a solution of 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine (120 mg, 0.35 mmol) in anhydrous THF (20 mL) at -78 °C under N2 was added n-BuLi (0.3 mL, 2.5 M, 0.70 mmol) dropwise. The reaction mixture was stirred at that temperature for 1 h. To the above solution was added dry ice (150 mg, 3.5 mmol) in one potion. The resulting reaction mixture was stirred at that temperature for 2 h. The completion of the reaction was monitored by TLC. The reaction was quenched with water and the pH was adjusted to 5 using 1 N HC1 solution. The mixture was extracted with DCM (3 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure to provide crude7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine-2-carboxylic acid (20 mg, 0.05 mmol) as a yellow solid. LC-MS (ESI+): m / z 391 (MH ).

[0194] Synthesis of N-isopropyl-7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[ 3, 2- b ]pyridine-2-carboxamide

[0195] A solution of crude 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine-2- carboxylic acid (20 mg, 0.05 mmol), propan-2-amine (5 mg, 0.077 mmol), EDC1 (25 mg, 0.12 mmol) and HOBT (17 mg. 0.12 mmol) in DCM was stirred at rt overnight. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly and purified by preparative TLC with a elution of MeOH / DCM (1:15) to provide N-isopropyl-7-morpholino- 5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine-2-carboxamide (5.5 mg, 0.012 mmol) as a white solid. LC-MS (ESI+): m / z 432 (MH ). 'HNMR (300 MHz, CDCh) ™9.54 (d, J= 8.4 Hz, 1H), 9.06 (d, J= 2.7 Hz, 1H), 8.26 (d, J= 5.7 Hz, 1H), 7.91 (d, J= 6.9 Hz, 2H), 7.48-7.26 (m, 3H), 6.82 (d, J = 3.0 Hz, 1H), 6.61 (d, J = 6.0 Hz, 1H), 4.33-4.27 (m, 1H), 3.95-3.92 (m, 4H), 3.71-3.68 (m, 4H), 1.33 (d, J= 6.6 Hz, 6H).

[0196] General Procedure 2:

[0197] Compound 55: Synthesis of N-(methyl-d3)-N-((l-methyl-3-(7-morpholino-5-(3-(m- toIyI)-lH-pyrazoI-l-yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol-5-yl)methyl)methanamine-d3

[0199] To a solution of 3-bromo-l-methyl-lH-pyrazole-5-carbaldehyde (GP 2.1, 1.0 g, 5.29 mmol) in MeOH (30 mL) at rt was added bis(methyl-d3)amine hydrochloride (931 mg, 10.58 mmol), NaBHsCN (931 mg, 10.58 mmol) and 2 drops of AcOH. The solution was stirred at rt overnight. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (50 mL) and extracted with MeOH / DCM (1: 15, 3 x 50 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 3% MeOH / DCM to provide N-((3-bromo-l-methyl-lH- pyrazol-5-yl)methyl)-N-(methyl-d3)methanamine-d3 (683 mg, 5.42 mmol) as a yellow oil. LC- MS (ESI+): m / z 224 / 226 (MH+). ’HNMR (300 MHz, CDCh) 5 6.21 (s, 1H), 3.85 (s, 3H), 3.43 (s, 2H).

[0200] Synthesis of 5-chloro-7-morpholino-2-(tributylstannyl)furo[ 3, 2-b ]pyridine

[0201] To a solution of 5-chloro-7-morpholinofuro[3,2-b]pyridine (GP 1.4, 0.8 g, 3.38 mmol) in THF (40 mL) at -78 °C under N2 was added n-BuLi (1.6 mL, 2.5 M, 4.05 mmol). After stirred at -78 °C for 1 h, to the solution was added a solution of tributylchlorostannane (1.32 g, 4.05 mmol) in THF (10 mL). The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly. The resulting residue was purified by silica gel column chromatography with a gradient elution of 10% EtOAc / PE to 30% EtOAc / PE to provide 5- chloro-7-morpholino-2-(tributylstannyl)furo[3,2-b]pyridine (1.6 g, 3.03 mmol) as a yellow solid. 'HNMR (300 MHz, CDCh) <56.92 (s, 1H), 6.45 (s, 1H), 3.91-3.88 (m, 4H), 3.63-3.60 (m, 4H), 1.67-1.52 (m, 6H), 1.40-1.21 (m, 6H), 1.20-1.10 (m, 6H), 0.95-0.85 (m, 9H).

[0202] Synthesis of N-((3-(5-chloro-7-morpholinofuro[3, 2-b ]pyridin-2-yl) -1 -methyl- 1H- pyrazol-5-yl)methyl)-N-(methyl-d3)methanamine-d3

[0203] To a solution of 5-chloro-7-morpholino-2-(tributylstannyl)furo[3,2-b]pyridine (GP 2.3, 1.2 g, 2.27 mmol) in 1,4-dioxane (50 mL) at rt was added N-((3-bromo-l-methyl-lH-pyrazol-5- yl)methyl)-N-(methyl-d3)methanamine-d3 (GP 2.2, 560 mg, 2.50 mmol) and Pd(PPhy)4 (262 mg, 0.227 mmol). The reaction was stirred at 90 °C under N2 for 1 h. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly. The resulting residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 8% MeOH / DCM to provide N-((3-(5-chloro-7-morpholinofuro[3,2-b]pyridin-2- yl)-l -methyl- lH-pyrazol-5-yl)methyl)-N-(methyl-d3)methanamine-d3 (130 mg, 0.34 mmol) as a white solid. LC-MS (ESI+): m / z 382 / 384 (MH ). 'HNMR (300 MHz, CDCh) 6 7.02 (s, 1H), 6.57 (s, 2H), 3.99-3.91 (m, 7H), 3.69-3.63 (m, 4H), 3.47 (s, 2H).

[0204] Synthesis of N-(methyl-d3)-N-(( 1 -methyl-3-(7-morpholino-5-( 3-(m-tolyl)-lH-pyrazol-l- yl)furo[3.2-b]pyridin-2-yl)-lH-pyrazol-5-yl)methyl)methanamine-d3

[0205] To a solution of N-((3-(5-chloro-7-morpholinofuro[3,2-b]pyridin-2-yl)-l-methyl-lH- pyrazol-5-yl)methyl)-N-(methyl-d3)methanamine-d3 (GP 2.4, 50 mg, 0.13 mmol) in 1,4- dioxane (10 mL) was added 3-(m-tolyl)-lH-pyrazole (30 mg, 0.16 mmol), CS2CO3 (60 mg, 0.20 mmol), t-Buxphos (20 mg. 0.042 mmol) and Pd2(dba)3 (20 mg, 0.013 mmol). The reaction was stirred at 100 °C under N2 for 3 h. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly. The resulting residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 5% MeOH / DCM to provide N-(methyl-d3)-N-((l-methyl-3-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)-lH-pyrazol-5-yl)methyl)methanamine-d3 (54 mg, 0.107 mmol) as an off-white solid. LC-MS (ESI+): m / z 504 (MH+). ’HNMR (300 MHz, CD3OD) 58.76 (d, J= 2.7 Hz, 1H), 7.88 (s, 1H), 7.81 (d, J = 7.5 Hz, 1H), 7.44-7.35 (m, 2H), 7.31-7.25 (m, 3H), 7.14 (d, J = 2.7 Hz, 1H), 4.62 (s, 2H), 4.19-4.15 (m, 4H), 4.11 (s, 3H), 3.99-3.96 (m, 4H), 2.44 (s, 3H).

[0206] General Procedure 3:

[0207] Compound 2: Synthesis of 2-(l-methyl-lH-pyrazol-3-yl)-7-morpholino-5-(3- phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine

[0209] To a solution of 5-chloro-7-morpholinofuro[3,2-b]pyridine (GP 1.4,100 mg, 0.42 mmol) in THF (40 mL) at -78 °C under N2 was added LDA (0.3 mL, 2.0M, 0.63 mmol). After stirred at -78 °C for 1 h, to the solution was added a solution of NIS (113 mg, 0.51 mmol) inTHF (20 mL). The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (20 mL). The aqueous solution was extracted with EtOAc (3 x 20 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 10% EtOAc / PE to 20% EtOAc / PE to provide 5-chloro-2-iodo-7- morpholinofuro[3,2-b]pyridine (38 mg, 0.10 mmol) as a yellow solid. LC-MS (ESI+): m / z 365 / 367 (MH+). 'HNMR (300 MHz, CDCh) 6 7.02 (s, 1H), 6.45 (s, 1H), 3.91-3.87 (m, 4H), 3.60-3.56 (m, 4H).

[0210] Synthesis of5-chloro-2-(l-methyl-lH-pyrazol-3-yl)-7-morpholinofuro[3,2-b]pyridine

[0211] To a solution of 5-chloro-2-iodo-7-morpholinofuro[3.2-bJpyridme (GP3.1, 250 mg, 0.68 mmol) in l,4-dioxane / H2O (4 / 1, 18 mL) was added l-methyl-3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazole (160 mg, 0.82 mmol), K3CO3 (284 mg, 2.06 mmol) and PdCh(PPh3)2 (50 mg, 0.069 mmol). The reaction was stirred at 90 °C under N2 for 1 h. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly. The resulting residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 4% MeOH / DCM to provide 5-chloro-2-(l-methyl-lH-pyrazol-3- yl)-7-morpholinofuro[3,2-b]pyridine (205 mg, 0.64 mmol) as a white solid. LC-MS (ESI+): m / z 319 / 321 (MH+). 'HNMR (300 MHz. CDCL) 5 7 A3 (d, J= 2.1 Hz, 1H), 7.04 (s, 1H). 6.60 (d, J = 2.1 Hz, 1H), 6.52 (s, 1H), 4.23 (s, 3H), 3.99-3.94 (m, 4H), 3.67-3.64 (m, 4H).

[0212] Synthesis of 2-( l-methyl-lH-pyrazol-3-yl)-7-morpholino-5-(3-phenyl-lH-pyrazol-l- yl)furo[3, 2-b ] pyridine

[0213] A suspension of 5-chloro-2-(l-methyl-lH-pyrazol-3-yl)-7-morpholinofuro[3,2- b]pyridine (GP3.2, 60 mg. 0.19 mmol), 3-phenyl-lH-pyrazole (82 mg, 0.57 mmol) and CS2CO3 (250 mg, 0.76 mmol) in DMAc (4 mL) was stirred at 140 °C under microwave for 2 h. Thecompletion of the reaction was monitored by TLC. The reaction mixture was diluted with water (30 mL) and a large amount of solid was precipitated. After filtration, the filter cake was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 5% MeOH / DCM to provide 2-(l-methyl-lH-pyrazol-3-yl)-7-morpholino-5-(3-phenyl-lH-pyrazol-l- yl)furo|3,2-b]pyridine (17 mg, 0.040 mmol) as a white solid. LC-MS (ESI+): m / z 427 (MH+). 1HNMR (300 MHz, CDCh) 68.62 (d, J= 2.4 Hz, 1H), 7.96 (d, J= 1.2 Hz, 2H), 7.47-7.42 (m, 4H), 7.37-7.32 (m, 1H), 7.10 (s, 1H), 6.78 (d, J= 2.4 Hz, 1H), 6.64 (d, J= 2.4 Hz, 1H), 4.11 (s, 3H), 4.01-3.96 (m, 4H), 3.79-3.69 (m, 4H).

[0214] General Procedure 4

[0215] Compound 37: Synthesis of 5-(3-(cycIopent-l-en-l-yl)-lH-pyrazol-l-yI)-7- morpholino-2-(pyridin-2-yl)furo[3,2-b]pyridine

[0217] To a solution of 5-chloro-2-iodo-7-morpholinofuro[3,2-b]pyridine (GP 3.1, 500 mg,1.37 mmol) in DMF (50 mL) at rt was added 2-(tributylstannyl)pyridine (758 mg, 2.10 mmol). Cui (78 mg, 0.41 mmol) and PdC12(PPhs)2 (100 mg, 0.14 mmol). The reaction mixture was stirred at 110 °C under N2 for 1 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated. Theresulting residue was purified by silica gel column chromatography with a gradient elution of 10% EtOAc / PE to 50% EtOAc / PE to provide 5-chloro-7-morpholino-2-(pyridin-2-yl)furo[3,2- b]pyridine (419 mg, 1.33 mmol) as a yellow solid. LC-MS (ESI+): m / z 316 / 318 (MH+).

[0218] Synthesis of 3-bromo-l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazole

[0219] To a solution of 3-bromo-lH-pyrazole (500 mg, 3.4 mmol) in DCM (40 mL) at rt was added DHP (429 mg, 5.1 mmol) and TsOH (32 mg, 0.17 mmol). The reaction mixture was stirred at rt for 2 h. The completion of the reaction w as monitored by TLC. The reaction mixture was concentrated directly under reduced pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 2% EtOAc / PE to 4% EtOAc / PE to provide 3-bromo-l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazole (678 g, 2.95 mmol) as a colorless oil. LC-MS (ESI+): m / z 231 / 233 (MH+). HNMR (300 MHz, CDCh) 8 7.50 (s, 1H), 6.32 (s, 1H), 5.34-5.30 (m, 1H), 4.06-4.03 (m, 1H), 3.72-3.63 (m, 1H), 2.09-2.00 (m, 3H), 1.74-1.62 (m, 3H).

[0220] Synthesis of 3-(cyclopent-l-en-l-yl)-l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazole

[0221] To a solution of 3-bromo-l-(tetrahydro-2EI-pyran-2-yl)-lH-pyrazole (GP4.2, 100 mg, 0.43 mmol) in l,4-dioxane / H2O (4 / 1, 10 mL) at rt was added K.2CO3 (180 mg, 1.30 mmol), 2- (cyclopent-l-en-l-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (126 mg, 0.65 mmol) and Pd(PPhs)4 (50 mg, 0.04 mmol). The reaction was stirred at 80 °C under N2 for 1 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtrated and concentrated. The resulting residue was purified by silica gel column chromatography with a gradient elution of 2% EtOAc / PE to 4% EtOAc / PE to provide 3- (cy clopent- l-en-l-yl)-l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazole (90 mg. 0.41 mmol). LC-MS (ESI+): m / z 219 (MH+). 'HNMR (300 MHz, CDCh) 8 7.53 (s, 1H), 6.37 (s, 1H), 6.14 (s, 1H). 5.34-5.30 (m, 1H), 4.06-4.03 (m, 1H), 3.72-3.63 (m, 1H), 2.75-2.70 (m, 2H), 2.50-2.45 (m, 2H), 2.05-1.95 (m, 5H), 1.74-1.62 (m, 3H).

[0222] Synthesis of 3-(cyclopent-l-en-l-yl)-lH-pyrazole

[0223] To a solution of 3-(cyclopent-l-en-l-yl)-l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazole (GP4.3, 90 mg, 0.41 mmol) in DCM (2 mL) was added TFA (0.3 mL). The reaction mixture was stirred at rt for 2 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with aqueous NaHCOs solution to adjust pH = 8. The resulting mixture was extracted with DCM (3 X 10 mL). The combined organic phase was concentrated under reduce pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 2% EtOAc / PE to 10% EtOAc / PE to provide 3-(cyclopent-l-en-l-yl)-lH- pyrazole (45 mg, 0.34 mmol) as a light-yellow solid. LC-MS (ESI+): m / z 135 (MH+).1HNMR (300 MHz, CDCh) d 7.53 (s, 1H), 6.34 (s, 1H), 6.14 (s, 1H), 2.75-2.70 (m, 2H), 2.55-2.45 (m, 2H), 2.05-1.95 (m, 2H).

[0224] Synthesis of 5-(3-(cyclopent-l-en-l-yl)-lH-pyrazol-l-yl)-7-morpholino-2-(pyridine-2- yl)fiiro[3.2-b ]pyridine

[0225] To a solution of 5-chloro-7-morpholino-2-(pyridine-2-yl)furo[3,2-b]pyridine (GP4.1, 100 mg, 0.32 mmol) in DMAc (10 mL) was added 3-(cyclopent-l-en-l-yl)-lH-pyrazole (GP4.4, 85 mg, 0.63 mmol), Pd2(dba)s (145 mg, 0.16 mmol), t-Buxphos (135 mg, 0.32 mmol) and CS2CO3 (155 mg. 1.76 mmol). The reaction mixture was stirred at 150 °C under N2 overnight. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by preparative TLC with a elution of 50% EtOAc / PE to provide 5-(3-(cy clopent- 1- en-l-yl)-lH-pyrazol-l-yl)-7-morpholino-2-(pyridin-2-yl)furo[3,2-b]pyridine (10 mg. 0.024 mmol) as a white solid. LC-MS (ESI+): m / z 414 (MH+). ’HNMR (300 MHz, CDCh) 5 8.70 (t, J = 2.4 Hz, 1H), 8.54 (s, 1H), 7.81 (d, J= 3.9 Hz, 2H), 7.61 (s, 1H), 7.50 (s, 1H), 7.38-7.28 (m, 1H), 6.54 (t, J= 2.4 Hz, 1H), 6.29 (s, 1H), 4.02-3.98 (m, 4H), 3.79-3.76 (m, 4H), 2.86-2.82 (m, 2H), 2.55-2.52 (m, 2H), 2.09-2.00 (m, 2H)

[0226] General Procedure 5

[0227] Compound 56: Synthesis of 2-(2-methoxypyridin-3-yl)-7-morpholino-5-(3-(m- tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridine

[0229] To a solution of 5-chloro-2-iodo-7-morpholinofuro[3,2-b]pyridine (GP3,19120 mg,0.33 mmol) in l,4-dioxane / H2O (4 / 1, 10 mL) at rt was added Na2CO? (105 mg, 0.99 mmol), (2- methoxypyridin-3-yl)boronic acid (76 mg, 0.65 mmol) and Pd(PPh?) i (38 mg, 0.03 mmol). The reaction mixture was stirred at 80 °C under N2 for 1 h. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly. The resulting residue was purified by silica gel column chromatography with a gradient elution of 10% EtOAc / PE to 33% EtOAc / PE to provide 5-chloro-2-(2-methoxypyridin-3-yl)-7-morpholinofuro[3,2-b]pyridine (120 mg, 0.35 mmol) as a yellow solid. LC-MS (ESI+): m / z 346 / 348 (MH+).1HNMR (300 MHz, CDCh) 8 8.22-8.20 (m, 1H), 8.11-8.08 (m, 1H), 7.61 (s, 1H). 7.06-7.02 (m, 1H), 6.54 (s, 1H), 4.13 (s, 3H), 3.96-3.91 (m, 4H), 3.68-3.60 (m, 4H).

[0230] Synthesis of2-(2-methoxypyridin-3-yl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-I- yl)furo[3, 2-b ]pyridineCompound 56

[0231] To a solution of 5-chloro-2-(2-methoxypyridin-3-yl)-7-morpholinofuro[3,2-b]pyridine (GP5.1, 60 mg, 0.17 mmol) in 1,4-dioxane (5 mL) was added 3-(m-tolyl)-lH-pyrazole (55 mg, 0.34 mmol), Pd2(dba)3 (80 mg, 0.09 mmol), t-Buxphos (75 mg, 0.17 mmol) and CS2CO3 (115 mg, 0.34 mmol). The reaction mixture was stirred at 90 °C under N2 overnight. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 20% EtOAc / PE to 50% EtOAc / PE to provide 2-(2-methoxypyridin-3-yl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridine (46 mg, 0.1 mmol) as a yellow solid. LC-MS (ESI+): m / z 468 (MH+).1HNMR (300 MHz, CDCh) d 8.62 (d, J= 2.7 Hz, 1H), 8.22-8.20 (m, 1H), 8.15-8.12 (m, 1H), 7.78 (s, 1H). 7.73 (d, J= 7.5 Hz, 1H), 7.52 (s. 1H), 7.47 (s, 1H), 7.35 (t, J= 7.8 Hz, 1H), 7.17 (d, J= 7.8 Hz, 1H), 7.08-7.03 (m, 1H), 6.78 (d, J= 2.7 Hz, 1H), 4. 15 (s, 3H), 4.02- 3.98 (m, 4H), 3.80-3.77 (m, 4H), 2.44 (s, 3H).

[0232] General Procedure 6

[0233] Compound 57: Synthesis of 3-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)pyridin-2(lH)-one

[0234] Synthesis of 3-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3, 2-b ]pyridin-2- yl)pyridin-2(lH)-one

[0235] To a solution of 2-(2-methoxypyridin-3-yl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol- l-yl)furo[3,2-b]pyridine (Compound 56, 23 mg, 0.05 mmol) in DMF (2 mL) at rt was added LiCl (7 mg, 0.2 mmol) and TsOH (16 mg, 0.2 mmol). The reaction was stirred at 120 °C for 30 min. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic phase wasdried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 2% MeOH / DCM to provide 3-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)pyridin-2(lH)-one (8 mg, 0.018 mmol) as ayellow solid. LC-MS (ESI+): m / z 454 (MH^.’HNMR (300 MHz, CDCh) <5 8.64 (s, 1H), 8.11-8.08 (m, 1H), 7.92 (s, 1H), 7.78 (s, 1H), 7.74 (d, J= 7.5 Hz, 1H), 7.48-7.45 (m, 2H), 7.36 (t, J= 7.5 Hz, 1H), 7.18 (d, J = 7.5 Hz, 1H), 6.78 (d, J= 2.7 Hz, 1H), 6.53-6.48 (m, 1H), 4.02-3.99 (m, 4H), 3.80-3.78 (m, 4H), 2.44 (s, 3H).

[0236] General Procedure 7

[0237] Compound 61: Synthesis of N,N-bis(methyl-d3)-2-(4-(7-morpholino-5-(3-(m- tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol-l-yl)ethan-l-amine hydrogen

[0238] Synthesis of 5-chloro-7-morpholino-2-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-4- yl)furo[3, 2-b ]pyridine

[0239] To a solution of 5-chloro-2-iodo-7-morpholinofuro[3,2-b]pyridine (GP3.1, 600 mg, 1.65 mmol) in l,4-dioxane / H2O (4 / 1, 30 mL) was added l-(tetrahydro-2H-pyran-2-yl)-4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (550 mg, 1.98 mmol), K2CO3 (682 mg, 5.0 mmol) and PdCh(PPh3)2 (116 mg, 0.16 mmol). The reaction was stirred at 90 °C under N2 for 1 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated. The resulting residue w as purified by silica gel column chromatography with a gradient elution of 30% EtOAc / PE to 50% EtOAc / PE to provide 5-chloro-7-morpholino-2-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-4- yl)furo[3,2-b]pyridine (430 mg, 1.11 mmol) as ayellow solid. LC-MS (ESI+): m / z 389 / 391 (MHVHNMR (300 MHz, CDCls) d 8.03 (s, 1H), 7.88 (s, 1H), 6.75 (s, 1H), 6.50 (s, 1H), 5.47- 5.43 (m, 1H), 4.13-4.08 (m, 1H), 3.94-3.91 (m, 4H), 3.77-3.70 (m, 1H), 3.63-3.61 (m, 4H), 2.15- 2.05 (m, 3H), 1.75-1.62 (m, 3H).

[0240] Synthesis of7-morpholmo-2-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-4-yl)-5-(3-(m- tolyl)-lH-pyrazol-l-yl)furo[3, 2-b ]pyridine

[0241] To a solution of 5-chloro-7-morpholino-2-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol- 4-yl)furo[3,2-b]pyridine (GP7.1, 410 mg, 1.06 mmol) in 1,4-dioxane (40 mL) was added 3-(m- tolyl)-lH-pyrazole (334 mg, 2.11 mmol), CS2CO3(689 mg, 2. 11 mmol), t-BuXphos (450 mg, 1.06 mmol) and Pd2(dba)3 (484 mg, 0.53 mmol). The reaction was stirred at 90 °C under N2 for 3 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated. The resulting residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 3% MeOH / DCM to provide 7-morpholino-2-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-4-yl)-5-(3- (m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridine (600 mg, 1.17 mmol) as ayellow solid. LC-MS (ESI+): m / z 511 (MH+). 'HNMR (300 MHz, CDCh) S 8.59 (s, 1H), 8.00 (s, 1H), 7.90 (s, 1H), 7.77 (s. 1H), 7.73 (d, J= 7.8 Hz. 1H), 7.41 (s, 1H), 7.33 (t, .J - 1.5 Hz, 1H), 7.17 (d, J - 1.5 Hz, 1H), 6.81 (s, 1H), 6.76 (d, J = 2.4 Hz, 1H), 5.47-5.43 (m, 1H), 4.15-4.10 (m, 1H), 3.99-3.96 (m, 4H), 3.76-3.71 (m, 5H), 2.43 (s, 3H), 2.16-2.05 (m, 3H), 1.75-1.62 (m, 3H).

[0242] Synthesis of 7-morpholino-2-( lH-pyrazol-4-yl)-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3, 2-b ]pyridine

[0243] To a solution of 7-morpholino-2-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-4-yl)-5-(3- (m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridine (GP7.2, 600 mg, 1.17 mmol) in DCM (15 rnL) at rt was added TFA (5 mL). The solution was stirred at rt for 2 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with aqueous NaHCCh solution to adjust pH to 8. The aqueous solution was extracted with DCM (3 X 20 mL). The combined organic phase was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 5% MeOH / DCM to provide 7-morpholino-2-(lH-pyrazol-4-yl)-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridine (200 mg, 0.47 mmol) as a yellow solid. LC-MS (ESI+): m / z 427 (MH+).

[0244] Synthesis of 2-( l-(2-bromoethyl)-lH-pyrazol-4-yl)-7-morpholino-5-(3-(m-tolyl)-lH- pyrazol-l-yl)furo[3, 2-b ]pyridine

[0245] A suspension of 7-morpholino-2-(lH-pyrazol-4-yl)-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo [3, 2-b] pyridine (GP7.3, 190 mg, 0.445 mmol), 1,2-dibromoethane (832 mg, 4.45 mmol) and K2CO3 (420 mg, 1.29 mmol) in DMF (20 mL) was heated to 60 °C for 3 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtrated and concentrated under reduce pressure. The residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 5% MeOH / DCM to provide 2-( 1 -(2 -bromoethyl)- IH-py razol-4-y l)-7-morpholino-5-(3 -(m-tolyl)- IH-py razol- 1 - yl)furo|3,2-b]pyridine (150 mg, 0.28 mmol) as a yellow solid. LC-MS (ESI+): m / z 533 / 535 (MH+).1HNMR (300 MHz, CDCh) b 8.59 (s, 1H), 7.92 (s, 1H), 7.86 (s, 1H), 7.77 (s, 1H), 7.73 (d. . / - 7.8 Hz. 1H), 7.42 (s, 1H), 7.33 (t, J= 7.5 Hz, 1H), 7.17 (t, J= 7.5 Hz, 1H), 6.81 (s, 1H),6.76 (d, J= 2.4 Hz, 1H), 4.58 (t, J= 6.0 Hz, 2H), 3.99-3.96 (m, 4H), 3.82-3.75 (m, 6H), 2.41 (s, 3H).

[0246] Synthesis ofN,N-bis(methyl-d3)-2-(4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3.2-b ]pyridin-2-yl)-lH-pyrazol-l-yl)ethan-l-amine hydrogen chloride

[0247] A suspension of 2-(l-(2-bromoethyl)-lH-pyrazol-4-yl)-7-morpholino-5-(3-(m-tolyl)- lH-pyrazol-l-yl)furo[3,2-b]pyridine (GP7.4, 140 mg. 0.26 mmol), bis(methyl-d3)amine hydrochloride (35 mg, 0.40 mmol) and K2CO3 (73 mg, 0.53 mmol) in DMF (7 mL) was heated to 60 °C for 4 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (40 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtrated and concentrated under reduce pressure. The residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 5% MeOH / DCM to provide N,N-bis(methyl-d3)-2-(4-(7-morpholino-5-(3-(m- tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol-l-yl)ethan-l-amine (50 mg, 0.10 mmol) as a white solid. LC-MS (ESI+): m / z 504 (MH+).

[0248] To a solution of N,N-bis(methyl-d3)-2-(4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol-l-yl)ethan-l-amine (the ‘free base’, 50 mg. 0.10 mmol) in DCM (5 mL) was added Et2O / EICl (0.5 mL). The solution was stirred at rt for 10 min. The reaction mixture was concentrated directly. The resulting residue was slurry in Et20 to provide N,N-bis(methyl-d3)-2-(4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyri din-2- yl)-lH-pyrazol-l-yl)ethan-l -amine hydrochloride (50 mg, 0.09 mmol) as ayellow solid. LC-MS (ESI+): m / z 504 (MH ). 'HNMR (300 MHz, CD3OD) <5 8.74 (d, J= 2.7 Hz, 1H), 8.58 (s, 1H), 8.22 (s, 1H), 7.88 (s, 1H), 7.81 (d, J= 7.8 Hz, 1H), 7.37 (t, J= 7.5 Hz, 1H), 7.32-7.20 (m, 3H), 7.13 (d, J= 2.7 Hz, 1H), 4.73 (t, J= 5.7 Hz, 2H), 4.21-4.11 (m, 4H), 4.01-3.91 (m, 4H), 3.76 (t, .7 = 5 7 Hz. 2H). 2.44 (s, 3H).

[0249] General Procedure 8

[0250] Compound 10: Synthesis of 7-morpholino-5-(3-phenyI-lH-pyrazol-l-yl)-2-(lH- pyrazol-4-yl)furo [3, 2-b] pyridine and Compound 11: Synthesis of 3-(4-(7-morpholino-5-(3- phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol-l-yl)propan-l-ol

[0252] To a solution of 5-chloro-2-iodo-7-morpholinofuro[3,2-b]pyridine (GP3.1, 360 mg, 0.99 mmol) in l,4-dioxane / H2O (10 / 1, 20 mL) was added l-(tetrahydro-2H-pyran-2-yl)-4- (4,4,5,5-tetramethyl-1.3,2-dioxaborolan-2-yl)-lH-pyrazole (303 mg, 1.086 mmol), K2CO3 (410 mg, 2.96 mmol) and PdC12(PPh?)2 (70 mg, 0.079 mmol). The reaction was stirred at 80 °C under N2 overnight. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous NazSCU, filtrated and concentrated. The resulting residue was purified by silica gel column chromatography with a gradient elution of 20% EtOAc / PE to 40% EtOAc / PE to provide 5-chloro-7-morpholino-2-(l-(tetrahydro-2EI-pyran-2-yl)-lH-pyrazol-4- yl)furo[3,2-b]pyridine (320 mg, 0.82 mmol) as a yellow oil. LC-MS (ESI+): m / z 389 / 391 (MH+). ’HNMR (300 MHz, CDCh) <5 8.00 (s, 1H), 7.87 (s, 1H), 6.74 (s, 1H), 6.50 (s, 1H), 5.47- 5.43 (m, 1H), 4.13-4.08 (m, 1H), 3.94-3.91 (m, 4H), 3.77-3.71 (m, 1H), 3.64-3.61 (m, 4H), 2.15- 2.05 (m, 3H), 1.75-1.62 (m, 3H).

[0253] Synthesis of7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)-2-(l-(tetrahydro-2H-pyran-2- yl)-lH-pyrazol-4-yl)furo[ 3.2-b ]pyridine

[0254] To a solution of 5-chloro-7-morpholino-2-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol- 4-yl)furo[3,2-b]pyridine (GP8.1, 320 mg, 0.82 mmol) in 1,4-dioxane (15 mL) at rt was added 3- phenyl-lH-pyrazole (178 mg, 1.23 mmol), Pd2(dba)s (151 mg, 0.17 mmol), t-Buxphos (140 mg, 0.33 mmol) and Cs2CO3 (805 mg, 2.50 mmol). The reaction was stirred at 105 °C under N2 overnight. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 10 mL). The combined organic phase was dried over anhydrous NazSOi, filtrated and concentrated under reduce pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 20% EtOAc / PE to 33% EtOAc / PE to provide 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)-2-(l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazol-4-yl)furo[3,2-b]pyridine (280 mg, 0.56 mmol) as a yellow solid. LC-MS (ESI+): m / z 497 (Ml I ).1! 1NMR (300 MHz, CDCh) 5 8.60 (s, 1H), 8.00 (s, 1H), 7.96-7.90 (m, 2H), 7.47-7.32 (m, 5H), 6.81-6.77 (m, 2H), 5.47-5.43 (m, 1H), 4.13-4.08 (m, 1H), 3.94-3.91 (m, 4H), 3.77-3.71 (m, 5H), 2.15-2.05 (m, 3H), 1.75-1.62 (m, 3H).

[0255] Synthesis of7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)-2-(lH-pyrazol-4-yl)furo[3,2- b ]pyridine

[0256] To a solution of 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)-2-(l-(tetrahydro-2H- pyran-2-yl)-lH-pyrazol-4-yl)furo[3,2-b]pyridine (GP8.2, 280 mg, 0.56 mmol) in MeOH (3 mL) was added a solution of E12O / HC1 (3 mL). The reaction mixture was stirred at rt for 1 h and then concentrated directly. The resulting residue was slurry in Et20 to provide 7-morpholino-5-(3- phenyl-lH-pyrazol-l-yl)-2-(lH-pyrazol-4-yl)furo[3,2-b]pyridine hydrochloride (250 mg, 0.61 mmol) as a white solid. LC-MS (ESI+): m / z 413 (MH+).1HNMR (300 MHz, CD3OD) 5 8.74 (s,1H), 8.35 (s, 2H), 8.02 (d, J= 6.6 Hz, 2H), 7.65-7.42 (m, 3H), 7.27 (s, 1H), 7.20 (s, 1H), 7.13 (s, 1H), 4.15-4.10 (m, 4H), 3.96-3.90 (m, 4H).

[0257] Synthesis of 7-morpholino-5-( 3-phenyl-lH-pyrazol-l-yl)-2-(l -( 3-( ( tetrahydro-2H- pyran-2-yl)oxy)propyl)-lH-pyrazol-4-yl)furo[3,2-b]pyridine

[0258] A suspension of 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)-2-(lH-pyrazol-4- yl)furo[3,2-b]pyridine hydrochloride (Compound 10, 350 mg, 0.78 mmol), 2-(3- bromopropoxy)tetrahydro-2H-pyran (209 mg, 0.94 mmol) and CS2CO3 (1 .02 g, 3. 12 mmol) in DMF (10 mL) was heated to 60 °C for 2 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The residue was purified by silica gel column chromatography with a gradient elution of PE to EtOAc to provide 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)-2-(l-(3- ((tetrahydro-2H-pyran-2-yl)oxy)propyl)-lH-pyrazol-4-yl)furo[3,2-b]pyridine (180 mg, 0.32 mmol) as a white solid. LC-MS (ESI+): m / z 555 (MH ). 'HNMR. (300 MHz, CDCh) 58.60 (s. 1H), 7.96-7.94 (m, 2H), 8.87 (s, 1H), 8.82 (s, 1H), 7.47-7.35 (m, 4H), 6.77 (s, 2H), 4.60-4.58 (m, 1H), 4.34 (t, J= 6.6 Hz, 2H), 3.98-3.96 (m, 4H), 3.89-3.79 (m, 2H), 3.76-3.74 (m, 4H), 3.53-3.40 (m, 2H), 2.23-2.19 (m, 2H), 1.84-1.74 (m, 2H), 1.62-1.58 (m, 4H).

[0259] Synthesis of 3-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)- lH-pyrazol-l-yl)propan-l-ol

[0260] To a solution of 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)-2-(l-(3-((tetrahydro-2H- pyran-2-yl)oxy)propyl)-lH-pyrazol-4-yl)furo[3,2-b]pyridine (GP8.3, 180 mg, 0.32 mmol) in MeOH (6 mL) at rt was added a solution of Et2O / HCl (3 mL). The reaction mixture was stirred at rt for 1 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with NaHCCL aqueous solution until the pH = 8. The aqueous solution was extractedwith DCM (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was slurry' in EtaO to provide 3-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol- l-yl)propan-l-ol (205 mg, 0.44 mmol) as a yellow solid. LC-MS (ESI+): m / z 471 (MH^.'HNMR (300 MHz, CDCh) 5 8.60 (d, J= 2.4 Hz, 1H), 7.95-7.93 (m, 2H), 7.87 (s, 1H),7.81 (s, 1H), 7.47-7.42 (m, 3H), 7.37-7.35 (m, 1H), 6.79-6.77 (m, 2H), 4.38 (t, J= 6.4 Hz, 2H), 3.99-3.96 (m, 4H), 3.76-3.73 (m, 4H), 3.68 (t, J= 5.4 Hz, 2H), 2.30 (t, J= 5.4 Hz, 1H), 2.15- 2.11 (m, 2H).

[0261] General Procedure 9

[0262] Compound 17: Synthesis of 2,2-dimethyl-3-(4-(7-morpholino-5-(3-phenyl-lH- pyrazol- l-yl)furo [3,2-b] pyridin-2-yl)- IH-pyrazol- l-yl)propan- l-olG .

[0264] To a solution of 3-bromo-2,2-dimethylpropan-l-ol (300 mg, 1.80 mmol), DMAP (22 mg, 0.18 mmol) and EtaN (546 mg, 5.40 mmol) in DCM (10 mL) under N2 at 0 °C was added a solution of AC2O in DCM (3 mL) dropwise. The reaction mixture was stirred at rt for 3 h. Thecompletion of the reaction was monitored by TLC. The reaction mixture was quenched with water and extracted with DCM (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to provide crude 3-bromo- 2,2-dimethylpropyl acetate (380 mg. 1.83 mmol) as a light yellow oil. 'HNMR (300 MHz, CDCh) 6 3.94 (s, 2H), 3.35 (s, 2H), 2.08 (s, 3H), 1.06 (s, 6H).

[0265] Synthesis of 2,2-dimethyl-3-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2- b ]pyridine-2-yl)-lH-pyrazol-l-yl)propyl acetate

[0266] To a solution of 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)-2-(lH-pyrazol-4- yl)furo[3,2-b]pyridine (Compound 10, 35 mg, 0.085 mmol) in DMF (10 mL) at rt was added 3- bromo-2,2-dimethylpropyl acetate (GP9.1, 35 mg, 0.17 mmol) and CS2CO3 (325 mg, 0.17 mmol). The reaction mixture was stirred at 100 °C overnight. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water and was extracted with DCM (2 x 20 mL). The combined organic phase was dried over anhydrous NazSO-i, filtrated and concentrated under reduce pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 20% EtOAc / PE to 50% EtOAc / PE to provide 2,2- dimethyl-3-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine-2-yl)-lH- pyrazol-l-yl)propyl acetate (20 mg, 0.037 mmol) as a white solid. LC-MS (ESI+): m / z 541 (MH+).

[0267] Synthesis of 2, 2-dimethyl-3-( 4-(7-morpholino-5-( 3-phenyl-lH-pyrazol-l-yl)furo[3, 2- bJyridine-2-yl)-lH-pyrazol-l-yl)propan-l-ol

[0268] To a solution of 2,2-dimethyl-3-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol-l- yl)furo[3,2-b]yridine-2-yl)-lH-pyrazol-l -yl)propyl acetate (GP9.2, 20 mg, 0.037 mmol) in MeOH / ELO (3: 1, 4 mL) was added NaOH solid (3 mg, 0.074 mmol). The reaction mixture was stirred at rt overnight. The completion of the reaction was monitored by TLC. The reactionmixture was diluted with water and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by preparative HPLC to provide 2,2-dimethyl-3-(4-(7- morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol-l-yl)propan-l-ol (17 mg, 0.034 mmol) as a white solid. LC-MS (ES1+): m / z 499 (MH+). 'HNMR (300 MHz, CDCh) 88.61 (d, J= 2.4 Hz, 1H), 7.95-7.93 (m, 2H), 7.87 (s, 1H), 7.74 (s, 1H), 7.44-7.42 (m, 3H), 7.37-7.35 (m, 1H), 6.80-6.77 (m, 2H), 4.08 (s, 2H), 4.01- 3.95 (m, 4H), 3.74-3.70 (m, 4H), 3.38-3.31 (m, 1H), 3.26-3.20 (m, 2H), 0.99 (s. 6H).

[0269] General Procedure 10

[0270] Compound 18: Synthesis of 2-methyl-4-(4-(7-morpholino-5-(3-phenyl-lH-pyrazoI- l-yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol-l-yl)butan-2-ol

[0271] Synthesis of 2-methyl-4-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)-lH-pyrazol-l-yl)butan-2-ol

[0272] A suspension of 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)-2-(lH-pyrazol-4- yl)furo[3,2-b]pyridine (Compound 10, 25 mg, 0.06 mmol), 4-bromo-2-methylbutan-2-ol (20 mg, 0.12 mmol) and CS2CO3(39 mg, 0.12 mmol) in DMF (10 mL) was heated to 50 °C and stirred for 3 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The residue was purified by preparative TLC with a elution of DCM / MeOH (15: 1) to provide 2-methyl-4-(4- (7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol-l-yl)butan-2- ol (20 mg, 0.04 mmol) as a white solid. LC-MS (ESI+): m / z 499 (MH+). 'HNMR (300 MHz, CDCh) 3 8.61 (d, J= 2.4 Hz, 1H), 7.95-7.93 (m, 2H), 7.85 (s, 1H), 7.80 (s, 1H), 7.47-7.42 (m, 3H), 7.37-7.32 (m, 1H), 6.77 (s, 2H), 4.38 (t, J= 6.9 Hz, 2H), 4.01- 3.97 (m, 4H), 3.80-3.74 (m, 4H), 2.12 (t, J= 7.5 Hz, 2H), 2.03 (s, 1H), 1.31 (s, 6H).

[0273] General Procedure 11

[0274] Compound 19: Synthesis of 7-morpholino-2-(l-(3-morpholinopropyl)-lH-pyrazol-4-yl)-5-(3-phenyl- IH-pyrazol- l-yl)furo [3, 2-b] pyridine

[0276] A suspension of 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)-2-(lH-pyrazol-4- yl)furo[3,2-b]pyridine (Compound 10, 30 mg, 0.07 mmol). 1,3-dibromopropane (147 mg. 0.73 mmol) and CS2CO3 (47 mg, 0.15 mmol) in DMF (2 mL) was heated to 50 °C and stirred for 3 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC with a elution of DCM / MeOH (15: 1) to provide 2-(l-(3- bromopropyl)-lH-pyrazol-4-yl)-7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine (20 mg, 0.04 mmol) as a white solid. LC-MS (ESI+): m / z 533 / 535 (MH+).

[0277] Synthesis of 7 -morpholino-2-( 1 -(3-morpholinopropyl)-lH-pyrazol-4-yl)-5-(3-phenyl- lH-pyrazol-l-yl)furo[3, 2-b ]pyridine

[0278] To a solution of 2-(l-(3-bromopropyl)-lH-pyrazol-4-yl)-7-morpholino-5-(3-phenyl- lH-pyrazol-l-yl)furo[3,2-b]pyridine (GP11.1, 20 mg, 0.04 mmol) in THF was added morpholine (33 mg, 0.4) and Nal (1 mg, 0.008 mmol). The reaction mixture was stirred at rt overnight. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (20 mb) and extracted with EtOAc (2 x 20 rnL). The combined organic phase was dried over anhydrous NazSCU, filtrated and concentrated under reduce pressure. The residue was purified by preparative TLC with a elution of DCM / MeOH (20: 1) to provide 7-morpholino- 2-(l-(3-morpholinopropyl)-lH-pyrazol-4-yl)-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine (15 mg, 0.028 mmol) as a white solid. LC-MS (ESI+): m / z 540 (MEL). 'HNMR (300 MHz, CDCh) 8 8.61 (d, J= 2.4 Hz, 1H). 7.95-7.93 (m, 2H). 7.86 (s, 1H), 7.79 (s. 1H), 7.47-7.42 (m. 3H), 7.37-7.32 (m, 1H), 6.77 (s, 2H), 4.27 (t, J= 6.9 Hz, 2H), 3.97 -3.90 (m, 4H), 3.80-3.60 (m, 8H), 2.44-2.34 (m, 6H), 2.11 (t, J = 6.9 Hz, 2H).

[0279] General Procedure 12

[0280] Compound 29: Synthesis of N,N-bis(methyl-d3)-2-(4-(7-morpholino-5-(3-phenyl- IH-pyrazol- l-yl)furo [3,2- b ] pyridin-2-yl)- IH-pyrazol- l-yl)ethan- 1 -amine

[0281] Synthesis of 2-(l-(2-bromoethyl)-lH-pyrazol-4-yl)-7-morpholino-5-(3-phenyl-lH- pyrazol-l-yl)furo[3, 2-b ]pyridine

[0282] A suspension of 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)-2-(lH-pyrazol-4- yl)furo[3,2-b]pyridine (Compound 10, 120 mg, 0.27 mmol), 1,2-dibromoethane (505 mg, 2.7 mmol) and CS2CO3(351 mg, 1.08 mmol) in DMF (5 mL) was heated to 50 °C and stirred for 2 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 20% EtOAc / PE to 50% EtOAc / PE to provide 2-(l-(2-bromoethyl)-lH-pyrazol-4-yl)-7-morpholino-5-(3-phenyl- lH-pyrazol-l-yl)furo[3,2-b]pyridine (95 mg, 0.18 mmol) as a yellow solid. LC-MS (ESI+): m / z 519 (MH+).1HNMR (300 MHz, CDCh) 3 8.61 (d, J= 2.7 Hz, 1H), 7.95-7.93 (m, 3H), 7.86 (s, 1H), 7.47-7.42 (m, 3H), 7.37-7.32 (m, 1H), 6.82 (s, 1H), 6.78 (d, J= 2.7 Hz, 1H), 4.58 (t, J= 6.3 Hz, 2H), 4.01- 3.96 (m, 4H), 3.82-3.74 (m, 6H).

[0283] Synthesis qfN,N-bis(methyl-d3)-2-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol-l-yl)ethan-l-amine

[0284] To a solution of 2-(l-(2-bromoethyl)-lH-pyrazol-4-yl)-7-morpholino-5-(3-phenyl-lH- pyrazol-l-yl)furo[3,2-b]pyridine (GP12.1, 95 mg. 0.18 mmol) in DMF (3 mL) was added bis(methyl-d3)amine hydrochloride (161 mg, 1.83 mmol) and CS2CO3(596 mg, 1.83 mmol). The reaction mixture was stirred at rt for 3 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 15 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 2% MeOH / DCM to 5% MeOH / DCM to provide N,N-bis(methyl-d3)- 2-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol-l -yl)furo[3,2-b]pyri din-2 -yl)-lH-pyrazol-l- yl)ethan-l -amine (34 mg, 0.069 mmol) as a white solid. LC-MS (ESI+): m / z 490 (MH*).'HNMR (300 MHz, DMSO-cfe) d 8.64 (d, J = 2.4 Hz, 1H), 8.38 (s, 1H), 8.03-7.96 (m, 3H), 7.49- 7.44 (m, 2H), 7.40-7.33 (m, 2H), 7.05-7.03 (m, 2H), 4.27 (t, J= 6.6 Hz, 2H), 3.87-3.83 (tn, 4H), 3.71-3.68 (m, 4H), 2.69 (t, J= 6.6 Hz, 2H).

[0285] General Procedure 13

[0286] Compound 47: Synthesis of (S)-2-methyl-4-(4-(7-morpholino-5-(3-phenyl-lH- pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol-l-yl)butan-2-yI 2-amino-3- methylbutanoate hydrochloride

[0288] To a solution of 2-methyl-4-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)-lH-pyrazol-l-yl)butan-2-ol (Compound 18, 100 mg, 0.20 mmol) in anhydrous DCM (5 mL) at rt was added DMAP (73.5 mg, 0.60 mmol), DIC (75.9 mg, 0.60 mmol) and scandium trifluoromethanesulfonate (60 mg, 0. 12 mmol). The reaction mixture was stirred at rt overnight. The reaction mixture was diluted with water (20 mL) and extracted with DCM (3 x 10 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 2% MeOH / DCM to 10% MeOH / DCM to provide (S)-2-methyl-4-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)-lH- pyrazol-l-yl)butan-2-yl 2-((tert-butoxycarbonyl)amino)-3-methylbutanoate (65 mg, 0.09 mmol)as a white solid. LC-MS (ESI+): m / z 698 (MH ). 'HNMR (300 MHz, CDCh) 88.61 (s, 1H), 7.95-7.93 (m, 2H), 7.85-7.84 (m, 2H), 7.47-7.42 (m, 3H), 7.37-7.32 (m, 1H), 6.78 (s, 2H), 4.29 (t, J= 7.5 Hz, 2H), 4.00-3.96 (m, 4H), 3.76-3.74 (m, 4H), 2.52-2.35 (m, 2H), 2.16-2.10 (m, 1H), 1.57 (s, 3H), 1.49 (s, 3H), 1.46 (s, 9H), 1.00 (d, J= 6.9 Hz, 3H), 0.93 (d, J= 6.9 Hz, 3H).

[0289] Synthesis of (S)-2-methyl-4-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)-lH-pyrazol-l-yl)butan-2-yl 2-amino-3-methylbutanoate hydrochloride

[0290] To a solution of (S)-2-methyl-4-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol-l-yl)butan-2-yl 2-((tert-butoxycarbonyl)amino)-3- methylbutanoate (20 mg, 0.03 mmol) in DCM (1 mL) at rt was added a solution of Et2O / HCl (0.5 mL). The solution was stirred at rt for 2 h. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly. The resulting residue was slurry in DCM to provide (S)-2-methyl-4-(4-(7-morphohno-5-(3-phenyl-lH-pyrazol-l-yl)furo|3,2-b]pyridin-2- yl)-lH-pyrazol-l-yl)butan-2-yl 2-amino-3-methylbutanoate hydrochloride (15 mg, 0.024 mmol) as a yellow solid. LC-MS (ESI+): m / z 598 (MH+). 'HNMR (300 MHz, CD3OD) 88.74 (d, J= 2.7 Hz, 1H), 8.53 (s, 1H), 8.13 (s, 1H), 8.04 (d, 6.9 Hz, 2H), 7.51-7.43 (m, 3H), 7.27 (s, 1H).7.17-7.15 (m, 2H). 4.45- 4.40 (m, 2H), 4.21-4.11 (m, 4H), 4.04-3.94 (m, 4H), 3.89-3.88 (m, 1H), 2.54-2.26 (m, 3H), 1.64 (s, 3H), 1.60 (s, 3H), 1.10 (d, .7= 6.9 Hz, 6H).

[0291] General Procedure 14

[0292] Compound 51: Synthesis of (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(4-(4-(7- morpholino-5-(3-phenyl- IH-pyrazol- l-yl)furo [3,2-b] pyridin-2-yl)- IH-py razol- 1- yl)butoxy )tetrahydro-2II-pyran-3.4.5-triol

[0294] To a solution of (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-hydroxytetrahydro-2H-pyran- 3, 4, 5-triyl triacetate (500 mg, 1.44 mmol) in anhydrous DCM (5 mL) at rt was added K2CO3(595 mg, 4.31 mmol) and CCI3CN (415 mg, 2.87 mmol). The reaction mixture was stirred at rt for 3 h. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated under reduce pressure to provide crude (2R.3R,4S,5R,6R)-2-(acetoxymethyl)-6- (2,2,2-trichloro-l-iminoethoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (300 mg, 0.86 mmol) as a colorless oil.1HNMR (300 MHz, CDCh) 88.71 (s, 1H), 6.57-6.54 (m, 1H), 5.57-5.22 (m, 1H), 5.19-5.12 (m, 2H), 4.31-4.02 (m, 3H), 2.08-2.02 (m, 12H).

[0295] Synthesis of (2R, 3R, 4S.5R, 6R)-2-(acetoxymethyl)-6-(4-bromobutoxy)tetrahydro-2H- pyran-3.4, 5-triyl triac etate

[0296] To a solution of crude (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2,2,2-trichloro-l- iminoethoxy)tetrahydro-2H-pyran-3, 4, 5-triyl triacetate (GP14.2, 250 mg, 0.01 mmol) in anhydrous DCM (5 mL) at rt was added 4-bromobutan-l-ol (97 mg, 0.01 mmol), 4A molecular sieve and TMSOTf (10 drops). The reaction mixture was stirred at rt overnight. The completionof the reaction was monitored by TLC. The reaction mixture was quenched with water (10 mL) and extracted with DCM (3 x 10 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to provide crude (2R,3R,4S,5R,6R)-2- (aceloxymelhyl)-6-(4-bromobuloxy)tetrahydro-2H-pyran-3.4.5-lriyl triacetate (250 mg, 0.52 mmol) as a colorless oil. LC-MS (ESI+): m / z 483 / 485 (MH+).

[0297] Synthesis of(2R, 3R, 4S,5R, 6R)-2-(acetoxymethyl)-6-( 4-( 4-(7-morpholino-5-( 3-phenyl- lH-pyrazol-l-yl)fiuro[3, 2-b ]pyridin-2-yl)-lH-pyrazol-l-yl)butoxy)tetrahydro-2H-pyran-3, 4, 5- triyl triacetate

[0298] To a solution of crude (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(4- bromobutoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (GP'14.2, 100 mg, 0.2 mmol) in anhydrous DMF (10 mL) at rt was added 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)-2-(lH- pyrazol-4-yl)furo[3,2-b]pyridine (50 mg, 0.12 mmol) and CS2CO3(260 mg, 0.8 mmol). The solution was stirred at 50 °C for 4 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtrated and concentrated under reduce pressure. The resulting residue was purified by preparative TLC with a elution of 8% MeOH / DCM to provide (2R,3R.4S.5R,6R)-2-(acetoxymethyl)-6-(4-(4-(7-morpholino-5-(3- phenyl- IH-pyrazol- 1 -yl)furo[3,2-b]pyridin-2-yl)- IH-pyrazol- 1 -yl)butoxy)tetrahy dro-2H-pyran- 3,4,5-triyl triacetate (6 mg, 0.007 mmol) as a white solid. LC-MS (ESI+): m / z 815 (MH+).

[0299] Synthesis of (2R, 3S, 4S,5R, 6R)-2-(hydroxymethyl)-6-(4-(4-(7-morpholino-5-(3-phenyl- lH-pyrazol-l-yl)furo[3, 2-b ]pyridin-2-yl)-lH-pyrazol-l-yl)butoxy)tetrahydro-2H-pyran-3, 4, 5- triol

[0300] To a solution of (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(4-(4-(7-morpholino-5-(3- phenyl- IH-pyrazol- 1 -yl)furo[3,2-b]pyridin-2-yl)- IH-pyrazol- 1 -yl)butoxy)tetrahy dro-2H-pyran-3,4,5-triy 1 triacetate (GP14.3, 6 mg, 0.007 mmol) in MeOH (1 mL) at rt was added NaOMe (1.5 mg, 0.028 mmol). The reaction mixture was stirred at rt for 0.5 h. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly under reduce pressure. The resulting residue was purified by preparative TLC with a elution of 12% MeOH / DCM to provide (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(4-(4-(7-morpholino-5-(3-phenyl-lH-pyrazol- l-yl)furo[3,2-b]pyridin-2-yl)-lH-pyrazol-l-yl)butoxy)tetrahydro-2H-pyran-3,4,5-triol (2.6 mg, 0.004 mmol) as a white solid. LC-MS (ESI+): m / z 647 (MH+).1HNMR (300 MHz, CD3OD) 8 8.54 (d, J= 2.4 Hz, 1H), 8.27 (d, J= 8.4 Hz, 1H), 7.98 (s, 1H), 7.94-7.92 (m, 2H), 7.44-7.42 (m. 2H), 7.38-7.36 (m. 2H), 6.90-6.89 (m. 2H), 4.80-4.79 (m. 1H), 4.29-4.27 (m. 2H), 3.97-3.94 (m. 4H), 3.79-3.76 (m, 4H), 3.65-3.45 (m, 4H), 3.42-3.35 (m, 2H), 3.29-3.27 (m, 2H), 2.04-1.95 (m, 2H), 1.70-1.60 (m, 2H).

[0301] General Procedure 15

[0302] Compound 46: Synthesis of N-(2,2-difluoro-3-hydroxypropyl)-7-morpholino-5-(3- phenyl- IH-pyrazol- l-yl)furo [3,2-b] pyridine-2-carboxamide

[0304] To a solution of 5-chloro-7-morpholinofurot3.2-b|pyridine (GP1.4, 1.0 g, 4.20 mmol) in THF (40 rnL) at -78 °C under N2 was added n-BuLi (2.5 mL, 2.5M, 6.30 mmol). After stirred at -78 °C for 1 h, to a solution was added anhydrous DMF (2 mL). The completion of the reaction was monitored by TLC. The reaction mixture was quenched with NH4Q aqueous solution (40 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 10% EtOAc / PE to30% EtOAc / PE to provide 5-chloro-7-morpholinofuro[3,2-b]pyridine-2-carbaldehyde (1.0 g,4.20 mmol) as a yellow solid. LC-MS (ESI+): m / z 267 / 269 (MH+).1HNMR (300 MHz, CDCh)89.88 (s, 1H), 7.57 (s, 1H), 6.64 (s, 1H), 3.93-3.90 (m, 4H), 3.69-3.67 (m, 4H).

[0305] Synthesis of (5-chloro- 7-morpholinofuro[3, 2-b ]pyridin-2-yl)methanol

[0306] To a solution of 5-chloro-7-morpholinofuro[3.2-b]pyridine-2-carbaldehyde (GP15.1, 5.2 g, 19.55 mmol) in MeOH / DCM (1: 1, 100 mL) at 0 °C was added NaBH4(1.48 g, 39.1 mmol). After stirred at 0 °C for 1 h, TLC showed the reaction was completed. The reaction mixture was quenched with NH4C1 aqueous solution (100 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 10% EtOAc / PE to 50% EtOAc / PE to provide (5-chloro-7- morpholinofuro[3,2-b]pyridin-2-yl)methanol (4.5 g, 16.8 mmol) as a white solid. LC-MS (ESI+): m / z 269 / 271 (MH^.'HNMR (300 MHz, CDCh) <5 6.73 (s, 1H), 6.58 (s, 1H). 4.77 (d, J = 4.8 Hz, 2H), 3.91-3.87 (m, 4H), 3.71-3.61 (m, 4H), 2.28-2.24 (m, 1H).

[0307] Synthesis of (7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3, 2-b ]pyridin-2- ylfmethanol

[0308] To a solution of (5-chloro-7-morpholinofuro[3,2-b]pyridine-2-yl)methanol (GP15.2, 100 mg, 0.37 mmol) in 1,4-dioxane (10 mL) was added 3-phenyl-lH-pyrazole (107 g, 0.74 mmol), Pd2(dba)3 (102 g, 0.11 mmol), t-Buxphos (95 mg, 0.22 mmol) and Cs2CO8(182 mg, 0.56 mmol). The reaction mixture was stirred at 110 °C under N2 overnight. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (150 mL) and extracted with EtOAc (2 x 100 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 30% EtOAc / PE to 50% EtOAc / PE to provide (7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)methanol (65mg, 0.17 mmol) as an off-white solid. LC-MS (ESI+): m / z 377 (MH+).1HNMR (300 MHz, CD3OD) b 8.54 (s, 1H), 7.92 (d, J= 7.2 Hz, 2H), 7.46-7.33 (m, 4H), 6.88 (d, J= 2.7 Hz, 1H), 6.78 (s, 1H), 4.71 (s, 2H), 3.93-3.90 (m, 4H), 3.77-3.73 (m, 4H).

[0309] Synthesis of 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3, 2-b ]pyridine-2- carbaldehydeGP15.4

[0310] To a solution of (7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2- yl)methanol (GP15.3, 75 mg, 0.20 mmol) in DCM / THF (1 : 1, 10 mL) at rt was added Dess- Martin (128 mg, 0.30 mmol). The reaction was stirred at rt for 3 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with NaHCCh aqueous solution (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure to provide crude 7- morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine-2-carbaldehyde (67 mg, 0.18 mmol) as a white solid. The crude product used directly for the next step without further purification. LC-MS (ESI+): m / z 375 (MH+). 'HNMR (300 MHz, CDCh) <59.90 (s, 1H), 8.62 (s, 1H), 7.93 (d, J= 7.2 Hz, 2H), 7.61 (d, J= 2.7 Hz, 2H), 7.46-7.33 (m, 3H), 6.80 (d, J= 2.4 Hz, 1H), 3.98-3.94 (m, 4H), 3.88-3.78 (m, 4H).

[0311] Synthesis of 7-morpholino-5-( 3-phenyl-l H-pyrazol-1 -yl)furo[ 3, 2-b ]pyridine-2- carboxylic acidGP15.5

[0312] To a solution of crude 7-morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine- 2-carbaldehyde (GP15.4, 50 mg, 0.13 mmol) in t-BuOH / THF / CTLCN (1 : 1: 1, 9 mL) at 0 °C was added NaH2?4 (60 mg, 0.39 mmol), NaC102 (23 mg, 0.26 mmol), 2-Methyl-2-butene (36 mg, 0.52 mmol) and water (1 mL). The reaction was stirred at 0 °C for 1 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with ice water and thepH was adjusted to 4 using IN HC1 aqueous solution. A large amount of white solid was precipitated after acidification. After filtration, the filter cake was dried to provide 7- morpholino-5-(3-phenyl-lH-pyrazol-l-yl)furo[3,2-b]pyridine-2-carboxylic acid (70 mg, 0.18 mmol) as a white solid. LC-MS (ESI+): m / z 391 (MH+). 'HNMR (300 MHz, DMSO-cL) 88.65 (s, 1H), 8.06-7.98 (m, 2H), 7.64 (s, 1H), 7.49-7.45 (m, 3H), 7.41-7.36 (m, 1H), 7.07 (s, 1H), 3.92-3.86 (m, 4H), 3.79-3.72 (m, 4H).

[0313] Synthesis of N-(2, 2-difluoro-3-hydroxypropyl)-7-morpholino-5-(3-phenyl-lH-pyrazol- l-yl)furo[3, 2-b ]pyridine-2-carboxamideCompound 46

[0314] To a solution of 7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridine-2- carboxylic acid (GP15.5, 50 mg, 0.13 mmol) in DCM (10 mL) at rt was added 3-amino-2,2- difluoropropan-l-ol (21 mg, 0.19 mmol), EDC1 (50 mg, 0.26 mmol) and DMAP (31 mg, 0.26 mmol). The reaction was stirred at rt overnight. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with NH4CI solution (10 mL) and extracted with DCM / MeOH (50: 1, 3 x 10 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtrated and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 2% MeOH / DCM to provide N-(2,2-difluoro-3-hydroxypropyl)-7-morpholino-5-(3-phenyl-lH- pyrazol-l-yl)furo[3,2-b]pyridine-2-carboxamide (36 mg, 0.074 mmol) as ayellow solid. LC-MS (ESI+): m / z 484 (MH+). ’HNMR (300 MHz, CDCh) 8 8.61 (s, 1H), 7.94 (d, J= 8.4 Hz, 2H), 7.60 (s, 2H), 7.48-7.43 (m, 2H), 7.39-7.34 (m, 1H), 6.9-6.80 (m, 2H). 4.03-3.93 (m, 5H), 3.86- 3.78 (m, 2H), 3.74-3.71 (m, 4H), 3.50-3.49 (m, 2H).

[0315] General Procedure 16

[0316] Compound 64: Synthesis of N-(2,3-dimethoxypropyl)-7-morpholino-5-(3-(m- tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridine-2-carboxamide

[0318] To a solution of 3-(benzyloxy)propane-l,2-diol (2.0 g, 11 mmol) in DMF (10 mL) at 0 °C was added NaH (1.06 g, 60%, 26.4 mmol). After stirred at 0 °C for 1 h, to the above mixture was added CHsI (4.68 g, 33 mmol) dropwise. The reaction mixture was stirred at rt overnight. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 5% EtOAc / PE to 20% EtOAc / PE to provide ((2,3-dimethoxypropoxy)methyl)benzene (2.19 g, 10.4 mmol) as a yellow oil.1HNMR (300 MHz, CDCh) 8 7.58-7.26 (m, 5H), 4.55 (s, 2H), 3.60-3.50 (m, 5H), 3.67 (s, 3H), 3.23 (s. 3H).

[0319] Synthesis of 2,3-dimethoxypropcm-l-ol

[0320] To a solution of ((2,3-dimethoxypropoxy)methyl)benzene (GP16.1, 2.19 g, 10.4 mmol) in MeOH (100 mL) at rt was added Pd / C (200 mg). The reaction mixture was stirred under the hydrogen atmosphere for 2 days. The completion of the reaction was monitored by TLC. After filtration, the filtrate was concentrated directly to provide crude 2,3- dimethoxypropan-l-ol (1.08 g, 9.0 mmol) as colorless oil.1HNMR (300 MHz, CDCh) 83.82- 3.75 (m, 1H), 3.68-3.62 (m, 1H), 3.58-3.53 (m, 2H), 3.50 (s, 3H), 3.46-3.42 (m, 1H), 3.40 (s, 3H), 2.16-2.12 (m, 1H).

[0321] Synthesis of 2.3 -dimethoxypropyl 4-methylbenzenesulfonate

[0322] To a solution of crude 2,3-dimethoxypropan-l-ol (GP16,29500 mg, 4.17 mmol) in DCM (20 mL) at rt was added EtsN (463 mg, 4.59 mmol) and 4-methylbenzene-l -sulfonyl chloride (872 mg, 4.59 mmol). The reaction mixture was stirred at rt for 4 h. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly under reduced pressure. The resulting residue was purified by preparative TLC with a elution of 33% EtOAc / PE to provide 2,3-dimethoxypropyl 4-methylbenzenesulfonate (378 mg, 1.38 mmol) as a colorless oil. LC-MS (ESI+): m / z 297 (M+Na). 'HNMR (300 MHz, CDCh) <5 7.82 (d, J= 7.2 Hz, 2H), 7.37 (d, J= 8.1 Hz, 2H), 4.19-4.13 (m, 1H), 4.09-4.04 (m, 1H), 3.62-3.52 (m, 1H), 3.49-3.62 (m, 2H), 3.39 (s, 3H), 3.31 (s, 3H), 2.47 (s, 3H).

[0323] Synthesis of 2-(2, S-dimelhoxypropyljisoindoline-l .3-dione

[0324] To a solution of 2,3-dimethoxypropyl 4-methylbenzenesulfonate (GP16.3, 378 mg, 1.38 mmol) in DMF (20 mL) at rt was added potassium l,3-dioxoisoindolin-2-ide (280 mg, 1.52 mmol). The reaction mixture was stirred at 80 °C for 4 h. The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over anhydrous Na^SOr. filtered and concentrated under reduced pressure. The resulting residue was purified by preparative TLC with a elution of 50% EtOAc / PE to provide 2-(2,3-dimethoxypropyl)isoindoline-1.3-dione (207 mg, 0.83 mmol) as a colorless oil. LC-MS (ESI+): m / z 272 (M+Na).

[0325] Synthesis of 2,3-dimethoxypropan-l-amine

[0326] To a solution of 2-(2.3-dimethoxypropyl)isoindohne-l,3-dione (GP16.4, 207 mg, 0.83 mmol) in EtOH (50 mL) at rt was added NH2NH2.H2O (104 mg, 2.08 mmol). The reactionmixture was stirred at 80 °C for 1 h. The completion of the reaction was monitored by TLC. After filtration, the filtrate was concentrated directly under reduced pressure to provide crude 2,3-dimethoxypropan-l -amine (100 mg, 0.92 mmol) which was used directly for the next step without further purification.

[0327] Synthesis ofN-(2.3-dimethoxypropyl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3, 2-b ]pyridine-2-carboxamideCompound 64

[0328] GP16.6 was prepared by the same method used for GP1.6 with 3-(m-tolyl)-lH- pyrazole substituted for 3-phenyl-lH-pyrazole. To a solution of crude 7-morpholino-5-(3-(m- tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridine-2-carboxylic acid (GP16.6, 100 mg, 0.25 mmol) in DCM (20 mL) at rt was added 2,3-dimethoxypropan-l -amine (GP16.5, 35 mg. 0.29 mmol), EDO (120 mg, 0.63 mmol) and DMAP (75 mg, 0.63 mmol). The reaction mixture was stirred at rt overnight. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly under reduced pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 3% MeOH / DCM to provide N-(2,3-dimethoxypropyl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridine-2-carboxamide (58.6 mg, 0.17 mmol) as a yellow solid. LC-MS (ESI+): m / z 506 (MH+). 'HNMR (300 MHz, CDCh) 88.60 (d, J= 3.0 Hz, 1H), 7.76 (s, 1H), 7.72 (d, J= 8.1 Hz, 1H), 7.55 (s, 1H), 7.50 (s, 1H), 7.36-7.31 (t, J= 7.2 Hz, 1H), 7.18 (d, J= 8.1 Hz, 1H), 7.02-6.96 (m. 1H), 6.78 (d. J= 3.0 Hz. 1H), 3.99-3.88 (m. 5H), 3.75-3.72 (m. 4H), 3.62-3.55 (m. 4H), 3.49 (s, 3H), 3.43 (s, 3H), 2.44 (s, 3H).

[0329] General Procedure 17

[0330] Compound 60: Synthesis of l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propan- 1-one

[0332] GP17.1 was prepared by the same method used for GP15.4 with 3-(m-tolyl)-lH- pyrazole substituted for 3-phenyl-lH-pyrazole. To a solution of 7-morpholino-5-(3-(m-tolyl)- lH-pyrazol-l-yl)furo[3,2-b]pyridine-2-carbaldehyde (GP17.1, 550 mg. 1.42 mmol) in anhydrous THF (40 mL) at 0 °C under N2 was added CHsMgBr (2.5 mL, 2.84 mmol) dropwise. The solution was stirred at 0 °C for 1 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with NH4CI aqueous solution (30 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure to provide crude l-(7-morpholino-5-(3-(m-tolyl)-lH- pyrazol-l-yl)furo[3,2-b]yridine-2-yl)ethanol (550 mg, 1.36 mmol). LC-MS (ESI+): m / z 405 (MH+). 'l INMR (300 MHz, CDCh) 8 8.58 (d, J = 2.4 Hz, 1H), 7.77 (s, 1H), 7.72 (d, J= 7.8 Hz, 1H), 7.42 (s, 1H), 7.33 (t, J= 7.5 Hz, 1H). 7.17 (d, J= 8.1 Hz, 1H). 6.76 (d, J= 2.4 Hz, 1H). 6.73 (s, 1H), 5.04-5.02 (m, 1H), 3.97-3.93 (m, 4H), 3.73-3.70 (m, 4H), 2.44 (s, 3H), 1.65 (d, J = 6.6 Hz, 3H).

[0333] Synthesis of l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[ 3, 2-b ]pyridine-2- yl)e than- 1 -oneGP17.3

[0334] To a solution of crude l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)ethanol (GP17.2, 550 mg, 1.36 mmol) in CH3CN (50 mL) was added IBX (648 mg, 2.31 mmol). The solution was stirred at 70 °C for 1 h. The completion of the reaction was monitored by TLC. After filtration, the filtrate was concentrated directly under reduce pressure to provide crude 1 -(7 -morpholino-5 -(3 -(m-toly 1)- 1 H-pyrazol- 1 -y l)furo [3 ,2-b]yridine-2-yl)ethan- 1-one (650 mg, 1.62 mmol). LC-MS (ESI+): m / z 405 (MH ).1HNMR (300 MHz, CDCh) 8 8.59 (s, 1H), 7.77 (s, 1H), 7.72 (d, J= 7.8 Hz, 1H), 7.57-7.55 (m, 2H), 7.33 (t, J= 7.5 Hz, 1H), 7.17 (d, J= 8.1 Hz, 1H), 6.79 (d, J= 2.4 Hz, 1H), 3.99-3.96 (m, 4H), 3.81-3.78 (m, 4H), 2.62 (s, 3H), 2.44 (s, 3H).

[0335] Synthesis of €-l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2- yl)-3-(tetrahydro-2H-pyran-4-yl)prop-2-en-l-one

[0336] To a solution of l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2- yl)ethan-l-one (GP17.3, 18 mg, 0.045 mmol) in anhydrous THF (10 mL) at 0 °C under N2 was added T1CI4 (115 mg, 0.61 mmol). After stirred at that temperature for 25 min. to the above solution was added EtsN (1.83 g, 41 mmol) in one potion. After stirred for another 20 min, a solution of tetrahydro-2H-pyran-4-carbaldehyde (50 mg, 0.44 mmol) in anhydrous THF (2 mL) was added to the above mixture dropwise. After addition, the reaction mixture was allowed to warm to room temperature. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with NH4CI aqueous solution (20 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtrated and concentrated under reduce pressure. The residue was purified by preparative TLC with a elution of DCM / MeOH (15: 1) to provide (E)-l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)prop-2-en-l-one (20 mg, 0.04 mmol) as a white solid. LC-MS (ESI+): m / z 499 (MH+).

[0337] Synthesis of l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3, 2-b ]pyridin-2-yl)- 3-(telrahydro-2H-pyran-4-yl)propan-l-olGP17.5

[0338] To a solution of (E)-l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)prop-2-en-l-one (GP17.4, 20 mg, 0.04 mmol) in THF / EtOH (1:1, 2 mL) was added a catalytic amount of PtCh. The reaction mixture was stirred under the hydrogen atmosphere for 1 h. The completion of the reaction was monitored by LC- MS. After filtration, the filtrate was concentrated to provide crude l-(7-morpholino-5-(3-(m- tolyl)- IH-pyrazol- l-yl)furo[3.2-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propan- 1 -ol ( 10 mg, 0.02 mmol) which was used directly for the next step without further purification. LC-MS (ESI+): m / z 503 (MH+).

[0339] Synthesis of l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3, 2-b ]pyridin-2-yl)-Compound 60

[0340] To a solution of crude l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propan-l-ol (GP17.5, 10 mg, 0.02 mmol) in CEECN (50 mL) was added IBX (10 mg, 0.035 mmol). The solution was stirred at 70 °C for 1 h. The completion of the reaction was monitored by TLC. After filtration, the filtrate was concentrated under reduce pressure. The residue was purified by preparative TLC with a elution ofDCM / MeOH (20: 1) to provide l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3.2- b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propan-l-one (5 mg, 0.01 mmol) as a yellow solid. LC-MS (ESI+): m / z 501 (MH+).1HNMR (300 MHz, CDCh) 58.59 (d, J= 2.7 Hz, 1H), 7.76- 7.71 (m, 2H), 7.57- 7.54 (m, 2H), 7.36-7.31 (m, 1H), 7.20-7.17 (m, 1H), 6.79 (d, J= 2.7 Hz, 1H), 4.01-3.95 (m, 6H), 3.80-3.77 (m, 4H), 3.43-3.35 (m, 2H), 2.99-2.94 (m, 2H), 2.44 (s, 3H), 1.77-1.64 (m, 5H), 1.36-1.32 (m, 2H).

[0341] General Procedure 18

[0342] Compound 52: Synthesis of l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridine-2-yl)butane-l, 3-dione

[0343] Synthesis of l-(7-morpholmo-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[ 3, 2-b ]pyridine-2- yl)butane-l, 3-dioneCompound 52

[0344] To a solution of l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[-3.2- b]pyridineyridin-2-yl)ethanone (GP17.3, 40 mg, 0.10 mmol) in anhydrous THF (10 mL) at rt under N2 was added t-BuOK (11 mg, 0. 10 mmol). After stirred at rt for 40 min, to the mixture was added AC2O (11 mg, 0. 10 mmol) in one potion. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with NH4CI aqueous solution (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 10% EtOAc / PE to 50% EtOAc / PE to provide l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)butane-l,3- dione (12 mg, 0.027 mmol) as a yellow solid. LC-MS (ESI+): m / z 445 (MH ).114NMR (300 MHz, CDCk) b 8.57 (d, J= 2.4 Hz, 1H), 7.76-7.70 (m, 2H), 7.45 (s, 1H), 7.33 (t, J= 7.8 Hz, 1H), 7.18-7.16 (d, J= 7.5 Hz, 1H), 6.79 (s, 1H), 6.76 (d, J= 2.4 Hz, 1H), 5.73 (d, J= 2.4 Hz, 1H), 5.24 (d, J= 2.1 Hz, 1H), 3.96-3.93 (m, 4H), 3.74-3.71 (m, 4H), 2.43 (s, 3H), 2.32 (s, 3H).

[0345] General Procedure 19

[0346] Compound 21: Synthesis of 2-((lH-pyrazol-l-yl)methyl)-7-morpholino-5-(3-(m- tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridine

[0347] Synthesis of2-((lH-pyrazol-l-yl)methyl)-7-morpholmo-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3, 2-b ]pyridine

[0348] GP19.1 was prepared by the same method used for GP15.3 with 3-(m-tolyl)-lH- pyrazole substituted for 3-phenyl-lH-pyrazole. To a solution of (7-morpholino-5-(3-(m-tolyl)- lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)methanol (GP19.1, 50 mg, 0.13 mmol) in DCM (10 mL) at 0 °C was added MsCl (22 mg, 0.19 mmol) and EtsN (32 mg, 0.32 mmol). The reaction mixture was stirred at 0 °C for 3 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with ice water (10 mL) and extracted with DCM (3 x 10 mL). The combined organic phase was dried over anhydrous Na2SO4 and used directly for the next step without further work-up. After filtration, to the DCM organic phase was added pyrazole (200 mg, 2.94 mmol) in one potion. The reaction mixture was stirred at rt overnight and the reaction was monitored by TLC. The reaction mixture was diluted with water (10 mL) and extracted with DCM (3 x 10 mL). The resulting residue was purified by preparative TLC with a elution of 25% EtOAc / PE to provide 2-((lH-pyrazol-l-yl)methyl)-7-morpholino-5-(3-(m-tolyl)- lH-pyrazol-l-yl)furo[3,2-b]pyridine (50 mg, 0.11 mmol) as a white solid. LC-MS (ESI+): m / z 441 (MH ) , 'HNMR (300 MHz, CDsOD) 8 8.52 (d, J= 2.4 Hz, 1H), 7.83 (d, J= 2.1 Hz, 1H), 7.75-7.70 (m, 1H). 7.70-7.68 (m, 1H). 7.57 (d, J= 1.5 Hz, 1H). 7.38 (s. 1H), 7.30 (t, J = 1.5 Hz, 1H), 7.19-7.16 (m, 1H), 6.86 (d, .7= 2.4 Hz, 1H), 6.79 (s, 1H), 6.38 (L J = 2.1 Hz, 1H), 5.58 (s, 2H), 3.90-3.87 (m, 4H), 3.71-3.68 (m, 4H), 2.41 (s, 3H).

[0349] General Procedure 20

[0350] Compound 40: Synthesis of N-((7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)methyl)isobutyramide

[0351] Synthesis of 2-(bromomethyl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3.2- b ]pyridine

[0352] To a solution of (7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2- yl)methanol (G19.1, 1 g, 2.56 mmol) in THF (70 mL) at rt was added PBrs (690 mg, 2.58 mmol). The solution was stirred at rt for 3 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with NaHCOs aqueous solution (50 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phase was dried over anhydrous NazSCh, filtrated and concentrated under reduce pressure to provide 2-(bromomethyl)-7-morpholino-5- (3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridine (1.0 g, 2.21 mmol). LC-MS (ESI+): m / z 453 / 455 (MH ).'HNMR (300 MHz, CDCh) d 8.65 (s. 1H), 7.76-7.71 (m. 2H), 7.46 (s, 1H), 7.33 (t, .7= 7.2 Hz, 1H), 7.18 (d, J = 8.1 Hz, 1H), 6.94 (s, 1H), 6.77 (d, J= 2.7 Hz, 1H), 4.59 (s, 2H), 3.97-3.95 (m, 4H), 3.77-3.75 (m, 4H), 2.43 (s, 3H).

[0353] Synthesis of 2-(azidomethyl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b ] pyridine

[0354] To a solution of 2-(bromomethyl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridine (GP20.1, 50 mg, 0.11 mmol) in anhydrous DMF (10 mL) was addedNaN- (22 mg, 0.33 mmol). The reaction mixture was stirred at 60 °C for 3 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3 x 6 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to provide 2-(azidomethyl)-7- morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furot3,2-bJpyridine (50 mg, 0.12 mmol). LC-MS (ESI+): m / z 416 (MH+).

[0355] Synthesis of (7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[ 3, 2-b ]pyridin-2- yl)methanamineGP20.3

[0356] To a solution of 2-(azidomethyl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridine (GP20.2, 50 mg, 0.12 mmol) in EtOAc (5 mL) was added a catalytic amount of Pd / C. The reaction mixture was stirred under hydrogen atmosphere for 1 h. The completion of the reaction was monitored by TLC. After filtration, the filtrate was concentrated directly to provide crude (7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2- yl)methanamine (54 mg, 0. 14 mmol). The crude product was used directly for the next step without further purification. LC-MS (ES1+): m / z 390 (MH+).1HNMR (300 MHz. CDCh) <5 8.65 (s, 1H), 7.77-7.71 (m, 2H), 7.41 (s, 1H), 7.33 (t, J= 7.2 Hz, 1H), 7.17 (d, J= 6.6 Hz, 1H), 6.75 (s, 1H), 6.67 (s, 1H), 4.02 (s, 2H), 3.97-3.95 (m, 4H), 3.77-3.75 (m, 4H), 2.44 (s, 3H).

[0357] Synthesis ofN-((7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2- yl)methyl)isobutyramideCompound 40

[0358] To a solution of crude (7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)methanamine (GP20.3, 44 mg, 0. 11 mmol) in DMF (5 mL) at 0 °C was added a catalytic amount of DMAP and Na2CCh (22 mg, 0.21 mmol). After stirred at 0 °C for 10 min, to the above mixture was added isobutyryl chloride (17 mg, 0.16 mmol). The completion of the reaction was monitored by TLC. The reaction mixture was diluted with water (20 mL) andextracted with EtOAc (3 x 50 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtrated and concentrated under reduce pressure. The resulting residue was purified by preparative TLC with a elution of DCM / MeOH (15 : 1) to provide N-((7-morpholino-5-(3-(m- tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)methyl)isobutyramide (10 mg, 0.022 mmol) as a white solid. LC-MS (ESI+): m / z 460 (MH+). 'HNMR (300 MHz, CDCh) d 8.56 (d, J= 2.7 Hz, 1H), 7.76-7.73 (m, 2H), 7.70 (s, 1H), 7.35 (t, J= 7.5 Hz, 1H), 7.16 (d, J= 7.8 Hz, 1H), 6.70 (d, J = 2.7 Hz, 1H), 6.68 (s, 1H), 5.83 (brs, 1H), 4.63 (d, J= 5.7 Hz, 2H), 3.95-3.91 (m, 4H), 3.71- 3.68 (m, 4H), 2.46-2.39 (m, 4H), 1.25-1.20 (d, J= 6.9 Hz, 6H).

[0359] General Procedure 21

[0360] Compound 38: Synthesis of diethyl ((7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)methyl)phosphonate

[0361] Synthesis of diethyl ((7-morpholino-3-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b ]pyridin- 2-yl)methyl)phosphonate

[0362] To a solution of 2-(bromomethyl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo [3, 2-b] pyridine (GP20.1, 700 mg, 1.54 mmol) in toluene (20 mL) at rt was added triethyl phosphite (2.3 g, 13.8 mmol). The reaction mixture was stirred at 100 °C overnight. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly. The resulting residue was purified by silica gel column chromatography with a gradient elution of 30% EtOAc / PE to 50% EtOAc / PE to provide diethyl ((7-morpholino-5-(3-(m-tolyl)- lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)methyl)phosphonate (450 mg, 0.88 mmol) as a white solid. LC-MS (ESI+): m / z 511 (MH+). ’HNMR (300 MHz, CDCh) d 8.60 (s, 1H), 7.76-7.70 (m. 2H), 7.41 (s, 1H), 7.35-7.30 (m, 1H), 7.17-7.15 (m, 1H), 6.76 (d, J = 2.7 Hz, 2H), 4.19-4.09 (m, 4H), 3.95- 3.92 (m, 4H), 3.73-3.70 (m, 4H), 3.43 (s, 1H), 3.36 (s, 1H), 2.43 (s, 3H), 1.34-1.23 (m, 6H).

[0363] General Procedure 22

[0364] Compound 44: Synthesis of (S,E)-2-(2-(l,4-dioxan-2-yl)vinyl)-7-morpholino-5-(3-(m- tolyl)- IH-pyrazol- l-yl)furo[3, 2-b] pyridineCompound 44

[0365] Synthesis of (R)-l,4-dioxane-2-carbaldehyde

[0366] To a solution of (S)-(l,4-dioxan-2-yl)methanol (550 mg, 4.23 mmol) in CH3CN (50 mL) at rt was added IBX (2 g, 7.14 mmol). The reaction mixture was stirred at 75 °C for 1 h. The completion of the reaction was monitored by TLC. After filtration, the filtrate was concentrated under reduce pressure to provide crude (R)-l,4-dioxane-2-carbaldehyde (130 mg, 1.12 mmol) as a colorless oil.

[0367] Synthesis of (S,E)-2-(2-( 1.4-dioxan-2-yl)vinyl)-7-morpholino-5-(3-(m-tolyl)-l H- pyrazol-l-yl)furo[ 3, 2-b ]pyridine

[0368] To a solution of diethyl ((7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)methyl)phosphonate (Compound 38, 100 mg, 0.44 mmol) in anhydrous THF (10 mL) at 0 °C under N2 was added NaH (53 mg, 1.32 mmol). After stirred at that temperature for 25 min, to the above mixture was added a solution of crude (R)-l,4-dioxane-2-carbaldehyde (GP22.1, 45 mg, 0.39 mmol) in THF in one potion. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (20 mL) and extracted with DCM (3 x 50 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by preparative HPLC toprovide (S,E)-2-(2-(l,4-dioxan-2-yl)vinyl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridine (15 mg, 0.32 mmol) as a white solid. LC-MS (ESI+): m / z 473 (MH+). 'HNMR (300 MHz, CDCh) 88.56 (s, 1H), 7.76-7.73 (m, 2H), 7.70 (s, 1H), 7.42- 7.33 (m, 1H), 7.26-7.15 (m, 1H), 6.76-6.65 (m, 3H), 6.30-6.29 (m, 1H), 4.35- 4.25 (m, 1H), 3.97-3.94 (m, 4H), 3.89-3.86 (m, 3H), 3.81-3.68 (m, 6H), 3.46- 3.42 (m, 1H), 2.43 (s, 3H).

[0369] General Procedure 23

[0370] Compound 45: Synthesis of (S)-2-(2-(l,4-dioxan-2-yl)ethyl)-7-morpholino-5-(3-(m- tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridine

[0371] Synthesis of (S)-2-(2-(l,4-dioxan-2-yl)ethyl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-1 -yl) furo[3, 2-b ] pyridine

[0372] To a solution of (S,E)-2-(2-(l,4-dioxan-2-yl)vinyl)-7-morpholino-5-(3-(m-tolyl)-lH- pyrazol-l-yl)furo[3,2-b]pyridine (Compound 44. 15 mg, 0.32 mmol) in EtOAc (5 mL) was added a catalytic amount of Pd / C. The reaction mixture was stirred under hydrogen atmosphere for 3 h. The completion of the reaction was monitored by LC-MS. After filtration, the filtrate was concentrated directly to provide (S)-2-(2-(l,4-dioxan-2-yl)ethyl)-7-morpholino-5-(3-(m- tolyl)-lH-pyrazol-l-yl)furo [3, 2-b] pyridine (16 mg, 0.32 mmol) as a white solid. LC-MS (ESI+): m / z 475 (MH+). 'HNMR (300 MHz, CDCh) 88.57 (s, 1H), 7.77-7.71 (m, 2H), 7.38 (s, 1H), 7.35-7.30 (m, 1H), 7.18- 7.13 (m, 1H), 6.75 (d, J= 2.4 Hz, 1H), 6.52 (s, 1H), 3.96-3.93 (m, 4H), 3.81- 3.63 (m, 10H), 3.38-3.35 (m, 1H), 2.99-2.83 (m, 2H), 2.43 (s, 3H), 1.83- 1.81 (m, 2H).

[0373] General Procedure 24

[0374] Compound 62: Synthesis of N-methyl-N-(4-(7-morpholino-5-(3-(m-tolyl)-lH- pyrazol- l-yl)furo [3, 2-b] pyridin-2-yl)-4-oxobutyI)acetamide

[0376] To a solution of tert-butyl prop-2-yn-l-ylcarbamate (1 g, 6.45 mmol) in THF (50 rnL) at 0 °C was added NaH (310 mg, 12.38 mmol). The reaction mixture was stirred at 0 °C under N2 for 1 h. To the above mixture w as added CH3I (1.8 g, 12.9 mmol) dropwise. The reaction mixture was allowed to warm to rt and stirred overnight. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na^SOr. filtered and concentrated under reduced pressure to provide crude tert-butyl methyl(prop-2-yn-l- yl)carbamate (1.1 g, 7.1 mmol) as a yellow oil.

[0377] Synthesis of tert-butyl (4-hydroxy-4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)but-2-yn-l-yl)(methyl)carbamate

[0378] To a solution of tert-butyl methyl(prop-2-yn-l-yl)carbamate (GP24.1, 200 mg, 1.29 mmol) in THF (20 mL) at -78 °C under N2 was added n-BuLi (2.5M, 0.67 mmol). The reaction mixture was stirred at -78 °C under N2 for 1 h. To the above mixture was added a solution of 7- morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridine-2-carbaldehyde (GP17.1, 250 mg, 0.65 mmol) in THF (2 mL) drop wise. The completion of the reaction was monitored by TLC. The reaction was quenched with NH4CI solution (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by silica gel columnchromatography with a gradient elution of 20 % EtOAc / PE to 33% EtOAc / PE to provide tertbutyl (4-hydroxy-4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)but- 2-yn-l-yl)(methyl)carbamate (110 mg, 0.20 mmol). LC-MS (ESI+): m / z 558 (MH+).

[0379] Synthesis of tert-butyl (4-hydroxy-4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3, 2-b Jpyridin-2-yl)butyl)(methyl)carbamate

[0380] To a solution of tert-butyl (4-hydroxy-4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)but-2-yn-l -yl)(methyl)carbamate (GP24.2, 1 10 mg, 0.20 mmol) in EtOAc (2 mL) was added a catalytic amount of Pd / C. The reaction mixture was stirred under hydrogen atmosphere for 1 h. The completion of the reaction was monitored by LC-MS. After filtration, the filtrate was concentrated directly to provide crude tert-butyl (4-hydroxy-4-(7- morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)butyl)(methyl)carbamate (100 mg, 0. 18 mmol). The crude product was used directly for the next step without further purification. LC-MS (ESI+): m / z 562 (MH+).

[0381] Synthesis of tert-butyl methyl(4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl) furo[3.2-b ]pyridin-2-yl)-4-oxobuty!)carbamate

[0382] To a solution of tert-butyl (4-hydroxy-4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)butyl)(methyl)carbamate (GP24.3, 100 mg, 0.18 mmol) in CH3CN (50 mL) at rt was added IBX (80 mg, 0.28 mmol). The reaction mixture was stirred at 70 °C for 2 h. The completion of the reaction was monitored by TLC. After filtration, the filter cake was washed with EtOAc (3 x 10 mL). The combined filtrate was concentrated under reduced pressure to provide crude tert-butyl methyl(4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)-4-oxobutyl)carbamate (100 mg, 0.18 mmol). LC-MS (ESI+): m / z 560 (MH ).

[0383] Synthesis of 4-(methylamino)-l -(7-morpholino-5-(3-(m-tolyl)- IH-pyrazol-l - yl)furo[3, 2-b ]pyridin-2-yl)butan-l-one

[0384] To a solution of tert-butyl methyl(4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)-4-oxobutyl)carbamate (GP24.4, 100 mg, 0.18 mmol) in DCM (3 mL) at rt was added TFA (0.3 mL). The solution was stirred at rt for 1 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with NaHCOs solution to adjust the pH to 8. The aqueous phase was extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure. The resulting residue was purified by preparative TLC with a elution of EtOAc to provide 4-(methylamino)-l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2- yl)butan-l-one (40 mg, 0.087 mmol). LC-MS (ESI+): m / z 460 (MH+).

[0385] Synthesis of N-methyl-N-( 4-(7-morpholino-5-( 3-(m-tolyl)-lH-pyrazol-l-yl)furo[ 3, 2- b]pyridin-2-yl)-4-oxobutyl)acetamide

[0386] To a solution of 4-(methylamino)-l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)butan-l-one (GP24.5, 40 mg, 0.087 mmol) in DCM (3 mL) at rt was added AC2O (0.1 mL). The reaction was stirred at rt for 2 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water and extracted with DCM (2 x 5 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtered and concentrated under reduce pressure. The resulting residue was purified by preparative TLC using a elution of EtOAc to provide N-methyl-N-(4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)-4-oxobutyl)acetamide (9 mg, 0.018 mmol). LC-MS (ESI+): m / z 502 (MH+).1HNMR (300 MHz, CDCh) b 8.61 (d, J= 2.7 Hz, 1H), 7.78-7.73 (m, 2H), 7.60-7.56 (m, 2H), 7.36-7.28 (m, 1H), 7.20-7.17 (m, 1H), 6.80 (d, J= 2.7 Hz, 1H), 4.01-3.98 (m, 4H), 3.82- 3.79 (m, 4H), 3.50-3.48 (m, 2H), 3.05-2.99 (m, 5H), 2.46 (s, 3H). 2.12-2.02 (m, 5H).

[0387] General Procedure 25

[0388] Compound 65: Synthesis of l-(4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)-4-oxobutyl)pyrrolidin-2-one

[0389] Synthesis of 4 -chloro-l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b ]pyridin-2-yl)but-2-yn-l -ol

[0390] To a solution of 3 -chloroprop- 1-yne (290 mg, 3.87 mmol) in THF (20 mL) at -78 °C under N2 was added n-BuLi (2.5M, 0.67 mmol). The reaction mixture was stirred at -78 °C under N2 for 0.5 h. To the above solution was added a solution of 7-morpholino-5-(3-(m-tolyl)- lH-pyrazol-l-yl)furo[3,2-b]pyridine-2-carbaldehyde (GP17.1, 500 mg, 1.30 mmol) in THF (5 mL) dropwise. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with NH4CI solution (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic phase was dried over anhydrous Na2SO4, filtrated and concentrated under reduce pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 20 % EtOAc / PE to 33% EtOAc / PE to provide 4-chloro-l-(7-morpholino-5- (3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)but-2-yn-l-ol (400 mg, 0.86 mmol). LC- MS (ESI+): m / z 463 (MH+).

[0391] Synthesis of 4-azido-l-(7-morpholino-5-( 3-(m-tolyl)-lH-pyrazol-l-yl)furo[3, 2- b]pyridin-2-yl)but-2-yn-l-olGP25.2

[0392] To a solution of 4-chloro-l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)but-2-yn-l-ol (GP25.1, 400 mg, 0.76 mmol) in DMF (5 mL) at rt was added NaNs (148 mg. 2.27 mmol). The reaction mixture was stirred at rt overnight. The completion of the reaction was monitored by TLC. The reaction was quenched with water and extracted with EtOAc (2 x 30 mL). The combined organic phase was combined and dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to provide crude 4-azido-l-(7- morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)but-2-yn-l-ol (300 mg, 0.81 mmol). LC-MS (ESI+): m / z 470 (MH ).

[0393] Synthesis of 4-amino-l-(7-morpholino-5-(3-(m-tofyl)-lH-pyrcizol-l-yl)furo[3,2- b ]pyridin-2-yl)butan-l-ol

[0394] To a solution of 4-azido-l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3.2- b]pyridin-2-yl)but-2-yn-l-ol (GP25.2, 300 mg, 0.81 mmol) in EtOAc (6 mL) was added a catalytic amount of Pd / C. The reaction mixture was stirred under hydrogen atmosphere overnight. The completion of the reaction was monitored by HPLC. After filtration, the filtrate was concentrated directly to provide crude 4-amino-l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol- l-yl)furo|3,2-b]pyridin-2-yl)butan-l-ol (330 mg, 0.74 mmol). The crude product was used directly for the next step without further purification. LC-MS (ESI+): m / z 448 (MH+).

[0395] Synthesis of 4-chloro-N-(4-hydroxy-4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3.2-b ]pyridin-2-yl)bulyl)bulanamide

[0396] To a solution of 4-amino-l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)butan-l-ol (GP25.3, 330 mg, 0.74 mmol) and EtsN (150 mg, 1.48 mmol) in DCM (50 mL) was added a solution of 4-chlorobutanoyl chloride (103 mg, 0.74 mmol) in DCM (1 mL) dropwise. The reaction mixture was stirred at rt for 2 h. The completion of the reaction wasmonitored by TLC. The reaction mixture was concentrated directly under reduced pressure. The resulting residue was purified by silica gel column chromatography with a gradient elution of 1% MeOH / DCM to 10% MeOH / DCM to provide 4-chloro-N-(4-hydroxy-4-(7-morpholino-5-(3- (m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)butyl)butanamide (100 mg, 0.20 mmol) as a brown solid. LC-MS (ESI+): m / z 552 / 554 (MH+).

[0397] Synthesis of 4-chloro-N-(4-(7-morpholino-5-( 3-(m-tolyl)-lH-pyrazol-l-yl)furo[3, 2- b]pyridin-2-yl)-4-oxobiityl)butanamide

[0398] To a solution of 4-chloro-N-(4-hydroxy-4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)butyl)butanamide (GP25.4, 100 mg, 0.20 mmol) in CHsCN (50 mL) at rt was added IBX (112 mg, 0.40 mmol). The reaction mixture was stirred at 70 °C for 2 h. The completion of the reaction was monitored by TLC. After filtration, the filter cake was washed with EtOAc (3 x 10 mL). The combined filtrate was concentrated under reduced pressure to provide crude 4-chloro-N-(4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin- 2-yl)-4-oxobutyl)butanamide (33 mg, 0.074 mmol). LC-MS (ESI+): m / z 550 / 552 (MH+).

[0399] Synthesis of l-(4-(7-morpholino-5-( 3-(m-lolyl)-lH-pyrazol-l-yl)furo[3, 2-b ] pyridineyl) -4-oxobutyl)pyrrolidin-2-one

[0400] To a solution of 4-chloro-N-(4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)-4-oxobutyl)butanamide (GP25.5, 33 mg, 0.074 mmol) in THF (50 mL) at rt was added NaH (20 mg, 0. 148 mmol). The solution was stirred at rt for 3 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (10 ml) and extracted with EtOAc (2 x 30 mL). The combined organic phase was dried over Na2SO4, filtered and concentrated under reduce pressure. The resulting mixture was purified by preparative TLC with an elution of 7% MeOH / DCM to provide l-(4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)-4-oxobutyl)pyrrolidin-2-one (15 mg, 0.03 mmol) as a white solid. LC-MS (ESI+): m / z 514 (MH+).1HNMR (300 MHz, CDCh) 68.59 (s, 1H), 7.76-7.71 (m, 2H), 7.55 (d, J= 5.1 Hz, 2H), 7.34 (t, J= 7.6 Hz, 1H), 7.18 (d. J= 6.6 Hz, 1H), 6.77 (d, J = 2.7 Hz, 1H), 3.98-3.95 (m, 4H), 3.80-3.77 (m, 4H), 3.46-3.38 (m, 4H), 3.00 (t, J = 7.2 Hz. 2H), 2.44 (s. 3H), 2.34 (t, J = 7.8 Hz, 2H). 2.07-2.00 (m, 4H).

[0401] General Procedure 26

[0402] Compound 63: Synthesis of l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l- yl)furo[3,2-b]pyridin-2-yl)-3-(oxetan-3-yl)propane-l, 3-dione

[0403] Synthesis of oxetane-3-carboxylic acid

[0404] To a solution of oxetan-3-ylmethanol (1.0 g, 11.36 mmol) in CH3CN / H2O (2:1, 30 mL) at rt was added RuCh (234 mg, 1. 14 mmol) and NalCh (4.8 g, 22.72 mmol). The reaction mixture was stirred at rt overnight. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with NH4CI aqueous solution (200 mL) and followed by IM HC1 aqueous solution to adjust pH to 2. The aqueous solution was extracted with EtOAc (3 x 100 mL). The combined organic phase was dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to provide crude oxetane-3-carboxylic acid (600 mg, 5.88 mmol).1HNMR (300 MHz, DMSO-ds) 5 12.8 (brs. 1H), 4.71-4.66 (m. 2H), 4.64-4.58 (m. 2H),3.85-3.75 (m, 1H).

[0405] Synthesis of (lH-benzo[d] [l,2,3]triazol-l-yl)(oxetan-3-yl)methanone

[0406] To a solution of oxetane-3 -carboxylic acid (GP26.1, 600 mg, 5.88 mmol) in DCM (25 mL) was added EDC1 (1.3 g. 6.79 mmol) and lH-benzo[d][l,2,3]triazole (770 mg, 6.47 mmol). The solution was stirred at rt for 2 h. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated directly under reduced pressure. The resulting residue was purified by column silica gel chromatography with a gradient elution of 10 % EtOAc / PE to 30 % EtOAc / PE to provide (lH-benzo[d][1.2,3]triazol-l-yl)(oxetan-3-yl)methanone (840 mg, 4.13 mmol) as a white solid.1HNMR (300 MHz, DMSO-ufe) <5 8.28-8.25 (m, 2H), 7.84-7.79 (m, 1H), 7.66-7.61 (m, 1H), 5.32-5.10 (m, 1H), 4.95-4.67 (m, 4H).

[0407] Synthesis of 1 -(7-mor pholino-5-(3-(m-tolyl)-lH-pyr azol- 1-yl) fur o[ 3, 2-b ]pyridin-2-yl)-3-( oxetan-3-yl)propane-l, 3 -dione

[0408] To a solution of l -(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l -yl)furo[3,2-b]pyridin-2- yl)ethanone (GP17.3, 30 mg, 0. 15 mmol) in THF (10 mL) at rt was added NaH (8 mg, 0. 19 mmol). The reaction mixture w as stirred at rt for 1 h. To the above mixture w as added a solution of (lH-benzo[d][1.2.3]triazol-l-yl)(oxetan-3-yl)methanone (GP26.2. 60 mg, 0.15 mmol) in THF (2 mL) dropwise. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water and extracted with EtOAc (2 x 20 mL). The combined organic phase was dried over Na2SC>4, filtered and concentrated. The resulting residue w as purified by preparative TLC to provide l-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin- 2-yl)-3-(oxetan-3-yl)propane-l,3-dione (6 mg, 0.012 mmol) as a white solid. LC-MS (ES1+): m / z 487 (MH+). 'HNMR (300 MHz, CDCk) 5 8.59 (d, J= 1.5 Hz, 1H), 7.76-7.70 (m, 2H), 7.53 (s, 1H), 7.40-7.30 (m, 2H), 7.25-7.15 (m, 1H), 6.78 (d, J= 2.7 Hz, 1H), 6.11 (s, 1H), 5.30 (s, 1H), 4.81-4.75 (m, 1H), 4.57 (t, J= 11.8 Hz, 1H), 4.10-3.95 (m, 4H), 3.90-3.80 (m, 1H), 3.78- 3.70 (m, 4H), 3.00-2.85 (m, 1H), 2.44 (s, 3H). 2.05-1.95 (m, 1H).

[0409] General Procedure 27

[0410] Compound 53: Synthesis of (E)-2-(3,4-dimethoxybut-l-en-l-yl)-7-morpholino-5-(3-(m-tolyl)- IH-pyrazol- l-yl)furo [3,2- b] pyridine

[0411] Synthesis of 2, 2, 3, 3, 9, 9-hexamethyl-8, 8-diphenyl-5-vinyl-4, 7-dioxa-3, 8-disiladecane

[0412] To a solution of but-3-ene-l,2-diol (3 g, 34 mmol) in DMF (10 mL) at 0 °C was added imidazole (5.56 g, 68 mmol) under N2. To the solution was added TBDPSC1 (11.3 g, 40 mmol). TLC showed the starting material was consumed. After that, TBSC1 (6.2 g, 40 mmol) was added to the above mixture. The reaction mixture was heated to 50 °C for 2 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phase was dried over Na2SO4, filtered and concentrated. The resulting residue was purified by silica gel column chromatography with a gradient elution of 10% EtOAc / PE to 20% EtOAc / PE to provide 2,2,3,3,9,9-hexamethyl-8,8- diphenyl-5-vinyl-4,7-dioxa-3, 8-disiladecane (10 g, 22.7 mmol).

[0413] Synthesis of 2-((tert-butyldimethylsilyl)oxy)-3-((tert-butyldiphenylsilyl)oxy)propanal

[0414] To a solution of 2,2,3,3,9,9-hexamethyl-8,8-diphenyl-5-vinyl-4,7-dioxa-3,8- disiladecane (GP27.1, 2 g. 45 mmol) in THF / H2O (3: 1, 28 mL) at 0 °C was added a catalyticamount of OsCh. The solution was stirred at 0 °C for 1 h. To the solution was added a solution of NalCL (3 g, 14.1 mmol) in water (5 mL) dropwise. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phase was dried over Na2SO4, filtered and concentrated. The resulting residue was purified by silica gel column chromatography with a gradient elution of 5% EtOAc / PE to 10% EtOAc / PE to provide 2-((tert-butyldimethylsilyl)oxy)- 3-((tert-butyldiphenylsilyl)oxy)propanal (1.1 g, 2.5 mmol).

[0415] Synthesis of (E)-2-(3-((tert-butyldimethylsilyl)oxy)-4-((tert-butyldiphenylsilyl)oxy)but- l-en-l-yl)-7-morpholino-5-(3-(m-tofyl)-lH-pyrazol-l-yl)furo[3.2-blpyridine

[0416] To a solution of diethyl ((7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)methyl)phosphonate (Compound 38, 110 mg, 0.22 mmol) in THF (10 mL) at rt was added NaH (26 mg, 0.66 mmol) under N2. The reaction mixture was stirred at rt for 1 h. To the above mixture was added 2-((tert-butyldimethylsilyl)oxy)-3-((tert- butyldiphenylsilyl)oxy)propanal (GP27.2, 143 mg, 0.32 mmol). The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phase was dried over Na2SC>4. filtered and concentrated. The resulting residue was purified by silica gel column chromatography with a gradient elution of 10% EtOAc / PE to 20% EtOAc / PE to provide (E)-2-(3-((tert- butyldimethylsilyl)oxy)-4-((tert-butyldiphenylsilyl)oxy)but-l-en-l-yl)-7-morpholino-5-(3-(m- tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridine (110 mg, 0.14 mmol). LC-MS (ESI+): m / z 799 (MH+).

[0417] Synthesis of (E)-4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3.2-b]pyridin-2- yl)but-3-ene-l ,2-diol

[0418] To a solution of (E)-2-(3-((tert-butyldimethylsilyl)oxy)-4-((tert- butyldiphenylsilyl)oxy)but-l-en-l-yl)-7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridine (GP27.3, 110 mg, 0.14 mmol) in THF (10 mL) at rt was added TBAF (36 mg, 0.14 mmol). The reaction mixture was stirred at rt for 1 h. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phase was dried over Na2SO4, filtered and concentrated. The resulting residue was purified by silica gel column chromatography with a gradient elution of 20% EtOAc / PE to 50% EtOAc / PE to provide (E)-4-(7-morpholino-5-(3-(m- tolyl)-lH-pyrazol-l-yl)furo[3,2-b]pyridin-2-yl)but-3-ene-L2-diol (40 mg, 0.09 mmol). LC-MS (ESI+): m / z 447 (MH+).

[0419] Synthesis of (E)-2-(3,4-dimethoxybut-l-en-l-yl)-7-morpholino-5-(3-(m-tolyl)-lH- pyrazol-l-yl)furo[3, 2-b ]pyridine

[0420] To a solution of (E)-4-(7-morpholino-5-(3-(m-tolyl)-lH-pyrazol-l-yl)furo[3,2- b]pyridin-2-yl)but-3-ene-l,2-diol (GP27.4, 20 mg, 0.045 mmol) in DMF (5 mL) at rt was added NaH (26 mg, 0.66 mmol). The reaction mixture was stirred at rt for 1 h. To the above mixture was added CH3I (12 mg. 0.09 mmol). The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over Na2SC>4, filtered and concentrated. The resulting residue was purified preparative TLC with a elution of 50% EtOAc / PE to provide (E)-2-(3,4- dimethoxybut- 1 -en- 1 -y l)-7-morpholino-5-(3-(m-tolyl)- 1 H-py razol- 1 -yl)furo [3.2-b] pyridine (3 mg, 0.006 mmol) as a yellow solid. LC-MS (ESI+): m / z 475 (MH+). 'HNMR (300 MHz, CDCh) 5 8.57 (s, 1H), 7.76-7.71 (m, 2H), 7.43-7.33 (m, 1H), 7.30-7.26 (m, 1H), 7.18- 7.16 (m, 1H), 6.76-6.62 (m, 3H), 6.36-6.33 (m, 1H), 4.03-4.01 (m, 1H), 3.98- 3.95 (m, 4H), 3.74-3.71 (m, 4H), 3.55-3.53 (m, 2H), 3.44-3.41 (m, 6H), 2.43 (s, 3H).

[0421] General Procedure 28

[0422] Synthesis of Compound 67: (l-(2-(l-methyl-l W-pyrazol-4-yl)-7- morpholinofuro[3,2-Z>]pyridin-5-yl)-3-( / M-tolyl)-LH-pyrazol-5-yl)methanol

[0423] Synthesis of 5-chloro-7-morphohno-2-(trimethylsilyl)furo[3,2-b]pyridine

[0424] 2.0 g of GP1.4 was converted to GP28.1 using TMS-Cl / n-BuLi / dryTHF / -78 °C / 2 h.After work-up and purification, 1.6 g of GP28.1 was obtained.

[0425] Synthesis of 7 -morpholino-5-( 3-(m-tolyl)-lH-pyrazol-l-yl)-2-( trimethylsilyl)furo[3, 2- b ]pyridine

[0426] 1.6 g of GP28.1 was converted to GP28.2 using a mixture of t-BuXphos, CS2CO3, 3-(m-tolyl)-lH-pyrazole. Pd2(dba)3 in dioxane at 100 °C for 18h. After work-up and purification,1 .4 g of GP28.2 was obtained.

[0427] Synthesis of l-(7-morpholino-2-(trimethylsilyl)furo[3,2-b]pyridin-5-yl)-3-(m-tolyl)-lH- pyrazole-5-carbaldehyde

[0428] 1. 1 g of GP28.2 was converted to GP28.3 using dry DMF and LDA in THF at -78 °C over 2 h. After work-up, 1.1 g of crude product GP28.3 was obtained.

[0429] Synthesis of (l-(7-morpholino-2-(trimethylsilyl)furo[3.2-b]pyridin-5-yl)-3-(m-tolyl)- lH-pyrazol-5-yl)methanol

[0430] 1.1 g of crude GP28.3 was converted to GP28.4 w ith NaBH4 in THF at ambient temperature over 30 min. After work-up and purification, 810 mg of GP28.4 was obtained.

[0431] Synthesis of (l-(2-iodo-7-morpholinofuro[3,2-b]pyridin-5-yl)-3-(m-tolyl)-lH-pyrazol-5-yl)methanol

[0432] 100 mg of GP28.4 was converted to GP28.5 using KF, NIS in MeCN at 55 °C over 2 h. TLC showed a new major spot and LC-MS showed the desired product. After work-up and purification, 30 mg of 28.5 was obtained.

[0433] Synthesis of [2-[2-( 1 -methylpyrazol-4-yl)-7-morpholino-furo[3, 2-b ]pyridin-5-yl ]-5- ( m-tolyl)pyr azol- 3-yl ]methanol

[0434] 30 mg of GP28.5 was converted to Compound 67 by reaction with l-methyl-4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole with PdCh(PPh3)2, K2CO3 in dioxane / FhO at 90 °C over 3 h. TLC showed a new major spot and LC-MS showed the desired product. After work-up and purification. 16 mg of Compound 67 was obtained as a pale-yellow solid. LCMS (M+H)+: 471.29; HPLC purity: 99.3%; 1HNMR (300 MHz, CDC13) 6 7.85 (s, 1H), 7.76 (s, 1H), 7.72-7.67 (m, 2H), 7.36-7.30 (m, 2H), 7.16 (d, J = 7.5 Hz, 1H), 6.77 (s, 1H), 6.69 (s, 1H), 6.63 (t, J = 7.2 Hz, 1H), 4.73 (d, J = 7.2 Hz, 2H), 4.00-3.91 (m, 7H), 3.79-3.77 (m, 4H).

[0435] General Procedure 29

[0436] Synthesis of Compound 72: 5-[5-(methoxymethyl)-3-(m-tolyl)pyrazol-l-yl]-2-(l- methylpyrazol-4-yl)-7-morpholino-furo[3,2-b]pyridine

[0437] 20 mg of Compound 67 was converted to Compound 72 using Mel and NaH in dry TH F. The reaction was stirred at ambient temperature overnight. After work-up and purification, 8.0 mg of Compound 72 was obtained as a white solid. LCMS (M+H)+: 485.38; HPLC purity: 99.7%. 1HNMR (300 MHz. CDC13) 6 7.85 (s, 1H), 7.76-7.69 (m, 3H), 7.33-7.30(m, 2H), 7. 16 (d, J = 6.6 Hz, 1H), 6.79 (d, J = 6.6 Hz, 2H), 5.03 (s, 2H), 4.08-3.96 (m, 7H), 3.73-3.71 (m, 4H), 3.50 (s, 3H), 2.42 (s, 3H).

[0438] General Procedure 30

[0439] Synthesis of Compound 80: ethyl l-(2-(l-methyl-17 / -pyrazol-4-yl)-7- morpholinofuro[3,2-Z>]pyridin-5-yl)-3-( / M-tolyl)-177-pyrazole-5-carboxylate

[0440] Synthesis of l-(7-morpholino-2-(trimethylsilyl)furo[3,2-b]pyridm-5-yl)-3-(m-tolyl)-lH- pyrazole-5-carboxylic acid

[0441] 20 mg of GP28.3 was converted to GP30.1 using NaffcPCh / NaClCh with 2-Methyl-2- butene in a mixture of t-BuOH / MeCN / tbO at ambient temperature for 2 h. TLC showed a new major spot and LC-MS showed the desired product. After work-up and purification, 15 mg of GP30.1 was obtained.

[0442] Synthesis of ethyl l-(7-morpholino-2-(trimethylsilyl)furo[3,2-bJpyridm-5-yI)-3-(m- tolyl)-lH-pyrazole-5-carboxylate

[0443] 500 mg of GP30.1 was converted to GP30.2 using lodoethane and K2CO3 in acetonitrile at room temperature over 18 h. After work-up and purification, 475 mg of GP30.2 was obtained.

[0444] Synthesis of ethyl l-(2-iodo-7-morpholinofuro[ 3, 2-b ]pyridin-5-yl)-3-(m-tolyl)-lH- pyrazole-5 -carboxylate

[0445] 475 mg of GP30.2 was converted to GP30.3 using N-iodosuccinamide and potassium fluoride in acetonitrile after heating at 50 °C for 2 h. After work-up, 420 mg of GP30.3 was obtained.

[0446] Synthesis of ethyl l-(2-(l-methyl-lH-pyrazol-4-yl)-7-morpholinofuro[3.2-b]pyridin-5- yl)-3-(m-tolyl)-lH-pyrazole-5-carboxylate

[0447] 50 mg of GP30.3 was converted to Compound 80 by the reaction of (1 -methyl- 1H- pyrazol-4-yl)boronic acid in the presence of Pd (PPhs^Ch and K2CO3 in dioxane while heating at 90 °C for 18 h. After work-up and purification, 8.5 mg of Compound 80 was obtained as a yellow solid. LCMS (M+H)1: 512.76; HPLC purity: 96.4%; 1HNMR (300 MHz, CDC13) 67.84 (s, 1H), 7.76-7.74 (m, 2H), 7.68-7.66 (m, 1H), 7.36- 7.31 (m, 1H), 7.22-7.18 (m, 2H), 6.88 (s, 1H), 6.76 (s, 1H), 4.30 (q, J = 6.9 Hz, 2H), 4.02- 3.93 (m, 7H), 3.72-3.69 (m, 4H), 2.40 (s, 3H), 1.27 (t, J = 6.9 Hz, 3H).

[0448] General Procedure 31

[0449] Synthesis of Compound 86: 2-[2-(l-methylpyrazol-4-yl)-7-morpholino-furo[3,2- b] pyridin-5-yl]-5-(m-tolyl)pyrazole-3-carboxylic acid

[0450] 75 mg of Compound 80 was converted to Compound 86 by stirring with LiOH in H2O / MeOH at room temperature overnight. After work-up and purification, 60 mg of Compound 86 was obtained as an off-white solid. LCMS (M+H)+: 485.38; HPLC purity: 98.3%; lHNMR (300 MHz, DMSO-d6) 6 13.98 (brs. 1H), 8.38 (s, 1H), 8.04 (s, 1H). 7.78 (s, 1H), 7.75 (d, J = 7.8 Hz, 1H), 7.44 (s, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.20 (d, J = 7.8 Hz, 1H), 7.05 (s, 1H), 7.01 (s, 1H), 3.93 (s, 3H), 3.85-3.82 (m, 4H), 3.72-3.69 (m, 4H), 2.32 (s, 3H).

[0451] Compounds in Table 2 are prepared using methods identified in the table, or using methods analogous to those described herein.Table 2

[0452] Biological Example 1: Inhibition of PIKfyve

[0453] Full length human recombinant PIKFYVE expressed in baculovirus expression system as N-terminal GST-fusion protein (265 kDa) was obtained from Cama Biosciences (Kobe. Japan). The kinase substrate was prepared by mixing and sonicating fluorescently-labeled phosphatidylinositol 3-phosphate (PI3P) with phospho-L-serine (PS) at a 1 : 10 ratio in 50 mM HEPES buffer pH7.5.

[0454] The kinase reactions were assembled in 384-well plates (Greiner) in a total volume of 20 mL as follows. Kinase protein was pre-diluted in an assay buffer comprising 25 mM HEPES, pH 7.5, 1 mM DTT, 2.5 mM MgCh, and 2.5 mM MnCk, and 0.005% Triton X-100, and dispensed into a 384-well plate (10 pL per well). Test compounds were serially pre-diluted in DMSO and added to the protein samples by acoustic dispensing (Labcyte Echo). The concentration of DMSO was equalized to 1% in all samples. All test compounds were tested at 12 concentrations. Apilimod was used as a reference compound and was tested in identical manner in each assay plate. Control samples (0%-inhibition, in the absence of inhibitor, DMSO only) and 100%-inhi bition (in the absence of enzyme) were assembled in replicates of four and were used to calculate %-inhibition in the presence of compounds. The reactions were initiated by addition of 10 pL of 2x PI3P / PS substrate supplemented with ATP. The final concentration of enzyme was 2 nM, the final concentration of ATP was 10 mM, and the final concentration of PI3P / PS substrate was 1 pM (PI3P). The kinase reactions were allowed to proceed for 3 h at room temperature. Following incubation, the reactions were quenched by addition of 50 mL of termination buffer (100 mM HEPES, pH 7.5, 0.01% Triton X-100, 20 mM EDTA). Terminated plates were analyzed on a microfluidic electrophoresis instrument (Caliper LabChip® 3000, Caliper Life Sciences / Perkin Elmer). The change in the relative fluorescence intensity of the PI(3)P substrate and PI(3,5)P product peaks was measured. The activity in each test sample was detemiined as the product to sum ratio (PSR): P / (S+P), where P is the peak height of theproduct, and S is the peak height of the substrate. Percent inhibition (Pinh) was determined using the following equation:Pinh=(PSRo%inh - PSRcompound) / (PSRo%inh ~ PSR100%inh)* 100 in which PSRcompound is the product / sum ratio in the presence of compound. PSRo%inh is the product / sum ratio in the absence of compound, and the PSRioo%inh is the product / sum ratio in the absence of the enzyme. To determine the IC50 of test compounds (50%-inhibition) the %-inh cdata (Pinh versus compound concentration) were fitted by a four-parameter sigmoid doseresponse model using XLfit software (IDBS).Table 3

[0455] Biological Example 2: Antiviral effects of PTKfyve inhibitors in a Vero-E6 SARS- CoV-2 cytopathic assay

[0456] The aim of this study was to determine the cytotoxic and antiviral activity of two compounds against SARS-CoV-2 Wildtype (WT; aka Wuhan strain) and Delta (D) variants, using an immunofluorescence-based assay.

[0457] To determine the half maximal inhibitory concentration (IC50) of the compounds against SARS-CoV-2, antiviral screening was performed against two (2) SARS-CoV-2 strains, WT and D.

[0458] Test samples were Compound 11 and Compound 15 in 10 mM DMSO. which were stored in -20 °C before use.

[0459] Control samples were uninfected untreated cells, infected untreated cells, and Remdesivir (Selleckchem S8932 PHR1258).

[0460] The test system comprised the following components.

[0461] Cells: African Green Monkey kidney epithelial cells (Vero).

[0462] Virus: WT - SARS-CoV-2 isolate England / 02 / 2020 (BEI Resources NR52359) pl July 21; Delta - SARS-CoV-2 VOC-202104 / 02 (B E 617.2 lineage) Apl Jan 22.

[0463] Readout: Antiviral assay: Immunofluorescence; Cytotoxicity assay: MTT.

[0464] The key reagents were Complete medium and Infection medium.

[0465] Complete medium: Vero; M199 medium GlutaMax (Gibco, Cat No 41150087) + 5% FBS + p / s.

[0466] Infection medium: Vero; Ml 99 medium GlutaMax + 0.4% BSA (Gibco, Cat No 15260037) + p / s. , following SQP_LAB003 and SQP_LAB004

[0467] The experimental procedure is described below.

[0468] Cells were plated according to the following procedure: Cells were incubated on 5 clear 96 well plates (3 for antiviral assay; 2 for cytotoxicity assay). The cells were detached and counted, and the cell count was recorded. The number of cells necessary for the experiment (8000 / well) was divided by the cell concentration / mL, and the required number of cells were transferred into a falcon tube or other sterile container of a suitable size. Sufficient volume of complete media was added to bring the final volume to 100 pL / well. Then the plates were left at RT in the hood for 5 minutes for even distribution of the cells. The plates were then placed in an incubator at 37 °C and 5% CO2 until the next day.

[0469] The compounds were prepared according to the following procedure: All test compounds and remdesivir were prepared in DMSO as 10 mM stock solutions. Compoundswere prepared at twice the required final concentration in 50 pL volume, as they would be diluted to the final concentration by an equal volume of virus or media. Half log dilutions for compounds and 3 -fold serial dilution for Remdesivir were performed. The compounds were then prediluted from 10 mM to 1 mM in DMSO (e.g., 2 pL of lOmM compounds + 18 pL of DMSO). The volume of the stock needed to go into x mL of infection media to reach twice the final compound concentrations, with a top concentration of 300 nM (2x = 600 nM), was determined (e.g., 6 pL of 1 mM compounds + 10 mL of infection medium. The “Infection medium + DMSO'’ was prepared so that the concentration of DMSO in the compound is 0.06% (e.g.. 30 pL of DMSO in 50 mL of infection media).

[0470] Remdesivir was prepared according to the following procedure: The volume of the 10 mM stock needed to go into 1800 pL of infection media to reach twice the final compound concentration (40 pM) was determined (e.g., 7.2 pL of remdesivir in 1800 pL of infection media).

[0471] U bottom 96 well plates were titrated with remdesivir or a test compound according to the following procedure: In plates 1 and 2, to row 1 was added 260 pL of diluted test compound or infection media + DMSO per well according to plating scheme. In rows 2-12, 177.8 pL of infection media + DMSO were added per well. Serial dilutions were prepared in row 2 and so forth by transferring 82.2 pL of row 1 to row 2 and so on. Each 3. 16-fold dilution was mixed with a pipette 15 times. In plate 3, 255 pL of 40 pM Remdesivir, 225 pL of infection media, or nothing was added to row A according to the plating scheme. In rows B-H, 170 pL of infection media was added. Serial dilutions were prepared in row 2 and so forth by transferring 85 pL of row 1 to row 2 and so on. Each 3-fold dilution was mixed with a pipette 15 times. 1 plate of compound dilution was needed for each plate 1, 2 and 3.

[0472] Virus dilutions were prepared according to the following procedure, aiming for 50% infection 24 hpi. The MOI used as based on TCID50 and was kept this way for this study. Calculations based on TCID50 are shown below alongside IFU MOI for our records.

[0473] SARS-CoV-2 Eng stock (WT) was prepared to a concentration of 1 ,3e7 TCID50 / mL = 3.2e6 IFU / mL. The stocks were diluted 65x to 2e5 TCID50 / mL = 0.492e5 IFU / mL (e.g., 15.4 pL of virus stock to 984.6 pL of infection medium).

[0474] The amount of virus necessary w as calculated using the formula below: Number of cells / well* x (number of wells + 10% number of wells excess) x MOI**] / virus lU / ml* Double the number of cells plated the day before

[0475] The virus was infected with TCID50 MOI of 0.005= IFU MOI of 0.0012.

[0476] TCID50 calculation is shown as below:( 16000x300x0.005) / 0.2e6= 0.12 mL = 120 pL virus + 14.88 mL media (Total media = 50 pLx300=15 mL)

[0477] SARS-CoV-2 Delta stock was prepared to a concentration of 5.83e6 TCID50 / mL = 7e5 IFU / mL.

[0478] The amount of virus necessary was calculated using the formula below:Number of cells / well* x (number of wells + 10% number of wells excess) x MOI**] / virus lU / ml* Double the number of cells plated the day before

[0479] The virus was infected with TCID50 MOI of 0.3413= IFU MOI of 0.0350

[0480] TCID50 calculation is shown as below:(16000x300x0.3413) / 5.83e6= 0.281 mL = 281 pL virus + 14.72 mL media (Total media = 50 pLx300=15 mL)

[0481] Cell treatment and Infection Cytotoxicity: The media was removed and replaced with 50 pL of infection media (without DMSO) and 50 pL of diluted compounds and incubated for 24 hours at 37 °C, 5% CO2.

[0482] Infection with Pretreatment: The media was removed and replaced with 50 pL of infection media without DMSO and 50 pL of diluted compounds and incubated for 1 hour at 37 °C, 5% CO2. After removing the media, 50 pL of diluted compounds were added, then 50 pL of virus (columns A-G plates 1 and 2 and columns 1-4 and 7-9 of plate 3) was added, then 50 pL of infection media (column H of plates 1 and 2 and columns 5 and 10 of plate 3) was added. The antiviral plates were then incubated for 24h.

[0483] Fixation and development of antiviral plates: Media was removed from cells. The cells were washed once with 100 pL of PBS. The PBS was replaced with 120 pL of 4% formaldehyde in PBS and incubated at RT in the dark for 30 minutes. After washing IX with PBS, the cells were placed in 100 pL of PBS. The cells were stored at 4 °C for staining within one week.

[0484] MTT assay on cytotoxicity plates: The infected and cytotoxicity plates were processed as follows. Briefly, 20 pL of MTT reagent (5 mg / mL in PBS; Sigma, M5655) was added to the cell supernatants for 2h at 37 °C, 5% CO2, after which the media was removed and the precipitate was solubilized with 45 pL of a mixture of 1: 1 isopropanokDMSO for 20 minutes. The supernatant was transferred to a clean plate and signal was read at 560 nm. 2 pL of 10% triton X100 was added into column 11 and incubated for 10 minutes at 37 °C (100% value) before MTT addition.

[0485] IC50 and CC50 determination: Virus signals detected in the presence of each compound concentration were used to determine the IC50. After infection, cells were fixed and immunostained for a viral antigen, and the percentage of infected cells were quantified relative to an infected, untreated control using high content imaging. In parallel, the cytotoxicity of the same concentrations of each compound were tested in the absence of viral infection by MTT assay. As a positive control, remdesivir was included.

[0486] Representative PIKfyve inhibitors Compounds 11 and 15 were tested to determine their activity against two SARS-CoV2 strains: Wildtype (WT) and Delta (D). A summary of the results is shown in Table 4.Table 4: Antiviral activity of representative PTKfyve inhibitors against two strains of P- Corona virus SARS CoV-2

Claims

What is claimed is:

1. A method of blocking SARS-CoV-2 entry into a host cell and / or preventing an infection caused by SARS-CoV-2, comprising administering to a subject in need thereof a compound of(i) Formula (I): wherein:Y1is N or C-R1;Y2is N or C-R2;X is N, or CH; provided that when Y1is N, Y2is C-R2and when Y2is N, Y1is C-R1;R1is H. or C3-8aryl, Cs-sheteroaryl, Cs-scycloalkyl. or C3-8heterocyclyl, each optionally substituted with from 1 to 3 Rs;R2is H. or Cs-saryl, C3-8heteroaryl. Cs-scycloalkyL or C3-8heterocyclyl, each optionally substituted with from 1 to 3 Rs;R3is H, halo, OH, C1-4 alkyl, -NRpRq, C 1-4 alky l-NRpRq, C1-4 alkyl-OH, C1-4 alkyl-OC1-4 alkyl, OC1-4 alkyl, C(O)-C1-4 alkyl, C(O)-C 1-4 alky l-NRpRq, C(O)OH, C(O)-OC1-4alkyl, or C(O)-OC1-4 alkyl-NRpRq;R4is C3-8 aryl, C3-8 heteroaryl, C3-8 cycloalkyl, C3-8 heterocyclyl, C1-4 alkyl, C1-4 alkylP(O))(ORx)2, (C 1-4 alky l)C3-8 aryl, (Ci-4 alkyl)C3-8 heteroaryl, (C1-4 alkyl)C3-8 cycloalkyl, or (1i-4alkyl)C3-8 heterocyclyl each optionally substituted with from 1 to 3 Rs, or C(O)Ry, C(O)NRxRy, NRxC(O)Ry. C 1-4 alky lNRxC(O)Ry, or C(O)C1-4 alkylNRxC(O)Ry;Rsis halo, amino, oxo, OH, C3-8 heterocyclyl, OC1-ealkyl, C1-ealkyl, C1-ealkenyl, C1- ealkyl-OH, C1-6 alkyl-O-C i-4 alkyl, C 1-6 alkyl-O-Ci-4 alky l-O-Ci-4 alkyl, (Ci-4 alkyl)C3-8 aryl, (C1-4 alky l)C3-8 heteroaryl, (Ci-4alkyl)C3-8 cycloalkyl. (C 1-4 alkyl)C3-8 heterocyclyl or C1-6 alkyl-NRpRq;Rxis H or Ci-4alkyl, optionally substituted with R°;Ryis H, Ci-4alkyl-Rr, Ci ralkyl, -O-Ci-4alkyl, -SO2-Ci-4alkyl, Ci-4alkyl-SO2-Rr, cycloalkyl, (-Ci-4alkyl)cycloalkyl, heterocyclyl, (-Ci-4alkyl)heterocyclyl, O-heterocyclyl, Cs-s aryl, (-Ci-4alkyl)C3-s aryl, C3-8 heteroaryl, (-Ci-4alkyl)C3-8 heteroaryl, each optionally substituted with 1 to 3 R° substituents; or Rxand Rytaken together with the nitrogen to which they are attached form a heterocyclyl, optionally substituted with Ci-4alkyl; each Rris C i-4alky 1 or -NRpRq; each R° substituent is independently Ci-4alkyl, oxo, -OH, -OCi-4alkyl, halo, cyano, heterocyclyl, or -NRpRq;Rpand Rqare each independently H or Ci-4alkyl; or Rpand Rqtaken together with the nitrogen to which they are attached form a heterocyclyl;R5is H, Ci-ealkyl, halo, -OH, or -OCi-ealkyl; or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the infection caused by SARS-CoV-2 is COVID- 19.

3. The method of claims 1 or 2, wherein Y1is N, Y2is C-R2.

4. The method of claims 1 or 2, w herein Y2is N, Y1is C-R1.

5. The method of claims 1 or 2. w herein Y1is C-R1and Y2is C-R2.

6. The method of any one of claims 1, 2, or 5, wherein Y1is C-R1and Y2is C-R2. and wherein one of R1and R2is not H.

7. The method of any one of claims 1 to 6, wherein X is N.

8. The method of any one of claims 1, 2, or 6, wherein X is N, and one of Y1and Y2is N.

9. The method of any one of claims 1, 2, or 6, wherein X is N, Y1is C-R1. and Y2is C-R210. The method of any one of claims 1, 2, or 6, wherein X is N, Y1is C-R1, and Y2is C-R2, and wherein one of R1and R2is not H.

11. The method of claims 1 or 2, w herein X is CH.

12. The method of any one of claims 1, 2, or 11. wherein X is CH, and one of Y1and Y2isN.

13. The method of any one of claims 1, 2, or 11, wherein X is CH, and Y1and Y2are N.

14. The method of any one of claims 1, 2, or 4-12, w herein Y1is C-R1and R1is H, or phenyl or Cs-sheteroaryl each optionally substituted with from 1 to 3 Rs.

15. The method of any one of claims 1 - 14, wherein R1is phenyl pyridinyl, pyrimidinyl. pyrazolyl, or cyclopentenyl, each optionally substituted with 1 or 2 Rs.

16. The method of any one of claims 1 - 14, wherein R1is phenyl pyridinyl, or pyrazolyl each optionally substituted with 1 Rs.

17. The method of any one of claims 1-3, 5-12, or 14-16, wherein Y2is C-R2and R2is H, or phenyl or Cs-sheteroaryl each optionally substituted with from 1 to 3 Rs.

18. The method of any one of claims 1 - 17, wherein R2is phenyl, pyridinyl, pyrimidinyl, pyrazolyl or cyclopentenyl, each optionally substituted with 1 or 2 Rs.

19. The method of any one of claims 1 - 17, wherein R2is phenyl, pyridinyl, or pyrazolyl each optionally substituted with 1 Rs.

20. The method of any one of claims 1 - 19, wherein R3is H, Ci-4 alkyd -NRpRq, Ci-4alkyl- OH, Ci-4alkyl-OC i-4 alkyl, C(O)OH, or C(O)-OCi-4 alkyl.

21. The method of any one of claims 1 - 19, wherein R3is (CH2)NH2. (CH2)N(CH3)2, (CH2)OH, (CH2)OCH3, C(O)OH, or C(O)OCH2CH3.

22. The method of any one of claims 1 - 21, wherein R4is phenyl, pyridinyl, pyrimidinyl, or pyrazolyl, each optionally substituted with from 1 to 2 Rs.

23. The method of any one of claims 1 - 21, wherein R4is pyrazolylmethyl , imidazolylmethyl, morpholinomethyl, piperidinylmethyl, dioxanylmethy, dioxanylethyl, dioxanylethylenyl, dioxanylpropyl, dioxanylpropylenyl, cyclohexenyl, cyclopentenyl, dihydropyridinyl, each optionally substituted with from 1 to 2 Rs.

24. The method of any one of claims 1 - 23, wherein Rsis H, Cl, Br, F, NH2, oxo, OH, OCi-ealkyl. or Ci-6alkyl.

25. The method of any one of claims 1 - 23, wherein Rsis H, Cl, F, OH, oxo, methyl, ethyl, or propyl.

26. The method of any one of claims 1 - 23, wherein Rsis H or methyl.

27. The method of any one of claims 1 - 26, wherein R4is C(O)Ry, -C(O)NRxRy, NRxC(O)Ry, Ci-4alkylNRxC(O)Ry, or C(O)Ci-4alkylNRxC(O)Ry.

28. The method of any one of claims 1 - 27, wherein Rxis H, or methyl or ethyl, optionally substituted with one R°.

29. The method of any one of claims 1 - 27, wherein Rxis H or methyl.

30. The method of any one of claims 1 - 27, wherein Ryis Ci-4alkyl-Rr, Ci-4alkyl, -O-Ci-4alkyl, -SO2-Ci-4alkyl, Ci-4alkyl-SO2- Rr, cycloalkyl, , (Ci-4alkyl)cycloalkyl, heterocyclyl, (C1-4 alkyl)heterocyclyl, O-heterocyclyl, Cs-s aryl, (Ci-4alky l)C3-s aryl, C3-8 heteroaryl, (Ci-4alkyl)C3-8 heteroaryl,, each optionally substituted with 1 to 3 R° substituents.

31. The method of any one of claims 1 - 27, wherein Ryis Ci-4alkyl, optionally substituted with one, two, or three R° substituents.

32. The method of any one of claims 1 - 27, wherein Ryis methyl, ethyl, propyl, or isopropyl, each optionally substituted with one, two, or three R° substituents.

33. The method of any one of claims 1 - 27, wherein Ryis methyl, ethyl, isopropyl, methoxyethyl, dimethoxypropanyl, (dimethylamino)ethyl, or (dimethylamino)butyl.

34. The method of any one of claims 1 - 27, wherein Ryis methoxy.

35. The method of any one of claims 1 - 27, wherein Ryis -SCh-methyl.

36. The method of any one of claims 1 - 27, wherein Ryis cycloalkyl or -Ci-2alkyl(cycloalkyl), each optionally substituted with one, two, or three R° substituents.

37. The method of any one of claims 1 - 27, wherein Ryis monocyclic cycloalkyd, or (Ci-4 alkyl)monocyclic cycloalkyl, optionally substituted with one, two, or three R° substituents.

38. The method of any one of claims 1 - 27, wherein Ryis cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, or cyclopentenyl, each optionally substituted with one, two, or three R° substituents.

39. The method of any one of claims 1 - 27, wherein Ryis cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylmethyl. 1 -cyclopropylethyl, 2-cyclopropylethyl, cyclobutyl methyl, cyclopentylmethyl, cyclohexenylmethyl, cyclopentenylmethyl, cyclohexenylethyl, cyclopentenylethyl, cyclohexenylpropyl, or cyclopentenylpropyl.

40. The method of any one of claims 1 - 27, wherein Ryis heterocyclyl or -O- heterocyclyl, optionally substituted with one, two. or three R° substituents.

41. The method of any one of claims 1 - 27, wherein Ryis tetrahydrofuranyl, tetrahydropyranyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, dioxanyl, pyrazolyl, dihydropyridinyl, or oxetanyloxy, each optionally substituted with one, two, or three R° substituents.

42. The method of any one of claims 1 - 27, wherein Ryis tetrahydrofuranylmethyl, tetrahydropyranylmethyl, oxetanylmethyl, azetidinylmethyl, pyrrolidinylmethyl, piperidinylmethyl, morpholinylmethyl, piperazinylmethyl, dioxanylmethyl, pyrazolylmethyl, dihydropyridinylmethyl, or oxetanyloxymethyl, tetrahydrofuranylpropyl, tetrahydropyranylpropyl, oxetanylpropyl, azetidinylpropyl, pyrrolidinylpropyl, piperidinylpropyl, morpholinylpropyl. piperazinylpropyl. dioxanylpropyl, pyrazolylpropyl, dihydropyridinylpropyl, or oxetanyloxypropyl, each optionally substituted with one, two, or three R° substituents.

43. The method of any one of claims 1 - 27, wherein Rxand Rytaken together with the nitrogen to which they are attached form a heterocyclyl, optionally substituted with Cwalkyl.

44. The method of any one of claims 1 - 27, wherein Rxand Rytaken together with the nitrogen to which they are attached form a heterocycloalkyl, optionally substituted with Ci- 4alkyl.

45. The method of any one of claims 1 - 27, wherein Rxand Rytaken together with the nitrogen to which they are attached form a monocyclic heterocyclyl, optionally substituted with methyl.

46. The method of any one of claims 1 - 27, wherein Rxand Ryare taken together with the nitrogen to which they are attached to form azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 6-oxa-l-azaspiro[3.3]heptanyl, or 2-oxa-6-azaspiro[3.3]heptanyl, each optionally substituted with methyl.

47. The method of any one of claims 1 - 46, wherein each R° substituent is independently Ci-4alkyl, -OH. oxo, -OCwalkyl, or -NRpRq.

48. The method of any one of claims 1 - 46, wherein at least one R° substituent is Cn 4alkyl.

49. The method of any one of claims 1 - 46, wherein at least one R° substituent is -OH.

50. The method of any one of claims 1 - 46, wherein at least one R° substituent is -NRpRq.

51. The method of any one of claims 1 - 46, wherein at least one R° substituent is oxo.

52. The method of any one of claims 1 - 51, w herein Rpand Rqare each independently H or methyl.

53. The method of any one of claims 1 - 51, wherein Rpand Rqtaken together with the nitrogen to which they are attached form a heterocyclyl.

54. The method of any one of claims 1 - 51, wherein Rpand Rqtaken together with the nitrogen to which they are attached form azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl 6-oxa-l-azaspiro[3.3]heptanyl, or 2-oxa-6-azaspiro[3.3]heptanyl.

55. The method of any one of claims 1 - 54, wherein R5is H, methyl, ethyl, propyl. Cl. Br. or -OH.

56. The method of any one of claims 1 - 54, w herein R5is H or methyl.

57. The method of any one of claims 1 - 54, wherein R5is H.

58. The method of any one of the preceding claims where the compound is chosen from any of the compounds in Table 1, and pharmaceutically acceptable salts thereof.

59. The method of any one of claims 1 - 58, wherein one or more hydrogen atoms attached to carbon atoms of the compound are replaced by deuterium atoms.

60. The method of any one of claims 1-59, wherein the compound and / or the pharmaceutically acceptable salt is in a pharmaceutical composition.

61. The method of claim 60, w herein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

Citation Information

Patent Citations

  • Enhancement of the efficacy of nifedipine by deuteration

    US5846514A

  • Method of using deuterated calcium channel blockers

    US6334997B1

  • Novel inhibitors of pikfyve and methods using same

    WO2022086993A1

  • 7-morpholino-5-(3-phenyl-1 h-pyrazol-1 -YL)-FURO[3,2-b]pyridine derivatives and similar compounds as pikfyve kinase inhibitors for the treatment of e.g. amyotrophic lateral sclerosis (ALS)

    WO2022256299A1

  • Methods and treatment of viral infection with substituted FURO-pyrimidines

    WO2022261068A1

Cited By

  • Anti-viral compounds

    US12630538B2

  • SLC inhibitors and uses thereof

    WO2026217866A1